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Background: The prevalence of sleep-disordered breathing (SDB) in stroke is
high. One study showed SDB had a negative impact on the functional capacity of
stroke patients on discharge and another that SDB was associated with a higher
mortality rate. However, these findings are disputed. The impact of SDB in stroke
patients on cognition and health-related quality of life is also not clear. The one
randomized controlled trial of nasal continuous positive airway pressure (CPAP) in
stroke patients with SDB showed CPAP improved wellbeing but not other outcomes.
I hypothesised that: (1) SDB is related to stroke outcome and (2) treatment of SDB in
stroke patients with CPAP would improve functional outcome.
Methods: There are three parts of the thesis: (1) a study of the prevalence of SDB
after stroke; (2) a randomized controlled trial (RCT) of CPAP after stroke and (3) a
longitudinal cohort study to investigate the impact of SDB on outcome after stroke.
On day 14-19 after stroke, recruited patients underwent a limited sleep study using a
validated system (Embletta PDS, Medcare Flaga, Iceland). Baseline assessments
were performed on the morning following the sleep study. On day 21-25 following
stroke, patients who had (A+H)-h"' > 30 with < 30% of central events were
randomized to 8 weeks of CPAP treatment with Autoset T (ResMed, SanDiego
USA) or conservative treatment for SDB. All outcomes were recorded in the 8th week
after randomization or 3 months after stroke for non-randomized patients. All
recruited patients received follow-up at six months after stroke. If available, patients
also received 12 months and 18 months follow-up until the last recruited patient had
had his 6 months follow-up. The Nottingham Extended ADL Index (EADL) was
chosen as the primary outcome measure. Secondary outcome measures included:
Subscales of EADL, NIH Stroke Scale (NIHSS), Barthel Index (BI), Stanford
Sleepiness Scale (SSS), Addenbrooke's Cognitive Examination (ACE) and Mini-
Mental State Examination (MMSE), Hospital Anxiety and Depression Scale
(HADS), MOS Short Form 36 Health Survey (SF-36) and ambulatory blood pressure
- measured with Spacelabs 90207 (Spacelabs, Redmond, USA).
iii
Results: We screened 658 patients with recent strokes and excluded those with
dementia, confusion, severe dysphasia or insufficient hand function to use CPAP.
Only 96 of 658 patients remained eligible of whom 25 declined to give informed
consent. 71 patients were thus successfully recruited for overnight limited sleep study
14-19 days following stroke. Sixty-six patients with adequate recording were
included in the study: 45 men and 21 women, median age 74yrs. The sleep study
showed 50% of patients had more than 30 apnoeas + hypopnoeas per hour in bed
[expressed as (A+H)-h~*]. Pulse oximetry alone had lower sensitivity (70%) but high
specificity (90%) to predict (A+H)-h4 > 30. A combination of age, body mass index,
snoring and excessive daytime sleepiness based on logistic regression model is useful
as a screening tool at the bedside (sensitivity = 85%, specificity = 70%) to predict
(A+H)-h_1 > 30 in stroke before referring patients for overnight sleep study.
Interaction of lowest oxygen saturation and lowest heart rate is independently
associated with stroke during sleep in patients with (A+H)-h_1 < 30 (p = 0.023).
Patients with (A+H)-h_1 > 30 more often had their stroke during daytime than patients
with (A+H)-h_1 < 30 (p = 0.006). Thirty patients who had (A+H)-h_1 > 30, with < 30%
central apnoea or Cheyne-Stokes respiration, proceeded to a randomized controlled
trial starting from the 4th week after stroke with 15 patients randomized to CPAP and
15 to conservative treatment for SDB. Conventional stroke treatment was maintained
in all patients. Duration of treatment was 8 weeks and blind outcome assessment was
performed at 3 months and 6 month after stroke. The result showed compliance with
CPAP was poor with mean 1.40 hours and median 0.16 hours per night. There was
no statistically significant difference in the outcomes, sleepiness and ambulatory
blood pressure with CPAP therapy. Increased length of keeping CPAP was correlated
with higher score of language subscale in the Addenbrooke's Cognitive Examination
(Spearman's rho = 0.544, p = 0.036) and lower score in the depression subscale of
the Hospital Anxiety and Depression Scale (HADS, Spearman's rho = -0.538, p =
0.039). All 66 patients with adequate sleep studies received longitudinal follow-up at
3, 6 12 and 18 months following stroke. The patients with (A+H)-h4 > 30 had a trend
to worse functional capacity in both Barthel Index and Nottingham Extended ADL
Index (EADL) than patients with (A+H)-h_1 < 30 but there was only a statistically
iv
significant difference in the mobility subscale of EADL. The negative influence of
(A+Hj-h"1 > 30 on functional capacity and health-related quality of life following
stroke was only statistically significant in patients with mild stroke (NIH Stroke
Scale, NIHSS < 7) at both 3 and 6 months, lesser emotional distress (HADS < 8) at
both 3 and 6 months and lesser cognitive impairment (Mini Mental State
Examination > 28) at 6 months after stroke in subgroup analysis. The difference of
Modified Rankin Scale between groups was significant at 6 months after stroke (p =
0.026). There was no difference in cognitive or emotional outcome. No significant
difference ofmortality rate was noted.
Conclusions: We focused on a group of patients with mild to moderate stroke
(median NIHSS = 6) within a narrow time span (14-19 days) and confirmed a high
prevalence of SDB in stroke. CPAP compliance was a major problem but might be
enhanced by selecting patients with higher functional capacity, higher cognitive
function especially language and less depression in the acute or subacute phase of
stroke. We also found that sleep-disordered breathing had little or no effect on
cognitive and emotional outcomes, health-related quality of life and mortality in
stroke patients. Many other factors resulting from brain damage or complications of
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Chapter 1 Obstructive Sleep Apnoea/Hypopnoea
Syndrome: A Critical Review
1
1.1 Introduction
Sleep-disordered breathing (SDB) comprises apnoeas and hypopnoeas during
sleep. This includes obstructive (obstructive sleep apnoea and hypopnoea, OSAH),
central (central sleep apnoea) and mixed events (mixed sleep apnea). Obstructive
sleep apnoea/hypopnoea syndrome (OSAHS) means OSAH plus excessive daytime
sleepiness (EDS) with or without daytime or nighttime symptoms including
unrefreshed sleep, and choking and suffocating episodes during sleep. Sleep apnoea
and hypopnoea are measured by a validated device incorporating at least the
following sensors: (1) nasal pressure or oral thermistor; (2) thoraco-abdominal
movement; (3) finger pulse oximetry. The examples of obstructive, central and mixed
apnoea and hypoponoea taken from present study conducted by myself are shown to
help explain this (Figure 1.1, P. 35).
The Epworth Sleepiness Scale (ESS) is a commonly used measure of subjective
EDS. It asks how likely (scored 0-3) they are to fall asleep in eight situations. A total
ESS score of more than 10 is considered significant for subjective EDS. The multiple
sleep latency test (MSLT) is a commonly used measure of objective EDS. Individual
sleep latencies across four to five naps are averaged to generate mean sleep latency
(MSL). A MSL of less than 10 minutes is considered significant for objective EDS.
The obstructive sleep apnoea/hypopnoea syndrome is almost always associated
with snoring, a sound made by vibration of soft tissue in the upper airway during
inspiration. Snoring is usually associated with decreased airflow through either the
nose or mouth and when this decrease is total, obstructive sleep apnoeas occur.
Obstructive sleep apnoea/hypopnoea syndrome and snoring are more common in
men than in women and in adults than in children. The diagnosis of SDB is made
through overnight recording of breathing during sleep. Consequences of SDB include
impairment of cognitive function, mood and health-related quality of life. Nasal
continuous positive airway pressure (CPAP) is the mainstay in treating OSAHS but
conservative treatment, oral appliance and surgery are useful in certain clinical
situations.
2
1.2 Diagnostic criteria of sleep apnoea and hypopnoea
According to the report of American Academy of Sleep Medicine [1999], an
episode of apnoea is defined as cessation of airflow for 10 or more seconds. An
episode of hypopnoea is defined as one of the following three features: (1) reduction
of airflow to < 50% of the baseline; (2) reduction of airflow to > 50% of the baseline
associated with desaturation (> 3%); (3) reduction of airflow to > 50% of the baseline
associated with electroencephalographic arousals. Apnoea/hypopnoea Index (AHI),
i.e. Respiratory disturbance index (RDI), is calculated as the total number of apnoeas
and hypopnoeas per hour of sleep. The severity of sleep apnoea is further classified
as mild (5 < AHI < 15, moderate (15 < AHI < 30) and severe (AHI > 30). Oxygen
desaturation index (ODI) is calculated as the total number of oxygen desaturations
per hour of sleep. The definition of desaturation varies from 2% to 4 % drop from the
baseline oxygen level recorded by pulse oximetry.
We could not absolutely define whether events were central or obstructive in
this study as we recorded neither respiratory muscle EMG nor oesophageal pressures.
However as is reported later in the thesis (chapter 4.4.2) very few events had the
respiratory pattern of central events, the large majority being obstructive in pattern.
As obstructive apnoeas can be confidently diagnosed from the respiratory pattern, it
is likely that the vast majority of the events we recorded were obstructive.
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1.3 History of Sleep-disordered breathing
Pickwickian syndrome is named after Mr. Pickwick, the central character in The
Posthumous Papers of the Pickwick Club written by the famous British writer,
Charles Dickens. This syndrome is so named because of the "fat and red-faced boy in
a state of somnolency" named Joe. This boy is thought by some possibly to have had
the Prader-Willi syndrome:
After a "most violent and startling knocking" is heard, Mr. Lowton hurries to the door.
"The object that presented itself to the eyes of the astonished clerk was a boy-a wonderfully fat
boy--.... standing upright on the mat, with his eyes closed as if in sleep. He had never seen such
a fat boy, in or out ofa travelling caravan; and this, coupled with the utter calmness and repose
ofhis appearance, so very different from what was reasonably to have been expected of the
inflicter ofsuch knocks, smote him with wonder.
"What's the matter?" inquired the clerk.
"The extraordinary boy replied not a word; but he nodded once, and seemed, to the clerk's
imagination, to snore feebly."
Joe suddenly awakens. When asked why he knocked "like forty hackney-coachmen, "Joe
replies:
"Because master said, I wasn't to leave offknocking till they opened the door, for fear I
should go to sleep."
Joe, we have learned, "goes on errands fast asleep and snores as he waits at table." He
sleeps through cannon fire, and is hard to rouse: "Be good enough to pinch him, sir—in the leg,
ifyou please; nothing else wakes him."
In history, snoring was reported to be caused not only by exogenous factors such
as excessive drinking or eating but also by endogenous factors such as old age, body
features or illness affecting the nose [Esser 2002]. In a famous Roman comedy,
"Miles Gloriosus" (204 BC), the cellarer's assistant to the captain and his colleague
Palaestrio talk about their fellow slave Sceledrus:
Lucrio: He (Sceledrus) is slurping in his sleep.
Palaestrio: What (should it mean), he is slurping?
Lucrio: He is snoring, that was what I intended to say:
But since it is almost the same whether you snore or slurp -
Palaestrio: Listen, so Sceledrus is sleeping inside?
Lucrio: Not his nose, that is calling all the louder. He stealthily has touched the goblet.
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This paragraph emphasized that the acoustic phenomenon of snoring was similar
to slurping sounds. Snoring was not only recorded in ordinary people but also in
emperors including those who were large with a well-fed neck (Emperor Claudius) or
were moderately built (Emperor Ortho).
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1.4 The upper airway and sleep-disordered breathing
The upper airway can be divided into four parts:
• Nasopharynx
• Velopharynx or retropalatal oropharynx
• Oropharynx
• Hypopharynx
They are covered by mucosa, muscular layer and fat tissue. There are three
factors in determination of the patent upper airway: (1) anatomical structures; (2)
dilator muscular activity; (3) neuromuscular reflex. The pathophysiology of
obstructive sleep apnoea/hypopnoea syndrome is based on both abnormal calibre and
muscle tone of the upper airway [Arens and Marcus 2004],
1.4.1 Anatomical structure of upper airway
Changes of anatomical structure can cause obstruction of the upper airway.
Adenoid hyperplasia in children and enlarged palatal tonsils, tongue base and lingual
tonsil in both children and adults can cause SDB which might benefit from surgical
removal of excessive tissues.
Apart from pathology of anatomical structures, other neck structures also play a
role. There was significantly 42% greater volume of fat tissue in the anterolateral
segments of the neck (52% greater if the fat within the jaw line was analyzed)
measured by magnetic resonance image (MRI) in nine nonobese male patients with
OSAHS than in nine nonobese, nonsnoring male controls [Mortimore et al. 1998],
Even when controlled for BMI and neck circumference the percentage of neck fat are
increased in patients with OSAHS in comparison with controls. A study on body fat
had similar findings.
6
1.4.2 Muscle tone of upper airway
There are 20 or more muscles surrounding the upper airway. The upper airway
dilator muscles which are closely related with OSAHS can be classified into four
groups:
• Soft palate muscles
• Tongue muscles
• Hyoid muscles
• Muscles of posterolateral pharyngeal wall
During wakefulness with quiet nasal breathing, these muscles show phasic
inspiratory activity. The muscle tone of upper airway decreases from light sleep to
deep NREM sleep to reach the minimum in REM sleep [Trudo et al. 1998].
A study compared the mechanics of paralyzed pharynx between normal control
(oxygen desaturation index, ODI < 5, n = 17), mild sleep-disordered breathing (SDB;
ODI between 5 and 20, n = 18) and severe SDB (ODI > 20, n = 22) [Isono et al.
1997]. There was an exponential pressure-area relationship of the passive
velopharynx and oropharynx. There was a substantial difference between airways of
patients with SDB and those of controls. Active negative pressure was required to
close the upper airway in normal subjects whereas the upper airway was closed even
at atmospheric pressure in patients with SDB.
Upper airway dimensions are enlarged by reflex contraction and activity of the
upper airway muscle [Kobayashi et al. 1996]. In the experimental animal model,
increased reflex was seen under the effect of induced negative pressure of upper
airway simulating the situation in SDB [Eastwood et al. 1998]. In clinical studies
applied to patients with SDB, the reflex contraction of upper airway dilator muscles
are accentuated through the daytime which can compensate for anatomical narrowing
of the upper airway [Mezzanotte et al. 1996]. The reflex is absent in some of the
dilator muscles during episodes of sleep apnoea. This means sleep can suppress the
reflex. One of the possible explanations is that hypoxaemia resulting from SDB
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might cause brain stem neuronal dysfunction and impair reflex contraction of the
upper airway during sleep.
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1.5 Diagnosis of sleep-disordered breathing
1.5.1 Polysomnography
Overnight polysomnography (PSG) including EEG, EOG, EMG, nasal/oral
airflow, respiratory movement and pulse oximetry conducted in a sleep laboratory
has been considered to be the gold standard for the diagnosis of SDB. The clinical
guidelines which have been reviewed and proposed by the American Academy of
Sleep Medicine show that PSG is routinely indicated for the diagnosis of SDB
[1997]. But, there has been no good evidence to show that concomitant recording of
sleep electrophysiology in terms of EEG, EOG and EMG is of diagnostic value for
SDB [Douglas et al. 1992].
The variability of AHI was assessed by recruiting 243 patients referred for the
diagnosis of SDB [Le et al. 2000]. Repeated PSG was conducted in 27 of 101
patients who had AHI > 20 but did not receive nasal CPAP treatment and 142
patients who had AHI < 20. The first PSG showed significantly lower AHI and less
severe oxygen desaturation although the correlation between the 1st and 2nd AHI was
highly significant. Bland-Altman plots showed the difference between the 1st and 2nd
AHI increased in the higher AHI group. Variability of AHI was also found between
technologists in different sleep laboratories or centres [Collop 2002], The AHI was
compared with total sleep time. There was a significant higher coefficient of
variation (mean divided by standard error) in AHI than in total sleep time. The higher
the AHI scored, the more the variability. AHI also varies night-to-night.
As there is increasing demand of PSG required in diagnosing patients with SDB
the split-night study is developed based on a positive technician-attended partial
night PSG conducted in a sleep laboratory with CPAP titration initiation on the
second half of the night. A case control study comparing 46 split-night patients with
92 matched full-night patients was conducted in the sleep centre of Edinburgh
University [McArdle et al. 2000]. There was no significant difference between split
and full night titration in the outcomes of therapy measured by nightly CPAP use,
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frequency of nursing intervention, frequency of clinic visit and post-treatment
Epworth Sleepiness Scale. The median time from referral to treatment was less for
the split-night patients than for full-night patients. The Kaplan-Meier analysis
showed there was no difference between the groups in long-term CPAP compliance
with a follow-up median of 22 months for split-night and 27 months for full-night
studies.
Polysomnography is not always available for the diagnosis of SDB because of:
• Rapidly increased number of patients being referred.
• PSG is time-consuming and not cost-effective.
• Some geriatric, paediatric and severely ill patients are not suitable for PSG.
1.5.2 Portable sleep study
Portable sleep study is also employed to reduce the cost and resource required to
diagnose patients with SDB. Recently, many portable devices have become available
for home study which can reduce cost compared with expensive in-lab
polysomnography [Douglas 2003], Portable devices are usually used for unattended
or semi-attended limited sleep studies in stroke patients to made diagnosis of SDB
more feasible. There are many types of portable sleep study devices. One is full
unattended polysomnography, which is the same as an in-laboratory device apart
from portable function [Fry et al. 1998]. Another is limited sleep study, which is
usually focused on cardiorespiratory signals. Nasal airflow, chest and abdominal
respiratory movement and oximetry are three basic and minimal sensors in portable
limited sleep study [Douglas 2003].
The benefits of portable sleep study are:
• Saving cost over conventional in-lab PSG
• Saving time of long waiting list for in-lab PSG
• Saving labour work and personnel
• Possibly reduced first night effect as may sleep better at home with fewer
monitors
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• More available to disabled or hospitalized patients who need to be excluded
sleep-disordered breathing
The limitations of portable sleep study are:
• Inability to diagnose broad range of sleep disorders such as periodic limb
movement disorder
• Inability to diagnose upper airway resistance syndrome - if it exists
[Douglas 2000]
• Difficulty in distinguishing central from obstructive sleep apnoea
• Possibly more artefacts and technical failure
The pros and cons of an in-lab full polysomnography and a portable limited sleep
study were summarized and compared in Table 1.1 (P. 34).
A practice parameters for the use of portable sleep study in the assessment of
SDB was proposed by Standards of Practice Committee of the American Sleep
Disorders Association [Ferber et al. 1994], Evaluation studies for SDB were
classified into four levels:
• Level I: Standard PSG with full signal channels
• Level II: Comprehensive portable PSG with full signal channels
• Level HI: Modified portable PSG, minimum of four signal channels,
including ventilation, heart rate/ECG and oxygen saturation.
• Level IV: Continuous single- or dual-bioparameter recording, minimum of
one signal channel
Only level II and level IH of unattended portable recording are accepted for the
diagnosis and assessment of therapy for SDB. Portable sleep study is recommended
by the American Academy of Sleep Medicine only in the following situations [1994]:
• Patients with severe clinical symptoms of obstructive sleep apnoea when
standard PSG is not available and initiation of treatment is urgent.
• Patients unable to be studied in the sleep laboratory.
• Follow-up studies when a diagnosis has been established by standard PSG.
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There was no loss of diagnostic accuracy in SDB when the signals of EEG and
EMG were omitted [Douglas, Thomas, and Janl992]. ECG or heart rate is a good
adjunctive monitor. Portable devices with at least two cardiorespiratory signals are
not only as convenient as pulse oximetry but rated at higher levels (level II and III)
than pulse oximetry alone (level IV) for the diagnosis of SDB by the American
Academy of Sleep Medicine [1994].
1.5.3 Pulse oximetry
Pulse oximetry is commonly used in the hospital to detect hypoxaemia, as a
screening device for cardiopulmonary diseases and a commonly used device in stroke
units for casual or regular measurements. Continuous measurement using oximetry in
stroke is less frequent. SDB Oximetry is a component of polysomnography, but is
also used extensively either alone or in conjunction with other sensors in the
diagnosis of SDB. The diagnostic value of oximetry in SDB is controversial. In a
large European study described in the previous section, simple overnight oximetry
was used as a screening test and was analyzed before applying and scoring
polysomnography. There, the predictive value of oximetry could be looked at in
isolation [Deegan and McNicholas 1996]. The results showed although the odds ratio
of absolute number of > 4% dips in %Sa02 in predicting AHI > 15 was as high as 21
(95% CI = 10 - 45) only one third (32.4%) of patients could be correctly categorized
into SDB or non-SDB using clinical features and oximetry data (absolute number of
> 4% dips in Sa02 + lowest Sa02) alone. High diagnostic accuracy was reported
(sensitivity and specificity > 90%) to predict SDB with cut-off point of AHI at 15/hr
[Vazquez et al. 2000]. However, relatively low sensitivity was found in not only
patients with minimal daytime sleepiness [Hussain and Fleetham 2003] but also in
patients with moderately and severe SDB who could benefit from treatment
[Douglas, Thomas, and Janl992], Pulse oximetry, along with clinical features or with
a more specified index, for instance, A index derived from changes of Sa02 by
certain intervals over time calculated by an extra programme [Levy et al. 1996], is
useful as a screening instead of diagnostic package to decide which patient needs
further sleep study [Deegan and McNicholasl996].
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In a more recent study 30 patients who were suspected to have SDB (snoring
with or without witnessed apnoea) but denied excessive daytime sleepiness (ESS
score < 10) underwent overnight polysomnography [Hussain and Fleetham2003].
Significant SDB (AHI > 15) was found in 40% of them and all had 2% oxygen
desaturation index (ODI) < 10. The 2% ODI had a sensitivity of 33%, specificity of
88% and negative predictive value of 67% if the cut-off point was set at 6. The
sensitivity increased by decreasing the cut-off point of ODI but this decreased the
specificity. Another recent study recruited 424 patients to determine the role of
obesity affecting the predictive value of oximetry for SDB [Nakano et al. 2004]. The
sensitivity of oximetry was lower in the normal-weight group than in the over-weight
and obese groups. The specificity was lower in the obese group than in the normal-
weight group. Oximetry might be more useful by applying a different cut-off point
according to BMI. Another recent study used spectral analysis as an adjunctive to
oximetry (n = 233). Power density of oxygen saturation was calculated and the
presence of peak at spectrum of 30-70s was determined [Zamarron et al. 2003]. The
results showed spectral analysis for the presence of peak had higher sensitivity (78%)
and specificity (89%) than the predictive value in pulse oximetry.
1.5.4 Predictive value of clinical and anthropometric features
Comparison of clinically detected and screen-detected OSAHS showed 93% of
women and 82% of men who had moderate to severe OSAHS have not been
clinically diagnosed [Young et al. 1997a]. There is also a discrepancy between AHI
and self-reported SDB-related symptoms in the general population. One study
recruiting 129 patients [Dealberto et al. 1994] and another study recruiting 2,148
patients [Duran et al. 2001] who had obstructive sleep apnoea/hypopnoea (OSAH)
both showed breathing pauses during sleep and habitual snoring were significantly
associated with OSAH but daytime sleepiness was not. Many predictive models for
SDB derived from sleep questionnaires were developed and published with variable
results. One study using three specific questions about snoring found sensitivity was
high (90%) only in men and specificity was high (90%) only in women [Bliwise et al.
1991]. Another study found the predictive value of SDB-related symptoms was even
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lower than measurement of neck circumference [Davies et al. 1992]. The other study
revealed that self-reported sleep apnoea, neck circumference, age, and a tendency to
fall asleep unintentionally were all significant positive predictors of apnoea index
which explained 41.8% of the variability [Pillar et al. 1994]. The sensitivity of the
model for predicting SDB (Al > 10) was 92.2% but specificity was only 18.2%. A
study focused on a morphometric model including body mass index, neck
circumference and oral cavity measurements was published later [Kushida et al.
1997]. Oral cavity measurements for palatal height, maxillary intermolar distance and
mandibular intermolar distance were obtained by placing the caliper tips between the
oral cavity structures to be measured, carefully removing the caliper, and measuring
the distance between the caliper tips with a ruler. The morphometric model had a
sensitivity of 97.6% (95% CI = 95% - 98.9%), a specificity of 100% (95% CI = 92%
to 100%), a positive predictive value of 100% (95% CI = 98.5% - 100%), and a
negative predictive value of 88.5% (95% CI =77% - 96%).
According to a study of 594 patients to predict AHI by clinical variables of
snoring, nocturnal choking, excessive daytime sleepiness, impotence and witnessed
apnoea are distinctive between patients with SDB and without [Hoffstein and Szalai
1993], A further regression model showed interaction between BMI and age, male
sex, witnessed apnoea and abnormal pharyngeal examination can explain 36% of
variance in AHI (r = 0.3585, p = 0.0004). Subjective impression from the examining
physician has a sensitivity of 60% and a specificity of 63% in predicting SDB (AHI >
10). One hundred and fifty-two patients had overnight PSG in a large European study
and 52% of them had AHI > 15 [Deegan and McNicholasl996]. A stepwise multiple
linear regression analysis showed alcohol consumption, BMI and age were
significantly associated with AHI in men. However, age and neck circumference
were the only two factors in women. After controlling for BMI and age, waist
circumference correlated more closely with AHI than neck circumference in men,
while the opposite was true in women.
A questionnaire-based study which generated a cut-off point of symptoms score
based on a regression model to predict SDB could be more accurate than
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questionnaire alone [Flemons et al. 1994], In this study they found positive
likelihood ratio (LR+) for predicting SDB was as high as 5.17 (95% CI: 2.54 to
10.51) and post-test probability was 81%. Recently a computer-based artificial neural
network (ANN) was suggested as a good alternative to the regression model for
prediction of SDB but this needs extra software and training [El Solh et al. 1999].
A clinical decision rule was made according to 837 patients who were referred to
a university sleep centre [Rodsutti et al. 2004], Multiple logistic regression analysis
showed age > 60 (Odds Ratio, OR = 8.8), male (OR = 4.5), snoring (OR = 2.5), stop
breathing (OR = 2.4) and BMI (OR = 0.9) were significantly associated with SDB
defined as AHI > 5. The scoring scheme was developed using estimated coefficient
of the five significant variables. Data from the other 243 patients were used in the
validation phase. The area under the curve (AUC) by receiver operating characteristic
(ROC) analysis was high (AUC = 0.789). This decision rule might be useful in
prioritizing patients who are on the waiting list of polysomnography.
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1.6 Epidemiology of habitual snoring and sleep-disordered
breathing
In the past decade snoring and sleep-disordered breathing (SDB) have been
noted for their diversity of epidemiological and clinical consequence. Hospital-based
studies are biased by recruiting patients at sleep clinics or wards who are more likely
to have SDB than the general population recruiting for epidemiological studies. A
community-based large cohort study is the best model used to calculate the
prevalence of snoring and obstructive sleep apnoea.
1.6.1 Prevalence of snoring and SDB in adults
The Wisconsin sleep cohort study [Young et al. 1993] which recruited 602
employed men and women aged 30 to 60 years showed the prevalence of SDB
defined by apnoea/hypopnoea index (AHI) > 5 was 24% in men and 9% in women.
Four percent of men and 2% of women had both SDB and daytime hypersomnolence.
The prevalence of habitual snoring was 44% in men and 28% in women and self-
reported hypersomnolence was 16% in men and 23% in women.
A large population survey by computer-assisted telephone interview for non-
institulized residents in the UK was completed with 4972 subjects [Ohayon et al.
1997]. Habitual snoring was noted in 40% of the population (48% in men, 34% in
women) and breathing pauses was noted in 3.8% of the population (5.4% in men,
2.4% in women). Logistic regression analysis showed snoring and breathing pauses
was significantly associated with middle age, male gender, higher body mass index
and daytime sleepiness..
1.6.2 Age
Sleep problems are common in the elderly, particularly for SDB. A large cohort
study [Ancoli-Israel et al. 1991] randomly selected 427 elderly individuals in the
community (mean age = 72.6 years) for overnight limited sleep study (respiratory and
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EMG signals, wrist activity). One hundred of 420 valid data (24%) had AHI > 5,
including 20% of women and 28% of men. They followed most subjects (only 4 lost)
for 8-12 years [Ancoli-Israel et al. 1996]. Although there was a tendency that
subjects with higher AHI had higher mortality rate AHI was still not an independent
risk for mortality.
In the Cardiac Health Study (CHS) which recruited 5,201 subjects, aged 65 or
older [Enright et al. 1996] 13% of men and 4% women had witnessed sleep apnoea
according to single questionnaire. The prevalence of apnoeas and hypopnoeas in the
older age (age 60-70) appears to be 2-fold higher than the prevalence in middle age
(age 40-49) in men for AHI > 5 and 3-fold higher in women in the Spanish Cohort
Study [Duran, Esnaola, Rubio, and Iztueta2001]. Difference of prevalence between
ages was found in both sexes with an odds ratio of 2.2 for each 10-year increase. In
the Sleep Heart Health Study (SHHS), the prevalence with AHI > 15 was 1.7-fold
higher in older (age 60-99) compared to younger (age 40-60) participants [Young et
al. 2002].
1.6.3 Gender
The prevalence of sleep-disordered breathing is different between males and
females. In the Wisconsin Sleep Cohort Study snoring and symptomatic SDB was
twice as common in middle-aged men than women [Young et al. 1993]. A large-
sampled (n = 4,648) community-based questionnaire survey showed snoring as a
problem was reported by 14.6 % of men and 6.7% of women with a male to female
ratio of about 2:1 (p < 0.001) [Larsson et al. 2003]. A total of 1166 out of 1745
patients referred to a sleep centre had SDB based on either in-lab overnight
polysomnography (PSG), nap PSG or home PSG which showed male to female ratio
of 4.9: 1 [Quintana-Gallego et al. 2004], The possible underlying mechanisms which
discriminate men from women for the higher prevalence of SDB are:
• Craniofacial morphology: In a study recruiting 347 patients with SDB and
101 control subjects the most atypical craniofacial and upper airway
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abnormalities was shown in male patients with SDB and class I skeletal
subtype, measured by cephalometry [Lowe et al. 1996],
• Neck fat volume: One study showed men had more severe sleep apnoea than
women at the same degree of obesity, measured by BMI [Millman et al.
1995], Another study showed men had larger total neck soft tissue than
women. This difference was made up by non-fat soft tissue as there was no
significant difference in volume of fat [Whittle et al. 1999]. Both studies
might indicate that men have more prominent upper body obesity due to fat
deposition than women and that this results in upper airway narrowing.
• Pharyngeal collapsibility: Men have markedly greater pharyngeal
collapsibility than women in response to external applied loads during
NREM sleep [Pillar et al. 2000].
• Sex hormone: In the Wisconsin Sleep Cohort Study the prevalence of SDB
(AHI > 5) increased across menopausal categories: 10.8% (n = 498), 18.4%
(n = 125), 27.0% (n = 37) and 29.1% (n = 375) of pre-menopausal, peri-
menopausal, peri-menopausal/post-menopausal and post-menopausal
women respectively [Young et al. 2003], The adjusted odds ratio of SDB
(AHI > 15 vs. AHI < 5) was 1.07, 3.13 and 3.49 in peri-menopausal, peri-
menopausal/post-menopausal and post-menopausal groups.
1.6.4 Obesity
Obesity has been associated with SDB in many hospital-based cross-sectional
studies. In the longitudinal follow-up of the Wisconsin Sleep Cohort Study a 10%
weight gain predicted a 32% increase in AHI and on the contrary, 10% weight loss
predicted a 26% decreased in AHI [Peppard et al. 2000a].
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1.7 Clinical features of obstructive sleep apnoea/hypopnoea
syndrome
The major nighttime symptom of SDB is snoring. Others include choking or
gasping during sleep, recurrent awakenings from sleep and unrefreshing sleep. The
major day time symptom of SDB is EDS. Others include fatigue and impaired
concentration and cognitive functions which have been reported by the American
Academy of Sleep Medicine [1999]. The symptoms of SDB probably result from a
combination of (1) sleep fragmentation: frequent awakenings and arousals during
sleep; (2) change of sleep architecture: increased light sleep (stage I and II),
decreased slow wave sleep (stage in and IV) and rapid eye movement (REM) sleep;
(3) nocturnal hypoxaemia.
1.7.1 Night-time symptoms
Habitual snoring was reported in 40 % of the British population including 50%
of men and 35% of women [Ohayon, Guilleminault, Priest, and Cauletl997]. This
questionnaire-based study showed breathing pauses were only reported in 2.5% of the
sample including 5.4% of men and 2.4% of women. Further logistic regression
showed snoring was significantly associated with married men aged 35-64 and
obesity. Breathing pauses was significantly associated with men aged 35-44, non-
restorative sleep, and certain medical illness including thyroid disease, chronic
obstructive pulmonary diseases and anxiolytic medications.
A laboratory-based study supported the above findings and showed habitual
snoring, bed partner reports of nocturnal gasping or choking episodes, increased neck
circumference and hypertension were weak but significantly associated with SDB
(AHI > 10) diagnosed by nocturnal PSG (R2 = 0.34) [Flemons et al. 1994],
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1.7.2 Excessive daytime sleepiness
Excessive daytime sleepiness (EDS) is the key daytime feature of SDB which
may result from both sleep fragmentation and sleep deprivation. The mean Epworth
Sleepiness Score (ESS) of community-based normal sleepers collected from
Australian workers was 4.6 (SD = 2.8) out of a maximum of 24 [Johns and Hocking
1997]. The mean ESS in patients with SDB was 15 ± 6 rated by patients themselves
and 14 ± 6 rated by their partners [Engleman et al. 1996a], about 3-fold higher than
normal subjects.
Among 195 Asian patients with SDB (89% male) 52% had severe EDS with
mean sleep latency in Multiple Sleep Latency Test (MSLT) < 5 minutes and 35% had
moderate EDS with mean sleep latency in MSLT 5-10 minutes [Seneviratne and





• Periodic leg movement disorder
• Medications: sedative, withdrawal from stimulants




Impaired vigilance including focused and sustained attention and executive
function are two major neuropsychological deficits in SDB which suggest frontal
lobe dysfunction plays an important role [Beebe et al. 2003]. A case-control study
was performed to examine semantic memory, using the California Verbal Learning
Test, and executive function, using Verbal Fluency Test and Wisconsin Card Sorting
Test, in SDB [Salorio et al. 2002], They found patients with SDB had impaired word
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recall but preserved word retention in one category and impaired letter fluency but
preserved category fluency in the other. These findings support the major problem in
SDB being executive dysfunction probably resulting from damage of the frontal
lobes.
Two studies were performed which focused on the relationship between
neuropsychological assessment and nocturnal polysomnography. One study showed
deficit of sustained attention, a frontal lobe dependent parameter, was associated with
nocturnal hypoxemia and was not easily reversed by nasal CPAP treatment
[Valencia-Flores et al. 1996]. The other study designed for the elderly with SDB
showed verbal delayed recall in Hopkins Verbal Learning Test was associated with
both sleep fragmentation and oxygen desaturation. However, constructional abilities
in Visual Motor Integration was strongly associated with oxygen desaturation [Aloia
et al. 2003].
Cognitive deficits in SDB result from two major factors. One is sleep
fragmentation and excessive daytime sleepiness which have stronger influence on
attention, vigilance and memory. The other is nocturnal hypoxemia which has
stronger influence on executive and constructive functions. Short-term nasal CPAP
therapy for a couple of weeks seems to improve those related with sleep
fragmentation but has limited effect on those related with nocturnal hypoxemia
[Ferini-Strambi et al. 2003].
An animal study examined the isolated effect of hypoxia on cognitive functions
by controlling sleep fragmentation [Gozal et al. 2001]. Chronic episodic hypoxia was
induced mimicking SDB by adjusting oxygen concentration in a designed chamber
which accommodated rats. Sleep architecture was controlled by cortical EEG and
nuchal EMG recordings. Morris water maze was then used to study cognitive
functions. After that, rats were sacrificed for neuropathology of hypoxic brain
damage. The results showed rats exposed to 14 days of hypoxia (n = 18) had
significantly more difficulty learning the location of a hidden platform than did
controls (n = 19). The neuropathology showed cellular changes over time within CA1
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hippocampal region and cortex associated with cognitive functions. These findings
might explain learning and memory impairment found in patients with SDB.
The other animal study developed two systems, sleep-induced hypoxia or sleep
fragmentation without hypoxia, to two strains of mouse: DBA/2J strain with largest
ventilatory response to hypoxia and A/J with smallest ventilatory response to hypoxia
obtained in previous study [Rubin et al. 2003]. The results showed genetic factors
determine individual susceptibility to cognitive deficits in SDB. This finding raises
the possibility that individuals with low hypoxic sensitivity might be at a greater risk
for hypoxia-related injury.
A prospective study conducted in the sleep centre of Edinburgh University which
recruited 150 patients with OSAHS showed nocturnal sleep variables only weakly
correlated with daytime sleepiness (lowest Sa02 vs. MWT, rho = 0.19) and cognitive
functions in terms of Trail making B (vs. lowest Sa02, rho = -0.17), PASAT 4-s test
(vs. 2% Desaturation, rho = -0.17) and performance IQ (vs. AHI, 2-4% desaturation
and lowest Sa02, rho = -0.17 to -0.23) [Kingshott et al. 1998]. Another prospective
study was conducted in the same sleep centre which recruited 15 normal subjects. It
showed that one night of sleep fragmentation induced by repeated brief auditory
simulation resulted in decreases in mean sleep latencies in the multiple sleep latency
test (MSLT) and maintenance of sleepiness test (MWT) with big effect sized (>
0.75). The effect of sleep fragmentation on attention-based cognitive scores including
Trail Making-B and PASAT 4-s tests was smaller but still significant (effect size <
0.75) [Martin et al. 1996], This means at least some cognitive deficits in OSAHS
may be a secondary consequence of sleep disruption.
1.7.4 Health-related quality of life
MOS Short Form-36 Health Survey (SF-36) is the most commonly used generic
measure for health-related quality of life in patients with SDB [Moyer et al. 2001]. In
the Wisconsin Sleep Cohort Study SDB was associated with significant impairment
in 6 of 8 domains in SF-36 after adjusting for confounders in 760 individuals. These
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domains were mental health, social roles, role functioning due to physical problems,
physical functioning, vitality and general health perceptions [Finn et al. 1998],
SF-36 is also one of the most sensitive assessment tools to evaluate changes of
quality of life in patients with SDB before and after nasal CPAP treatment. In a
randomised controlled trial conducted by Oxford research group, SF-36 revealed
substantially lower scores in patients with SDB whereas nasal CPAP treatment
showed significant improvements demonstrated by medium to large effect sizes in
the energy/vitality dimension (0.98), mental summary score (0.76) and physical
summary score (0.57) [Jenkinson et al. 1997].
The Functional Outcome of Sleep Questionnaire (FOSQ) was developed specific
to the impact of EDS on multiple activities of daily living in the areas of physical,
mental and social functioning [Weaver et al. 1997]. It consists of 35 items in 5
domains: activity level, vigilance, intimacy and sexual relationships, general
productivity and social outcome. It has been widely used for both research and
clinical purposes and showed significant changes of clinically meaningful effect size
after CPAP treatment.
The Sleep Apnea Quality of Life Index (SAQLI) was developed in Calgary to
specifically identify the impact of sleep apnoea and nasal CPAP treatment on health-
related quality of life [Flemons and Reimer 1998]. It consists of 40 items in 5
domains: role functioning, social interactions, emotional functioning, symptoms, and
treatment-related symptoms. The correlation between SAQLI rating of change score
and SF-36 vitality domain change score was good (r = 0.81, p = 0.0002).
1.7.5 Mood
Many studies found an association between SDB and depressive symptoms.
About 25-50% of patients with SDB have depression. Depression is one of the major
factors affecting quality of life in patients with SDB.
One study applied Zung self-rated depression scale and SF-36 to 66 Japanese
patients with severe SDB (AHI > 20/h, Sa02 < 80% and EDS) and 34 controls
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[Akashiba et al. 2002], Depression measured by self-rated Zung Depression Scale
significantly correlated with subscales of general health, role physical, role
emotional, mental health and vitality in SF-36 but EDS was not correlated with Zung
self-rated depression scale. A randomized controlled trial conducted in our
department has shown that the beneficial effect of CPAP was stronger in the
depressive subscale than the anxiety subscale of HADS [Engleman et al. 1994a]. The
beneficial effect of CPAP in mild SDB was also shown in the depressive subscale of
HADS instead of anxiety subscale [Engleman et al. 1997]. This means depression in
SDB can be treated in non-stroke patients. Depression measured by the Beck
Depression Inventory also significantly correlated with self-reported sleep quality
measured by the Insomnia Severity Index in 135 patients referred to an American
sleep centre for polysomnographic evaluation of SDB [Wells et al. 2004].
Fatigue is a common symptom in SDB. A study on 60 patients with SDB (mean
age = 49.1, AHI = 48.8 and BMI = 29.5) found that, after severity of sleep apnoea
was controlled, significantly more fatigue measured by the fatigue-inertia subscale of
the Profile of Mood State (POMS) was seen in patients with higher depression
measured by Centre for Epidemiological Studies Depression Scale (CES-
D)[Bardwell et al. 2003]. Multivariate analysis suggested depression was
significantly associated with fatigue in patients with SDB.
1.7.6 Comments
The evidence that SDB causes daytime sleepiness [Young et al. 1993], cognitive
impairment [Salorio et al. 2002], reduces quality of life [Finn et al. 1998] and
impairs mood [Akashiba et al. 2002] is based on cross-sectional case-control studies
with adjustment for confounding factors in multivariate analysis. This evidence is
further strongly supported by many well-designed randomized controlled trials which
show CPAP treatment can significantly improve sleepiness, vigilance, quality of life
and mood [Engleman et al. 1998;Engleman et al. 1999;Engleman et al. 2002]. Thus
SDB can cause impairment of daytime functions rather than just being an associated
factor.
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1.8 Treatment of obstructive sleep apnoea/hypopnoea
syndrome
1.8.1 An overview
A good treatment for SDB should have the following merits:
• Lowering apnoea hypopnoea index (AHI) and eliminate abnormal sleep-
related physiological markers, e.g. desaturation, arousals
• Improving sleepiness and daytime function
• Well-tolerated by patients
1.8.1.1 Literature review
I did a comprehensive literature review including studies conducted in the
University of Edinburgh from 1 September 1999 to 31 May 2000. Searches were
performed on MEDLINE, OVID and Cochrane Library with the following search
terms:
• Sleep-disordered breathing (SDB)
• Sleep-related breathing disorder
• Obstructive sleep apnoea (OSA)
• Obstructive sleep apnoea/hypopnoea syndrome (OSAHS)
• Interventions
• Drug treatment
• Continuous positive airway pressure (CPAP)
• Compliance
• Oral appliances





Evidence-based literatures were obtained from "Cochrane Review" which is a
generic term for a systematic review performed under the auspices of the Cochrane
Collaboration.
Evidence-based medicine has been developed to determine the best medical care
for patients. Meta-analysis based on randomized controlled trials (RCT) which
should be adherent to original protocol with "intention-to-treat" analysis is the core
of evidence-based medicine. If a trial is not randomized, it might have "selection
bias". If it is not a controlled trial, it might have "regression to mean" effect and if
there is no placebo, it might have "placebo effect".
When we take a look at the results we not only concern ourselves with statistical
significance (p value) but clinical significance. One of the considerations is "effect
size" defined as mean divided by standard deviation which is independent of sample
size. When the p value is significant, effect size might still be small (<0.5) if the
sample size is large enough. When the p value is not significant, effect size might be
big if the sample size is inadequate (Type II error with low statistical power). The
other consideration is, even though the p value is low and effect size is big we should
explain the result very carefully if the only difference is in a subscale of a total scale
or if the difference has little clinical value.
1.8.2 Continuous positive airway pressure for obstructive sleep
apnoea/hypopnoea syndrome
1.8.2.1 Studies in Edinburgh University
A series of randomized placebo-controlled crossover trial for four weeks
conducted in the sleep centre of Edinburgh University based on an intention-to-treat
analysis supports the role of nasal CPAP as a safe and effective treatment for SDB.
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Thirty-four patients with SDB (median AHI = 28) completed the first study
published in 1994 [Engleman et al. 1994a]. Mean nightly CPAP usage was 3.7 ± 0.4
hours. The study showed CPAP improved objective daytime sleepiness measured by
multiple sleep latency test (MSLT), cognitive functions including vigilance, mental
flexibility and coding efficiency. CPAP also improved energetic arousal, mood and
health-related quality of life in moderate to severe SDB.
Thirty-four patients with mild SDB (median AHI = 10) completed the study
published in 1999 [Engleman et al. 1999]. Mean nightly CPAP usage was 3.2 ± 2.4
hours. The study showed CPAP improved general symptoms of SDB, subjective
sleepiness measured by Epworth Sleepiness Scale (ESS), cognitive functions
including vigilance, coding efficiency, mood and health-related quality life even in
mild SDB.
1.8.2.2 Cochrane review
Twelve randomized controlled trials (RCT) including the University of
Edinburgh studies were recruited in a Cochrane review for continuous positive
airway pressure (CPAP) treatment in middle-aged patients (age = 36-71) with mild to
severe SDB (AHI = 5-129) [White et al. 2002], All but three were randomized cross¬
over studies. Four studies used inactive oral medication [Engleman et al. 1994a;
Engleman et al. 1996a; Engleman et al. 1997; Engleman et al. 1999] and two used
sham CPAP as placebo [Dimsdale et al. 2000;Jenkinson et al. 1999]. Two studies
compared CPAP with conservative treatment [Ballester et al. 1999;Lojander et al.
1996], one with a positional therapy device [Jokic et al. 1999] and another three with
oral compliances [Clark et al. 1996;Ferguson et al. 1996;Ferguson el al. 1997].
The meta-analysis showed CPAP significantly improves subjective and objective
daytime sleepiness, Nottingham Health Profile part 2, General Health Questionnaire
(GHQ-28), depression component of Hospital Anxiety and Depression Scale (HADS)
and MOS Short Form 36 (SF-36) in the domains of vitality, physical role, bodily pain
and mental health. Nocturnal mean arterial blood pressure (MAP) was also
significantly reduced by CPAP.
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1.8.2.3 Predictors of effectiveness
Prediction of daytime functions by sleep fragmentation, architecture and
nocturnal oxygenation is limited [Kingshott et al. 2000]. The study showed
improvement of daytime functions was not well predicted by pretreatment arousal or
apnoea hypopnoea index in patients with SDB. Patients with more severe baseline
hypoxaemia had a greater improvement in the Maintenance of Wakefulness Test
(MWT), quality of life, SDB symptom ratings, reaction time, attention and
visuomotor speed but could only explain not more than 22% of the observed variance
in response.
1.8.2.4 Auto-titration continuous positive airway pressure (auto-
CPAP)
Traditional CPAP delivers a fixed pressure. The individual pressure might need
change according to sleep stages, body positions or alcohol consumption on a nightly
basis and changes of body weight on a long-term basis.
Continuous positive airway pressure with auto-titration mode has the following
benefits: (1) it can save beds and time of in-hospital manual titration if the titration is
done at home [Massie et al. 2003]. (2) It has variable pressure during the night so it
can adjust itself to fit the condition of patients at that particular night in long term
use. The pressure needed for elimination of obstructive sleep apnoea could be
variable according to different situations, for example, when patients have nasal stuff
or other medical situations.
The disadvantage of autotitration mode of CPAP is that the machine is more
expensive than traditional CPAP. An alternative way is to apply this machine to find
out and set up an ideal fixed pressure for subsequent use on conventional CPAP
[Series 2000].
It is not yet clear whether auto-CPAP is better than CPAP. Current evidence
shows it can be as effective as CPAP but can save time and cost of in-lab CPAP
28
titration and maintain the minimal necessary pressure in non- stroke apnoeic
population. Although auto-CPAP is recommended by the American Academy of
Sleep Medicine to be used during attended titration or for unattended treatment of
patients with SDB after attended standard or auto-CPAP titration [Littner et al.
2002], a few randomized control trials [Stradling et al. 1997] have shown that auto-
CPAP is promising for naive CPAP users to initially determine pressure by
unattended titration or self-adjusting CPAP treatment. This is more convenient for
stroke patients. In long term use it may have advantages in some patients [Massie et
al 2003].
1.8.2.5 CPAP acceptance and compliance
In different studies between 5-50% of patients with SDB refuse to use CPAP
after a single night of titration and about 10-46% of patients discontinued CPAP in a
follow-up period ranged from 2 weeks to 8 years [Engleman and Wild 2003].
Although compliance of CPAP is variable it can be as high as 80-90%. In a
European multi-centre study (n = 121) an "effective compliance" (time spent at
effective pressure > 4 hours per night and > 5 nights per week) to nasal CPAP was
80% at 3 months in patients with severe SDB (AHI > 50) [Pepin et al. 1999]. This
finding is compatible with a study conducted in Asia (n = 296) which showed
compliance to CPAP was 89% at 3 months with average usage of 5.9 hours per night
in patients with AHI of 64.4 ± 34.2 [Sin et al. 2002]. A retrospective study conducted
in the sleep centre in Edinburgh (n = 1,103) revealed the use of CPAP dropped to
around 84% at 12 months and reached a plateau at around 4 years when 68%
continue with treatment [McArdle et al. 1999].
Patients who refused CPAP were more often female, current smokers and
referred by specialists instead of general practitioners [McArdle et al. 1999]. An
initial problem reported at auto-titration was a predictor to good compliance to CPAP
(5.0 hours of CPAP usage in patients with initial problem vs. 2.4 hours in patients
without) [Lewis et al. 2004].
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Intensive support performed by trained sleep nurses incorporating (1) initial
CPAP education in patient's home; (2) additional two night of CPAP titration; (3)
home visits at 7, 14, 28 days and 4 months, in comparison with standard support
(CPAP education, mask fitting in sleep centre and one night of CPAP titration), can
improve compliance of CPAP from 3.8 ± 0.4 hours per night to 5.4 ± 0.3 hours [Hoy
et al. 1999]. In those with randomized controlled trials (RCT) that were under meta¬
analysis in Cochrane review [Haniffa et al. 2004], 24 randomized controlled trials
met the inclusion criteria, 13 of them were parallel and 11 cross-over design. The
results showed most participants preferred auto-CPAP. Although the effect of auto-
CPAP is still unclear there might be a subgroup of patients who respond better to
auto-CPAP than others. Intensive support including home visit and cognitive
behavioural therapy improved compliance to CPAP. Other interventions showed no
significant difference.
1.8.3 Other treatments for obstructive sleep apnoea/hypopnoea
syndrome
1.8.3.1 Conservative treatment
As previously described, obesity is associated with the obstructive sleep
apnoea/hypopnoea syndrome. Obesity increases either or both submental/
peripharyngeal fat which compromises upper airway dimension or abdominal/ chest
wall fat which decreases lung volume and further compromises upper airway
dimension [Strobel and Rosen 1996]. In the Wisconsin Sleep Cohort Study an
increase of body mass index of 1 SD (5.7 kg/m2) is associated with 4-fold increase of
risk of having AHI more than 5 per hour [Young, Palta, Dempsey, Skatrud, Weber,
and Badrl993],
One non-randomised controlled study with a follow-up of 5.3 months showed
significant body weight loss by dietary advice from 106 + 7.3 kg (mean ± SD) to 96.6
± 5.9 kg was associated with a significant decrease of AHI from 55.0 + 7.5 to 29.2 ±
7.1 per hour [Smith et al. 1985] in 15 patients with moderate to severe obstructive
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sleep apnoea/hypopnoea syndrome. There was no significant change in the other 8
patients as weight- and age-matched control. Most of the studies, although in favour
of weight loss for improvement of SDB, have been based on uncontrolled trials.
1.8.3.2 Drug treatment
Several medications have been tried to treat SDB including ventilatory
stimulants (e.g. medrooxyprogesterone acetate) and psychotropic agents (e.g.
protryptyline). According to meta-analysis, there is still no effective drug treatment
for SDB [Magalang and Mador 2003;Smith et al. 2002;Hudgel 1995].
1.8.3.3 Oral appliance
Oral appliances which advance the mandible and thus widen the retroglossal
airway have been shown in randomised controlled trials to be beneficial in snoring
[Stradling et al. 1998] and in SDB to help sleepiness, sleep and blood pressure
[Cistulli et al. 2004;Mehta et al. 2001].
A comparison between CPAP and oral appliance was also conducted in
Edinburgh University. Forty-eight patients with SDB (median AHI = 22/hr)
completed the RCT conducted in Edinburgh to compare the effect of CPAP (n = 24)
with mandibular repositioning splint (MRS, n = 24) [Engleman et al. 2002], Apnoea
hypopnoea index obtained by a home limited sleep study was reduced to 5 or less in
19% of patients on MRS and 34% of patients on CPAP. The mean AHI was 15 ± 16
in CPAP group and 8 ± 6 in MRS group (p = 0.001). Patients' effectiveness
treatment rating, Symptom Score, Epworth Sleepiness Score (ESS), Functional
Outcome of Sleepiness questionnaire (FOSQ), Short Form-36 health survey (SF-36)
mental component and health transition score were also significantly higher in the
CPAP than in MRS group (effect size = 0.34 - 0.57, p < 0.01). Another direct
comparison between oral devices and CPAP also showed better outcomes with
CPAP [Barnes et al. 2004].
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Fourteen randomized controlled trials (n = 553) were included in the meta¬
analysis in Cochrane review with five studies involving oral appliances vs. control
appliances, eight involving oral appliances vs. CPAP and one involving oral
appliances vs. surgery [Lim et al. 2004], Oral appliances were not only better than
control appliances but also better than surgery in reducing AHI and excessive
daytime sleepiness. In comparison with CPAP, although in two small studies,
participants preferred oral appliances to CPAP, CPAP was more effective than oral
appliance in reducing AHI and improving minimal oxygen saturation.
1.8.3.4 Surgery
No published papers fulfilled the criteria in Cochrane review [Bridgman and
Dunn 2000]. The following major problems in the research of surgical intervention
for SDB were proposed: (1) inadequate sample size; (2) only p values without
confidence intervals were presented; (3) not controlled or randomized controlled
trials; (3) follow-up period was as short as 1-2 months [Schechtman et al. 1995],
Surgical treatment of obstructive sleep apnoea/hypopnoea syndrome might either
cause some dangerous complications like mortality or impaired CPAP use after
surgery.
In the practice parameters proposed by the American Academy of Sleep
Medicine [1996], there are only two indications for the surgery of SDB: (1) patients
with underlying specific surgically correctable abnormality that is causing sleep
apnoea including narrow or collapsed retropalatal region and enlarged retrolingual
region; (2) patients for whom other non-invasive treatment have been unsuccessful or
rejected. Although no study was eligible for formal meta-analysis in Cochrane
review, adenotonsillectomy might be helpful in paediatric patients with both




Sleep-disordered breathing (SDB) has diverse influences on psychological and
cognitive functions. Patients who have SDB suffer from sleep fragmentation,
nocturnal hypoxaemia, excessive daytime sleepiness, impaired vigilance, memory,
executive function, depression and poor health-related quality of life. Stroke patients
who have SDB may therefore have decreased motivation to actively participate in
rehabilitation due to sleepiness, emotional or cognitive problems. This might impair
multi-dimensional outcomes including physical recovery, functional capacity,
cognition, mood and health-related quality of life.
The diagnosis of SDB in stroke is more difficult than that in the usual patients
referred to sleep centres. Transport of patients to a sleep centre for overnight
polysomnography can be difficult to arrange, especially at relatively short notice
given waiting times. Thus portable home study or limited sleep study conducted in
the ward seems to be more feasible than full polysomnography for the diagnosis of
SDB in stroke. Although major symptoms and signs of SDB and demographic data
have limited value in the diagnosis of SDB, a prediction model generated from these
variables may play a role as a first line screening tool especially for the physicians
who have little knowledge about SDB. Nasal continuous positive airway pressure
(CPAP) is also considered the first choice of randomized controlled trial for stroke
patients who have SDB. Surgery still has limited evidence, can only be applied on a
highly selected basis and is not suitable for acutely ill patients. Oral appliance is less
effective in comparison with CPAP in moderate to severe SDB.
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Table 1.1 A comparison of in-lab polysomnography and portable
limited sleep study in the diagnosis of SDB
Polysomnography Limited sleep study
Level of evidence by APSS I and II HI and IV
Recording type In-lab Portable
Sleep laboratory space Occupied Saved
Speed of diagnosis Faster Slower
Attendance Yes No
Artefacts of the sensors Less More
Data loss Lower Higher
The 1st night effect Higher Lower
Sleep staging Yes No
Diagnosis of other sleep disorders Yes No
Scoring of SDB AHI (A+H)-h_1
Split-night study Yes No
Cost Higher Lower
Patients' preference Lower Higher
CPAP use Higher Lower
APSS: The Associated Professional Sleep Societies (USA)
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Figure 1.1 Demonstration of respiratory events during sleep
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(c) Hypopnoea followed by mixed type sleep apnoea
Hjj tss is* i*« zfp&i* £«** sj^waw
;08»n «» fi x ;•
*
mn* >




w| ir loi i|| , jj* I f? H





3s is* 3* 3*1 ^ $ v
1 pulse





igj r& s^s %t* *&*« i*m* Mttym mpwu rmfo w&im mk>




























y \ j\j4 i<W»* (S • V','» ft 1X?4 y
\m
~€. SpQ2 _. __ »«««.








. ;S -S J|
II
h4
^|iiiiii^ »» •< « ^3,yiXl±'* %_« :y.zl.i *# * * * vas * ** *j 9 zj> ?■ « til
l 4 IsI.|j*Jwy fx*m'] —yj
I6#if : "Hum %&
36
Chapter 2 Obstructive Sleep Apnoea/Hypopnoea
Syndrome and Cardiovascular Diseases: A Critical Review
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2.1 Introduction
Patients with sleep-disordered breathing (SDB) experience sleep fragmentation
and nocturnal hypoxemia which might result in haemodynamic oscillations and
inflammatory changes of blood vessels. These draw the attention that SDB not only
has an influence on night time and daytime functions but also might be involved in
the initiation and progression of cardiovascular diseases. The cardiovascular systems
are mainly innervated by the autonomic nervous system (ANS). The ANS transmits
impulses from the central nervous system to peripheral organs. The ANS largely
consists of: (1) sympathetic division which is responsible for "flight or fight"; (2)
parasympathetic division which is responsible for "rest and digest". Autonomic
control of heart rate and blood pressure are two major functions related with sleep
and SDB. Several factors have been regarded in the pathogenesis of cardiovascular
diseases:
• Hypertension, diabetes and hyperlipidemia
• Atherosclerosis, thrombosis and coagulopathy
• Genetic and behavioural characters
Two major endpoints of cardiovascular diseases are coronary artery diseases in
terms of angina pectoris and acute myocardial infarction and cerebrovascular diseases
in terms of transient ischaemic attack and stroke.
In the beginning of this chapter I will be reviewing the association of SDB and
risk factors of stroke in terms of hypertension, coronary artery disease, cardiac
arrhythmia, diabetes, atherosclerosis, thrombosis, hypercoagulability, cerebrovascular
reactivity and cerebral blood flow. Then I will be reviewing the possible links
between SDB and stroke related to the hypothesis and studies of my thesis including
diagnosis and epidemiology of SDB in stroke, CPAP treatment for SDB in stroke and
impact of SDB on the outcome of stroke.
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2.2 Baroreflex sensitivity
Baroreflex sensitivity (BRS) is defined as the slope of linear regression of RR
intervals on the electrocardiogram (ECG) versus systolic blood pressure (SBP). The
steeper the slope, the higher the BRS indicating a stronger vagal reflex. The flatter
the slope, the lower the BRS indicating a weaker vagal reflex and a higher
sympathetic reflex. BRS can be studied by the sequence method. For example,
sequences of four or more consecutive beats where both pulse interval and SBP
progressively increased or decreased are identified. BRS is calculated as slope of
each sequence (msec/mmHg). A study showed stroke patients with impaired cardiac
BRS (n = 63) had a significantly higher mortality rate (28% vs. 8%) than those with
normal BRS (n = 61) over a median follow-up period of 1,508 days [Robinson et al.
2003].
An animal model of SDB was performed in three dogs by a permanent side-hole
tracheotomy and monitoring of electroencephalography (EEG), ECG and SBP
[Brooks et al. 1999]. No change of BRS was found 1 to 2 months before induction of
sleep apnoea, during 1 to 3 month of sleep apnoea and during the recovery period of
1 month after cessation of sleep apnoea.
Clinical studies were also performed for BRS. An earlier case-control study
showed both cardiac and muscle sympathetic BRS were depressed in patients with
SDB in comparison with controls [Carlson et al. 1996]. More strict criteria were used
in a later study which recruited 11 normotensive men free of any other diseases, with
newly diagnosed SDB, without medication and never been treated for sleep apnoea
[Narkiewicz et al. 1998]. Baroreceptor activation was induced by phenylephrine
infusion and baroreceptor deactivation was induced by nitroprusside infusion. There
was no significant difference between patients and controls in BRS. The patients with
SDB showed partial response in sympathetic activity (change of muscle sympathetic
nerve activity, MSNA divided by change of mean arterial blood pressure, MAP) to
deactivation of baroreceptor.
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A non-randomized trial showed eight middle-aged obese men with congestive
heart failure and SDB had nocturnal BRS improved on the second night of CPAP
trial [Tkacova et al. 2000]. A similar trial showed BRS decreased in 29 normotensive
patients with SDB in comparison with 11 age-matched normal controls and CPAP
treatment for at least three months in 10 patients with increased BRS [Bonsignore et
al. 2002]. Baroreceptor sensitivity was reduced even in non-apnoeic snorers and this
was corrected by CPAP [Gates et al. 2004]. The heart rate variability can be obtained
by spectral analysis of R-R interval (RRI). The R-R high frequency (HF) component
reflects mostly vagal modulation and the R-R low frequency (LF) component reflects
both sympathetic and vagal modulation [Monti et al. 2002], Another non-randomized
trial focused on heart rate variability showed CPAP treatment increased the high
frequency power of RRI and improved vagal heart rate control in patients with
moderate to severe SDB. Although compliance to CPAP was poor, the degree of
improvement increased with degree of compliance [Khoo et al. 2001].
All previous studies focused on the cardiac arm of the baroreflex. A study
focused on the arm of vascular resistance was conducted [Cooper et al. 2004]. It
showed breathing with an inspiratory resistance reduced the sensitivity of
baroreceptor control for vascular resistance which was calculated as mean arterial
pressure divided by mean blood flow velocity. Asphyxia caused an increased set
point of the baroreceptor-vascular resistance reflex.
The baroreflex activity is involved in the regulation of blood pressure. In
conclusion, the evidence that SDB impairs sympathoinhibitory baroreceptor function
was not consistently supported by an animal model and two cross-sectional clinical
studies although a few non-randomized clinical trials showed baroreceptor sensitivity
can be corrected by CPAP.
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2.3 Hypertension
The normal circadian rhythm of blood pressure resembles a sine-cosine pattern.
The blood pressure reaches the nadir in the early morning before getting up, then has
an early morning surge after getting up. It gradually increases to its peak in the late
afternoon with a small early afternoon dipand then gradually declines through the
evening to reach its nadir. A study classified elderly hypertensive patients into four
groups according to their nocturnal systolic blood pressure (SBP): 97 extreme-
dippers with > 20% SBP decrease; 230 dippers with > 10% but < 20% decrease; 185
non-dippers with > 0% but < 10% decrease and 63 reverse dippers with < 0%
decrease. The results showed non-dippers, extreme dippers and reverse dippers had
higher rate of developing stroke than dippers [Hoshide et al. 2002],
Snoring is a heterogeneous diagnostic entity mostly based on history taking and
questionnaire survey. Most studies about snoring and hypertension were cross-
sectional. The findings were inconsistent after adjusting for confounding factors.
More researches have shifted into the association between hypertension and sleep-
disordered breathing (SDB) instead of snoring alone. The following questions need to
be solved:
• Whether intermittent increased nocturnal blood pressure is a transient
phenomenon restricted to sleep?
• Can it be extended to the morning after getting up?
• Can it cause permanent hypertension?
2.3.1 Animal and cross-sectional studies for SDB and
sympathetic activity
An experimental was performed on rats for the effect of chronic intermittent
hypoxia mimicking SDB on sympathetic activity by intermittently flushing an
exposure chamber with 100% nitrogen for 30 days [Greenberg et al. 1999], A
significantly increased cervical sympathetic activity and mean arterial blood pressure
were noted in hypoxic rats but not in controls. As there was no difference between
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groups in baroreflex the authors concluded the influence of chronic intermittent
hypoxia on sympathetic activity might be through chemoreflex.
Increased arousals from sleep are the major feature of sleep fragmentation in
patients with SDB in comparison with normal subjects [Mathur and Douglas 1995].
Increased arousals not only impair daytime function [Martin et al. 1997] but also
activate sympathetic activity. An experiment recruited 12 healthy non-obese subjects
for concomitant polysomnography and cardiovascular monitoring showed external
stimuli can provoke cardiovascular response mediated by arousals and sympathetic
activation [Trinder et al. 2003]. In comparison with the pre-stimulus state, subjects
demonstrated significantly larger responses for heart rate, systolic blood pressure and
a measure for peripheral vasoconstriction at arousal to either the orienting stimuli or
startle stimuli which had a transient activation without returning to waking state.
An observational study showed there was significantly higher prevalence of
hypertension in sleep-fragmented non-apnoeic snorers (arousal index > 10, n = 50)
than in non-sleep-fragmented non-apnoeic snorers (arousal index < 10, n = 50)
[Lofaso et al. 1996]. Further study in six non-apnoeic snorers showed the magnitude
of increased systolic, diastolic pressure and heart rate following non-apnoeic non-
hypopnoeic events was higher in those with higher grade of arousal defined as longer
duration of EEG frequency changes [Lofaso et al. 1998],
A case-control study for sympathetic nerve activity using direct multiunit
intraneural recordings during wakefulness showed significantly higher sympathetic
burst frequency in patients with SDB (n = 10) than in age- and sex-matched controls
(n = 10) [Somers et al. 1995]. Large oscillations in sympathetic nerve activity and
blood pressure synchronous with the apnoeic episodes during sleep were terminated
by arousal response of electroencephalography and increased muscle activity. Nasal
CPAP treatment in four patients at the same night of recording decreased sympathetic
activity and blood pressure.
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2.3.2 Population-base cohort studies
From mid 1980's to early 1990's, many cross-sectional and case-control studies
were published regarding snoring, SDB and hypertension. There are two major weak
points to these studies: (1) lack of controlling confounding factors especially for age
and obesity; (2) lack of objective measurement of SDB. Two large population-based
prospective cohort studies have been under investigated for SDB and cardiovascular
diseases since early 1990's and some results from cross-sectional analysis have been
published. One is Wisconsin Sleep Cohort Study and another is Sleep Heart Health
Study.
2.3.2.1 Wisconsin Sleep Cohort Study (WSCS)
The aim of the WSCS is prospective investigation of cardiovascular diseases as
an outcome of sleep-disordered breathing. Overnight polysomnography was
performed and blood pressure was measured by standard sphygmomanometer.
Patients were stratified into five groups according to AHI: (1) AHI < 2 (n = 642); (2)
2 < AHI < 5 (n = 191); (3) 5 < AHI < 15 (n = 141); (4) 15 < AHI < 30 (n = 58); (5)
AHI > 30 (n = 37). Multiple linear regression revealed AHI was significantly
associated with systolic and diastolic BP. Sleep-disordered breathing was supported
as a risk factor for hypertension (OR = 1.8 for AHI > 15) with a dose-response linear
relationship between AHI and BP [Young et al. 1997b]. The magnitude was stronger
in the low BMI group.
In total, 709 participants completed follow-up for four years and 184 participants
completed follow-up for eight years [Peppard et al. 2000b]. The odds ratio for the
presence of hypertension in subjects with AHI > 15 at a follow-up for eight years
increased to 2.89 after adjusting for baseline hypertension, nonmodifiable risk factors
and habits. The presence of hypertension in this study group was 34%.
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2.3.2.2 Sleep Heart Health Study (SHHS)
The SHHS is a multi-centre study to determine cardiovascular and other
consequences of sleep-disordered breathing. 5,250 subjects were recruited for
overnight polysomnography [Nieto et al. 2000;Shahar et al. 2001], The first part was
a cross-sectional case-control study. The second part was a prospective cohort study.
The results of first part study showed there was a strong link between SDB and the
prevalence of heart failure (adjusted OR 2.20, CI 1.11-4.37) but weaker links to
coronary artery disease (adjusted OR 1.22, CI 0.93-1.59) and stroke (adjusted OR
1.55, CI 0.96-2.50). When some confounders, including variables related with
hypertension, cigarette smoking and body mass index were removed from the
statistical adjustment for confounders post hoc to avoid "over-adjustment", the odds
ratio increased to 1.27 (CI 0.99-1.62) in coronary artery disease and 1.58 (CI 1.08-
2.46) in stroke. However, the validity of this approach is questionable. The results
can only tell that SDB is an associated factor of congestive heart failure, coronary
artery disease and stroke rather than that SDB might cause CHF, CAD and stroke.
The prospective cohort study will be completed in August 2008 so the result has not
been published yet.
The prediction of SDB is different in older people than in younger adults. The
odds ratio of body mass index for an AHI > 15 decreased with age and became
statistically non-significant at age 80. The odds ratio of self-reported breathing
pauses for an AHI > 15 decreased with age and became statistically non-significant
after age 80 [Young et al. 2002].
2.3.2.3 Other epidemiological evidence
A study recruited 2677 adults (aged 20-85) referred to a sleep clinic for
evaluation of SDB [Lavie et al. 2000]. Hypertension was defined as either taking
anti-hypertensive medication or abnormal readings of blood pressure (> 140/90). The
study also supported SDB significantly contributed to hypertension independent of
all relevant confounders. An increase in 10 in the apnoea/hypopnoea index (AHI)
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increased the risk of having hypertension by about 11%. Each 10% decrease in
oxygen saturation nadir increased the risk of having hypertension by about 13%.
Another study included young and middle-aged subjects (1000 women and 741
men) randomly selected from a community for overnight polysomnography and
blood pressure measurement for hypertension [Bixler et al. 2000]. An independent
association between SDB and hypertension was stronger in young subjects with
normal BMI after adjustment for menopause and hormone replacement therapy.
2.3.3 The effect of CPAP trials on blood pressure
Many early clinical trials for the effect of nasal CPAP on blood pressure control
had some weak points: (1) lack of randomized control design; (2) limited sample
size. (3) lack of objective report of compliance of CPAP;
Ambulatory blood pressure monitoring is a better predictor for cardiovascular
diseases than casual blood pressure measurement. Higher mean systolic blood
pressure (SBP) and diastolic blood pressure (DBP) are associated with increased
relative risk of cardiovascular diseases [Clement et al. 2003]. Hypertensive patients
with higher nocturnal blood pressure (non-dippers, i.e. < 10% lower than daytime
mean blood pressure) may have a worse prognosis than dippers [Verdecchia et al.
1994].
Non-dippers were common in patients with SDB [Akashiba et al. 1999;Davies et
al. 2000]. Ambulatory blood pressure was measured in 38 patients with SDB (AHI =
54 ± 11) before and after CPAP treatment for three days [Akashiba et al. 1999]. The
average daytime and night time blood pressure decreased significantly after CPAP
treatment. Fifteen of 22 patients who were non-dippers before treatment reversed to
become dippers. The results were based on a non-randomized uncontrolled trial.
A small randomized controlled cross-over trial of nasal CPAP did not show any
effect of CPAP on systolic, diastolic and mean ambulatory blood pressure but the
sample size (n = 13) was too small (power 65-95%) to draw any firm conclusions
[Engleman et al. 1996b]. The effect of four weeks of CPAP on blood pressure in
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normotensive patients with SDB was further evaluated by the same research group
[Faccenda et al. 2001]. Sixty-eight patients completed the trial (median AHI = 35).
Ambulatory blood pressure monitoring (ABPM) was used. Although there was no
change in systolic blood pressure there was a 1.5-mmHg reduction of diastolic blood
pressure in the overall patients on CPAP therapy. In an a priori determined group
with more marked nocturnal hypoxaemia, there were significant falls in both systolic
(4mmHg) and diastolic (5mmHg) pressure. This is clinically meaningful as 5-mmHg
decrease in diastolic blood pressure results in 32% decrease in stroke and 21%
decrease in coronary artery disease [MacMahon et al. 1990]. The effect of CPAP was
independent of baseline blood pressure and more prominent in patients taking
antihypertensive medications [Pepperell et al. 2002].
2.3.4 Conclusions
Hypertension is the most powerful stroke risk factor. In my reviews, evidence
which support the link between SDB and hypertension is stronger. They are mainly
based on the cross-sectional parts of two large-scaled prospective cohort studies,
WSCS and SHHS after adjusting for confounding factors. Further evidence from
final results of a time-consuming longitudinal follow-up is expected.
More promising findings are based on several well-designed randomized
controlled trials which definitely support the benefits of CPAP treatment in reducing
blood pressure.
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2.4 Coronary artery disease
2.4.1 Concomitant sleep and Holter monitoring
Overnight polysomnography, Holter motoring and blood pressure measurement
every 30 minutes was performed in 51 patients suffering from coronary artery disease
(CAD) and SDB in comparison with 17 controls [Peled et al. 1999], Nocturnal ST-
segment depressions occurred during the rebreathing phase of the obstructive
apnoeas. Treatment with CPAP significantly decreased ST-segment depression time
from 78 to 33 minutes and double product value (systolic blood pressure x heart rate)
from 14,137 ± 2,827 to 12,083 ± 2,933.
A similar study with concomitant overnight limited sleep study and Holter
motoring was performed in 219 patients (127 men and 92 women) [Mooe et al.
2000]. Although there was no difference in oxygen desaturation index (ODI) and
AHI between patients with and without nocturnal ST-segment depressions, ST-
segment depression occurred within 2 minutes after an apnoea-hypopnoea or
desaturation in 12% of patients. Most of these ST-segment depressions were
preceded by a series of breathing events.
2.4.2 Cross-sectional studies
A case-control study recruited 289 patients for the evaluation of CAD [Schafer et
al. 1999]. All patients had coronary angiography and 209 patients had overnight
limited sleep studies. The obstructive sleep apnoea/hypopnoea was found in 30.5% of
CAD patients but only in 19.7% of controls. Patients with CAD (n = 223) had
significantly higher AHIs than patients without CAD (n = 66). Logistic regression
analysis revealed sleep apnoea/hypopnoea defined as AHI > 20 and hyperlipidemia
were both independent risk factors associated with CAD.
Another case-control study recruited 62 CAD patients and 62 age-matched
controls for overnight polysomnography [Peker et al. 1999]. Obstructive sleep
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apnoea/hypopnoea defined as AHI > 10) was noted in 19 CAD patients but only in 8
controls. The CAD group had significantly higher AHI than control group. Logistic
regression analysis showed current smoking, diabetes mellitus and SDB were
independently associated with CAD.
2.4.3 Prospective cohort studies
A prospective cohort study with 392 CAD patients (264 men and 128 women)
who completed overnight limited sleep studies entered a longitudinal follow-up for a
median period of 5.1 years [Mooe et al. 2001]. The risk ratio of combined
cardiovascular events and death in patients with AHI > 10 was 1.62. Among them the
risk ratio of cerebrovascular disease was higher (3.41) than for myocardial infarction
which was not significantly raised (1.02). An oxygen desaturation index (ODI) of >
or = 5 and an AHI of > or = 10 were both independently associated with
cerebrovascular events (hazard ratio 2.62, 95% CI 1.26-5.46, p = 0.01, and hazard
ratio 2.98, 95% CI 1.43-6.20, p = 0.004, respectively).
A 7-year follow-up was conducted on 182 middle-aged patients who were
referred to a sleep centre for the diagnosis of SDB [Peker et al. 2002]. Patients were
divided into two groups on the basis of the results of their overnight limited sleep
studies: those with an overnight total ODI > 30 being defined as having sleep apnoea/
hypopnoea (n = 60) and those with ODI < 30 non- sleep apnoea/ hypopnoea (n =
122). The incidence of at least one cardiovascular disease (hypertension, angina
pectoris, myocardial infarction, stroke or cardiovascular death) was significantly
higher in patients with ODI > 30 (36.7%) in comparison with those below (6.6%).
Multiple logistic regression showed SDB at baseline (apnoea index > 5) was an
independent predictor for cardiovascular diseases but efficient treatment (ODI < 30
after treatment) was associated with significant reduction of cardiovascular
incidence. The bias was CPAP, oral appliance or uvulopalatopharyngoplasty (UPPP)
was given depending on the clinical situation. Patients with OD > 30 were
completely or partially treated so might not reflect the natural course of SDB.
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2.4.4 Clinical trial of CPAP for SDB in CAD
Fifty-four patients with both CAD and SDB were recruited in a study for non¬
randomized treatment with either CPAP (n = 25) or upper airway surgery (n = 29)
[Milleron et al. 2004]. Median of follow-up was 86 months in the treatment group
and 90 months in the decline group. At least one cardiovascular event occurred
during follow-up in 24% of the treatment group but in 58% of the decline group (p <
0.01).
2.4.5 Conclusions
Coronary artery disease and stroke share common pathogenesis. In my reviews,
the influence of SDB on electrocardiogram (ECG) is shown by some observational
studies and a non-randomized trial. There was a few evidence to support the link
between SDB and coronary artery disease from case-control studies. Stronger
evidence from two prospective cohort studies showed that SDB was an independent
risk factor for cardiovascular diseases but not coronary artery disease alone.
Randomized controlled trials are needed to support the benefit of CPAP treatment in
reducing coronary artery or cardiovascular diseases.
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2.5 Atrial fibrillation
A prospective cohort study with one year of follow-up was performed to
investigate obstructive sleep apnoea and recurrent atrial fibrillation. Among patients
with atrial fibrillation/atrial flutter who were referred for electrical cardioversion 43
patients were identified as having a formal sleep study resulting in the diagnosis of
obstructive sleep apnoea [Kanagala et al. 2003]. Seventy-nine postcardioversion
patients who did not have obstructive sleep apnoea were randomly selected as
control. Both the questionnaire and phone interview were performed at 12 months.
Patients were considered to have recurrence of AF only if a physician had
documented them to be in AF by either clinical or ECG examination. Follow-up was
completed in 39 of 43 patients. Twenty-seven of 39 patients either did not receive
CPAP treatment or used CPAP inappropriately. Recurrence of AF was significantly
higher in these 27 patients (82%) in comparison with CPAP-treated (42%, p = 0.013)
and control group (53%, p = 0.009).
A further case-control study was performed by the same group. They recruited
151 consecutive patients with AF and 312 controls without past or current AF from
general cardiology practice. Obstructive sleep apnoea was diagnosed by validated
Berlin questionnaire. The results showed that the prevalence of SDB obstructive
sleep apnoea was significantly higher in AF (49%) than in control (32%) group (p =
0.0004) [Garni et al. 2004], In multivariate analysis, body mass index, neck
circumference, hypertension, diabetes and AF remained significantly associated with
obstructive sleep apnoea and the odds ratio was largest for AF (2.19, 95% CI = 1.40-
3.42, p = 0.0006).
On the contrary a recent prospective cohort study did not show the association
between SDB and AF [Roche et al. 2003]. One hundred and forty-seven patients
were recruited for time-synchronized polysomnography and ECG Holter monitoring.
Although nocturnal paroxysmal asystole (10.6% vs. 1.2%, p < 0.02) and bradycardia
(18.2% vs. 4.9%, p < 0.01) were more prevalent in patients with SDB increased risk
of atrial and ventricular fibrillation was not found. A similar finding was found in
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another case-control study. A limited sleep study was performed for 59 patients with
lone atrial fibrillation defined as atrial fibrillation without known causes and 56 age-,
sex- and cardiovascular morbidity-matched community controls [Porthan et al.
2004]. There was no significant difference of percentage of mild, moderate and
severe SDB between patient and control groups.
Atrial fibrillation is one of the major risk factors for stroke, particularly embolic
brain infarction. In conclusion, the association between SDB and AF is supported by
a prospective cohort study which showed patients with SDB had a higher recurrence
rate of AF. The shortcoming of this study is that they did not perform a randomized
controlled trial of CPAP for SDB in patients with AF. Some other case-control
studies including a study with a well-matched control did not support the association




More attention has been paid to the link between SDB and glucose intolerance,
insulin resistance and diabetes recently. Diabetes, like hypertension, shares some
confounders with SDB such as obesity and ageing.
A cross-sectional observational study was performed to investigate whether SDB
is an underlying cause of diabetes or glucose intolerance [Meslier et al. 2003]. In
total, 494 of 595 patients who had both polysomnography and 2-hour oral glucose
tolerance test (OGTT) had an SDB defined as AHI >10. After adjusting for age and
BMI, AHI was still significantly correlated with post-loading glucose level in OGTT
and insulin sensitivity evaluated by the ratio of fasting glucose to fasting insulin. The
authors drew a conclusion that SDB is an independent risk factor of glucose
intolerance which is usually an initial presentation of diabetes mellitus.
The above conclusion was only weakly supported by the cross-sectional results
from the Sleep Heart Health Study with similar methodology. In the first instance,
data generated from 4972 community-based subjects who had no cardiovascular risks
were published [Resnick et al. 2003]. Although significantly more diabetic subjects
(23.8%) had AHI > 15 than non-diabetic subjects (15.6%), there was no clear
association between SDB and diabetes after adjusting for confounders including age,
sex, BMI, race and neck circumference. Further analysis showed adjusted odds ratio
of fasting glucose intolerance was 1.27 (95% CI = 0.98 - 1.64 ) in subjects with mild
SDB (AHI = 5-14.9) and 1.46 (95% CI = 1.09 - 1.97, AHI > 15) in subjects with
moderate to severe SDB in comparison with those with AHI < 5 [Punjabi et al.
2004],
A non-randomized trial was performed for the effect of CPAP treatment on
insulin sensitivity. Forty patients (mean age 54 year-old) with SDB (mean AHI =
43.10 + 11.38) received CPAP treatment for three months [Harsch et al. 2004],
Improved insulin sensitivity index calculated from the insulin measurements and the
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corresponding glucose infusion rates during that period was found after 2 days and 3
months of CPAP treatment in comparison with baseline data (p < 0.001).
Diabetes, like hypertension, is a major cause of stroke. In conclusion, the
evidence which showed association between SDB and either insulin sensitivity or
diabetes is based on cross-sectional studies. It needs to be clarified whether SDB is
just a confounding factor for or independently associated with diabetes because SDB
was no longer an independent risk factor after adjusting for other confounders in the
observational part of Sleep Heart Health Study. The clinical trial of CPAP in this
review was biased as it was not a RCT.
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2.7 Atherosclerosis
There are many causes of atherosclerosis including hypertension, diabetes,
hyperlipidemia, cigarette smoking, elevated plasma homocysteine, infection, genetic
factors and oxidative stress. Atherosclerosis is the major cause of ischaemic stroke,
especially thrombotic stroke. One of the theories of atherosclerosis, the "response-to-
injury" hypothesis was first published in 1973 which emphasized the chronic
inflammatory process underlying atherosclerosis [Tegos et al. 2001].
A simple evidence of atherosclerosis was found by carotid duplex
ultrasonography performed in 23 male patients with severe SDB (AHI > 30 by
overnight limited sleep study) and controls matched by age, BMI and vascular risk
profiles [Silvestrini et al. 2002]. The study showed significant higher (P < 0.0001)
intima-media thickness (IMT) value of common carotid artery in the apnoeic group
(1.43 ± 0.34 mm) in comparison with control (0.98 ± 0.17 mm). This study could not
completely rule out the possibility that the difference in IMT could be explained by
an imperfect comparison of severity and duration of exposure of vascular risk factors.
2.7.1 Cell adhesion molecules
Adhesion molecules are produced in both endothelial cells and leukocytes
including intercellular adhesion molecules-1 (ICAM-1), vascular cell adhesion
molecules-1 (VCAM-1), L-selectin and E-selectin. Adhesion molecules increased
due to endothelial activation and dysfunction which might result from hypoxia or
oxidative stress in patients with SDB [Ohga et al. 1999]. Another study revealed that
soluble E-selectin and VCAM-1 decreased after CPAP treatment for 3-4 days and
ICAM-1 decreased after CPAP treatment for 6 months [Chin et al. 2000] but there
was no control group.
The expressions of cellular phenotypes of two adhesion molecules in peripheral
whole blood monocytes and granulocytes, CD15 and CDllc, were also increased in
patients with SDB [Dyugovskaya et al. 2002]. The percentage of CD15 (n = 8) and
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CD11c (n = 8) monocytes was significantly decreased after CPAP treatment for more
than 6 months, again with no control group.
2.7.2 Nitric oxide (NO)
Nitric oxide (NO) is continuously released from arterial and arteriolar
endothelium and is one of the most important vasodilators of small arteries and
arterioles. Deficiency of NO is thought to be involved in the pathogenesis of
atherosclerosis [Vallance and Collier 1994].
The serum level of NO was significantly lower in patients with SDB (AHI > 20,
n = 30) in comparison with controls (n = 40) and there was a significant negative
correlation between NO and AHI, and systolic blood pressure [Ip et al. 2000]. There
was a significant increase in NO after one night (n = 22) [Ip, Lam, Chan, Zheng,
Tsang, Fung, and Lam2000] or two nights (n = 21) of CPAP treatment and remained
constant at 5.5 months of follow-up [Schulz et al. 2000]. Nocturnal oxygen (1-2
1/min) via nasal prongs for one week can increase serum NO level in patients with
SDB (n = 24) in comparison with controls (n = 24) [Teramoto el al. 2003a].
2.7.3 Homocysteine
Homocysteine is auto-oxidized into hydrogen peroxide with accompanying free
radicals. The role of homocysteine in atherosclerosis is mainly in impairing
endothelial function, promoting migration of smooth muscle spindle cells and
enhanced platelet aggregation. Excessive homocysteine is usually neutralized by NO.
In patients with SDB, NO is reduced so homocysteine is increased.
Plasma homocysteine level was not different between patients with OSAH (AHI
> 20) and controls in one study [Svatikova et al. 2004] but was significantly higher in
patients with both ischaemic heart disease and SDB than control group, SDB-only
group and CAD-only group in another study [Lavie et al. 2001]. It remained
statistically significant after adjustment of covariates including age, BMI, creatinine
level, and diabetes.
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Treatment with CPAP can effectively lower plasma homocysteine level in a
small (n = 16) non-RCT study [Jordan et al. 2004].
2.7.4 Cytokines
Cytokines are systemic markers of inflammation which can be increased by
damage of endothelial and vascular smooth muscle cells due to oxidative stress in
SDB. Significantly higher concentration of interleukin-6 collected from expired
breath condense was found in patients with SDB (AHI > 20, n = 18) in comparison
with subjects with obesity (n = 10) and controls (n = 15) [Carpagnano et al. 2002],
2.7.5 Acute phase protein
Inflammation appears to play a major role in the pathogenesis of atherosclerosis.
C-reactive protein (CRP) has been associated with progression of CAD [Teramoto et
al. 2003b].
In the Cardiovascular Health Study (CHS), observational data from 5417 elderly
(> 65 year-old) under longitudinal follow-up for a median of 10.2 years were
analyzed [Cao et al. 2003]. In comparison with the 1st quartile of CRP, the adjusted
hazard ratios of stroke for the 2nd, 3rd and 4th quartiles of CRP were 1.19 (95% CI =
0.92 - 1.53), 1.05 (95% CI = 0.81 - 1.37) and 1.60 (95% CI = 1.23 - 2.08)
respectively. After additional adjustment for carotid intima media thickening (IMT)
the hazard ratio of the 4th quartile of CRP in comparison with the Is' quartile was still
significant (1.52, 95% CI = 1.16 - 1.98).
A case-control study compared patients with moderate to severe obstructive
sleep apnoea/hypopnoea (AHI > 20, n = 22) with controls (n = 20) [Shamsuzzaman
et al. 2002], Plasma CRP level was significantly higher in OSAH group (median =
0.33) than control (median = 0.09) by non-parametric test as distribution of CRP data
was skewed to the right. CRP was positively and independently associated with
severity of OSAH.
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Another study showed plasma level of CRP and interleukin (IL)-6 was
significantly higher in patients with moderate to severe OSAHS (AHI > 20) than in
patients with mild OSAHS (5 < AHI < 20) and obese controls [Yokoe et al. 2003].
Treatment with CPAP for one month in the randomized controlled trial for patients
with moderate to severe OSAHS significantly decreased AHI, increased lowest
Sa02, decreased percentage of time with Sa02 < 90% and decreased Epworth
Sleepiness Score.
2.7.6 Conclusions
Atherosclerosis is the most important pathogenesis for thrombotic brain
infarction. The studies which supported increased atherosclerosis-aggravating
biochemical markers and decreased atherosclerosis-alleviating markers in patients
with SDB were based on either observational or case-control design. The clinical
trials of CPAP were non-randomized although the results showed CPAP can decrease
cell adhesion molecules, homocysteine and CRP. It will be interesting to perform
further carotid duplex ultrasonography study which takes severity and duration of
exposure to vascular risk factors into account.
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2.8 Thrombosis and hypercoagulability
The role of SDB in the pathogenesis of thrombosis and hypercoagulability are
discussed in the following sections. Main findings in patients with SDB were:
• Increased in vivo and in vitro platelet activation and aggregation and
decreased after CPAP treatment
• Increased whole blood viscosity
• Increased fibrinogen level and decreased after CPAP treatment
• Hypercoagulability state by increased Willebrand factor antigen
2.8.1 Platelet activity
A few "in vitro" studies of platelet activity have been published. Platelet
activation, measured by monoclonal antibodies to P-selectin, and aggregation,
measured by proportion of platelets larger than resting platelets through light
scattered method, were compared in six patients with SDB (AHI = 87.2 ± 23.2) and
five controls who had no or mild SDB [Bokinsky et al. 1995]. Patients with SDB
were given CPAP for one night. Percentage of activated and aggregated platelets was
significantly higher in the baseline study night than in the CPAP night and controls.
A similar study also found P-selectin expression before polysomnography,
epinephrine level after PSG and blood pressure before and after PSG was
significantly correlated with AHI in 64 patients from normal to severe SDB
[Eisensehr et al. 1998]. Platelet aggregation to epinephrine, collagen, arachidonic
acid and adenosine diphosphate was also studied "in vitro" [Sanner et al. 2000].
Platelet aggregation in response to epinephrine was significantly higher in patients
with SDB (n = 17) than in controls (n = 15) and was significantly lowered by CPAP
therapy.
As "in vitro" studies could be influenced because platelet activity might be
activated through blood drawn from a catheter, an "in vivo" assessment was
performed [Geiser et al. 2002], The results showed patients with SDB (n = 12) had
an increased percentage of platelets positive for the activation-dependent epitopes
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CD63 and CD62P during sleep in comparison with controls (n = 6). The amount of
CD63- and CD62P-positive platelets in patients with SDB was significantly higher at
4 a.m. (during sleep) compared to 7 a.m. (after sleep) in the morning.
2.8.2 Whole blood viscosity
Variation of whole blood viscosity (WBV) was strongly influenced by
haematocrit (Hct). WBV-Hct normalized ratio was calculated in 12 patients with
SDB and 8 controls [Nobili et al. 2000]. The results showed significantly higher
ratios in the morning than in the evening only in patients with SDB.
Another similar study did not show any difference of WBV but significantly
higher plasma viscosity and fibrinogen level in the morning in 13 patients with SDB
in comparison with 8 controls [Reinhart et al. 2002].
2.8.3 Fibrinogen
Fibrinogen is a protein synthesized by the liver. Fibrinogen is broken down by
thrombin to form fibrin which helps with formation of blood clot. Fibrinogen and
factor VII clotting activity are independent predictors for cardiovascular mortality
including recurrent ischaemic stroke [Rothwell et al. 2004].
Overnight polysomnography was performed and blood was drawn for fibrinogen
level in a stroke rehabilitation ward about 1 month following stroke [Wessendorf et
al. 2000]. Final analysis was performed on 113 patients after excluding those with
evidence of underlying inflammatory diseases or central sleep apnoea. Plasma
fibrinogen level was positively correlated with increased AHI and negatively
correlated with oxygen saturation. Stepwise multiple regression analysis showed
average oxygen saturation and gender were independently associated with fibrinogen
level.
Fibrinolytic activity was assessed by the level of tissue plasminogen activator
(tPA) and plasminogen activation inhibitor (PAI-1) in 13 patients with SDB (mean
AHI = 32) and 10 male controls [Rangemark el al. 1995]. Eleven of 13 apnoeic
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patients were also hypertensive. The results showed significantly increased PAI-1 in
patients with SDB after adjustment of age, BMI and diastolic blood pressure as
hypertension is a confounder for elevated PAI-1.
In a small-sampled (n = 11) and non-randomized controlled trial, fibrinogen and
whole blood viscosity significantly decreased after CPAP treatment [Chin et al.
1996]. A further study by the same research group with similar design (n = 15)
showed factor VIIc level significantly decreased after 6 months of CPAP treatment
[Chin et al. 1998],
2.8.4 Coagulopathy
Three markers of hypercoagulability (1) thrombin/antithrombin III complex; (2)
fibrin D-dimer and (3) Willebrand factor antigen [von Kanel et al. 2001] were
studied in normotensive non-apnoeic (n = 19), normotensive apnoeic (n = 38),
hypertensive non-apnoeic (n = 11) and hypertensive apnoeic (n = 19) patients. There
was a significant main effect for hypertension but no significant main effect for
apnoea or interaction of hypertension and apnoea on either thrombin/antithrombin III
complex or fibrin D-dimer. There was no significant main effect for both
hypertension and apnoea but a significant interaction of hypertension and apnoea on
Willebrand factor antigen.
2.8.5 Conclusions
Thrombosis and hypercoagulability are two direct causes of ischaemic stroke but
their association with SDB is still not clear. The sample size of the studies for platelet
function was small. The studies about whole blood viscosity had inconsistent
findings. The results of cross-sectional studies for the link between SDB and
fibrinogen and fibrinolytic activity showed oxygen saturation but not AHI was
significantly associated with plasma fibrinogen level after adjusting for confounding
factors. No significant influence of SDB alone on coagulating factors was found. The
CPAP trials for platelet activity, blood viscosity and fibrinogen level were not RCT.
60
2.9 Cerebrovascular reactivity and cerebral blood flow in SDB
SDB not only has influence on physiological and biological markers of
cardiovascular diseases described above but also has direct central haemodynamic
effect.
2.9.1 Cerebrovascular reactivity
A case control study recruited eight consecutive men with SDB (mean oxygen
desaturation index, ODI = 65.6 ± 25.5) and eight controls (mean ODI = 5 + 3.1)
matched for the age and presence of hypertension and smoking for cerebrovascular
reactivity to hypercapnia, which was calculated by breathing holding index (BHI) by
means of Transcranial Dopper (TCD) [Placidi et al. 1998]. A significantly lower BHI
to hypercapnia was found in normocapnic SDB patients in comparison with controls
in the morning following nocturnal sleep. Decreased morning cerebrovacular
reactivity to hypercapnia could contribute to most strokes happening in the morning
[Qureshi et al. 1999].
2.9.2 Cerebral flood flow
The cerebral blood flow (CBF) in normal NREM sleep remains constant and
there is increased CBF in REM sleep especially in the visual cortex which is thought
to be associated with the dreaming state. The influence of SDB on cerebral blood
flow was variable. Studies were biased as there was no direct measure of CBF but
measure of cerebral blood flow velocity (CBFV) by Transcranial Doppler (TCD).
A study showed increased CBFV during apnoeic episodes [Klingelhofer et al.
1992]. Further study performed by the same group showed patients with SDB had
lower CBFV in NREM sleep through stage II to IV but higher CBFV in REM sleep
[Hajak et al. 1996]. This means that patients with SDB might have fast and profound
nocturnal CBF fluctuation. It is interpreted by increased partial pressure of end-tidal
carbon dioxide (ETC02) and sensitivity of C02 or PH receptors in the brain.
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However, the fall of CBFV upon termination of the apnoea was so abrupt that
arousals and neuronal activation were the most likely explanation.
On the contrary, decreased CBFV was also reported in patients with SDB during
awake and all sleep stages in association with apnoeic or hypopnoeic episodes
[Fischer et al. 1992]. Another study supported decreased CBFV especially during
prolonged apnoeic episodes. It showed changes of CBFV were associated with
changes of mean arterial pressure in the same direction so arterial blood pressure
could be a major factor for CBF [Balfors and Franklin 1994]. CBFV dropped below
baseline level after termination of apnoea episodes before coming back to normal and
this drop could contribute to the pathogenesis of cerebral infarction.
There was a direct relationship between individual apnoeas and reduction of
middle cerebral artery (MCA) CBFV in association with longer events and the more
severe desaturation of obstructive sleep apnoeas or hypopnoeas instead of central
ones [Netzer et al. 1998]. Intracranial pressure (ICP) is increased during sleep
especially in sleep apnoea which is associated with increased arterial pressure and
central venous pressure near the end of sleep apnoea [Jennum and Borgesen 1989].
Increased ICP further decreased cerebral perfusion and reduced CBF. All these could
predispose to cerebral infarction.
2.9.3 The haemodynamic aspect of CPAP treatment
Studies dealing with the effect of CPAP on cardiac output and cerebral blood
flow also led to variable results. I draw figure 2.1 (P. 88) to illustrate the
haemodaynamic interaction between CPAP, SDB and cerebrovascular system based
on literature review.
The haemodynamic effect of CPAP on the heart depends on cardiac function. A
normal heart is "preload" sensitive but a failing heart becomes "afterload" sensitive.
This can explain the reason why CPAP might reduce cardiac output on the normal
heart but can be used to treat congestive heart failure (CHF). CPAP improves cardiac
output through enhancing contractility in patients with CHF [Genovese et al. 1995].
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CPAP is also effective in improving cardiac output in patients with concomitant CHF
and SDB through abolition of SDB, associated sympathetic hyperactivity and
systemic hypertension [Kaneko et al. 2003a;Mansfield et al. 2004]. On the contrary,
the haemodynamic effect of CPAP on the normal heart is either neutral or negative.
A study using Doppler echocardiography for normal subjects and sleep apnoea
patients found there was no negative effect with increased CPAP pressure (0-15 cm
H20) on heart rate, pulmonary arterial pressure, ventricular size and cardiac index
[Leech and Ascah 1991]. The other study using oesophageal catheter to detect
intrathoracic pressure and an arterial line to detect Sa02, transmural pulmonary
pressure and transmural atrial pressure found both CPAP and bilevel positive airway
pressure decreased cardiac index [Becker et al. 1995].
CPAP can normalize cerebrovascular reactivity in patients with SDB [Diomedi
et al. 1998] but only a few studies have been published about the effect of CPAP on
CBF. One study revealed CBFV was decreased rather than increased with
incremental levels of CPAP pressure in normal adults [Scala et al. 2003], The
authors found study subjects had concomitant hypocapnia so they proposed that
hyperventilation induced by anxiety when they were wearing CPAP might be the
major cause of decreased CBF. From the other point of view, CPAP increases
intrathoracic pressure and decreases venous return to heart. This may result in
increased intracranial pressure (IICP) and decreased CBF according to the formula:
Cerebral perfusion pressure (CPP) = Mean arterial pressure (MAP) - Intracranial
pressure (ICP).
A normal cerebrovascular system has autoregulation by means of vasodilatation
in response to decreased CBF and vasoconstriction in response to increased CBF.
The study conducted by Scala et al. reminds us that even though autoregulation is
intact, decreased CBF may still happen when autoregulation cannot respond to rapid
haemodynamic change. This is even more important when we apply CPAP to stroke
patients who have had a damaged brain and impaired autoregulation.
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Although TCD measures cerebral blood flow velocity (CBFV), TCD is only a
surrogate measure of cerebral blood flow (CBF). In summary, CPAP can improve
quality and quantity of blood supply to the brain through normalizing Sa02 and
improving cerebrovascular reactivity. But, CPAP might decrease CBF through
decreasing systemic blood pressure and cardiac output. The net effect of CPAP on
CBF also depends on function and response rate of autoregulation in the brain.
2.9.4 Conclusions
All clinical studies about SDB and CBF were indirect as the true measurement
was CBFV measured by Transcranial Doppler (TCD). Some studies showed
decreased CBFV during apnoeic or hypopnoeic episodes which might predispose
ischaemic stroke but other studies, on the contrary, showed increased CBFV which
might have protective effect. The studies about the effect of CPAP treatment on
CBFV also varied. Although CPAP can normalize cerebrovascular reactivity in
patients with SDB one study showed CPAP might be harmful for patients with stroke
as it decreased CBFV in normal volunteers.
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2.10 Sleep-disordered breathing after Stroke
One major problem with interpretation that SDB causes a stroke is trying to
disentangle the effect of the stroke itself on the development of SDB. Two models
may help with clarifying this issue. One is to deal with pre-stroke snoring as this may
reflect pre-stroke obstructive sleep apnoea and hypopnoea. This will be reviewed in
chapter 2.10.1. Another is to use TIA population as there is no neurological sequela
in this group of patients. This will be reviewed in chapter 2.10.2.
2.10.1 Snoring as a risk factor for stroke
A few large-scaled cross-sectional case-control studies have reported the
association between snoring and stroke. The odds ratio for stroke in patients with
snoring was mildly but significantly increased. It ranged from 2.1 (177 patients with
cerebral infarction and 177 controls) [Palomaki 1991], 2.2 (300 patients with
vascular diseases including stroke and 330 controls) [Smirne et al. 1993], 3.2 (326
patients with stroke and 345 controls) [Spriggs et al. 1992] to 3.4 (133 patients with
cerebral infarction and 133 controls) [Neau et al. 1995]. They were still biased in the
following points:
• They recruited patients with previous stroke.
• They used questionable control group including (1) controls from patients
with non-vascular disease; (2) patients from the other hospitals; (3) not an
age- and sex-matched control.
• Recall bias
• Incomplete control for confounding factors
A matched case-control study was subsequently performed by the research group
in the University of Newcastle [Davies et al. 2003]. Patients with first-ever stroke
and community control subjects matched individually for age, gender and source
(general practitioner) were recruited. A structured questionnaire was used to identify
snoring, daytime sleepiness and stroke risk factors. The results showed that there was
no significant difference of reported snoring between stroke patients and control
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subjects with an odds ratio of 1.44 (96% = 0.88-2.41, p = 0.15). However, daytime
sleepiness was significantly associated with stroke which might reflect the
relationship between SDB and stroke.
A prospective cohort study showed a higher stroke incidence in snorers (28 out
of 302 snorers) than in non-snorers (21 out of 396 non-snorers) during the 6-year
follow-up period [Jennum et al. 1994], The odds ratio was 1.82 (95% CI = 1.09-3.64,
p < 0.05). After adjusting for confounding factors by a Cox regression model, snoring
was no longer an independent risk factor for stroke with a relative risk of 1.26 (95%
CI = 0.70-2.29, p = 0.42).
The above two studies with better methodology than previous publications tell us
that simple snoring may not be an independent risk factor for stroke.
2.10.2 Prevalence of SDB after stroke
In the past decade, more attention has been paid to the link between SDB and
hypertension since cross-sectional parts of large population-based cohort studies have
been published. Sleep Heart Health Study (SHHS) with large sample size (n > 1000)
found that increased apnoea/hypopnoea index (AHI) and percentage of time with
oxyhaemoglobin saturation (Sa02) < 90% were associated with increased risk of
hypertension after adjusting for confounding factors [Nieto et al. 2000]. Although
they also found that the association between SDB and stroke was stronger than SDB
and coronary heart disease (CAD), the relative odds ratio of the highest quartile of
AHI in predicting stroke was not high (1.58, CI 1.02-2.46) [Shahar et al. 2001]. The
shortcoming is that they used self-reported history of stroke only.
High prevalence of SDB after stroke and transient ischaemic attack (TIA) was
reported in four cross-sectional studies with or without controls. They are
summarized and compared (Table 2.1, P. 85). The sample size, definitions of SDB
and stroke in these studies varied. The first study with full PSG, detailed clinical
stroke assessment and sufficient power (n = 128) found that the prevalence of SDB in
TIA was similar to that in stroke. This led to the conclusion that SDB could be a
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cause rather than a consequence of stroke [Bassetti and Aldrich 1999b]. The second
study with similar methodology and power (n = 161) further supported this concept
by conducting a longitudinal follow-up from the acute phase to the stable phase of
stroke and showing that obstructive sleep apnoea remained little changed while
central sleep apnoea became less frequent during the course of either infarction or
haemorrhage [Parra et al. 2000;Harbison et al. 2002b]. The third study also showed
decline of AHI during the course of stroke without further clarification of the
difference between obstructive and central events [Harbison et al. 2002b].
There had been no strong objection to the link between SDB and cerebrovascular
diseases until the fourth study, a individually matched case-control TLA. study, was
published with competitive methodology which showed no significant difference of
AHI (21/hour) between TLA and a matched control group from the community
[McArdle et al. 2003]. Although this was a well designed study with sufficient power
(n = 86 pairs), there are still some controversial points as they acknowledged: (1)
There is a recall bias because TLA is a diagnosis based on history only; (2) There is a
selection bias because the TLA patients who declined could have less SDB symptoms
and on the contrary, the controls who attended could have more SDB symptoms; (3)
Cerebrovascular diseases comprise a spectrum of heterogeneous entities and TLA can
not stand for all of them. Thus further evidence is still needed to either support or
refute previous hypotheses and findings.
2.10.3 Screening of SDB in stroke
Prediction models of SDB in the general population, which have been reviewed
in chapter 1 could help in the screening of SDB. Prediction models of SDB in stroke
patients might be more helpful as it is more difficult to perform sleep studies for
patients with acute or subacute stroke. A study applied a structural SDB
questionnaire to stroke patients with a standardized score and cut-off point, which
has been shown to have good sensitivity and specificity (> 80%) to predict SDB in
non-stroke subjects based on the diagnosis of PSG [Bassetti and Aldrichl999b], It
concluded that the diagnostic accuracy of questionnaire-based predictive models in
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stroke was low. It is still convenient for first-line physicians if a similar prediction
model can be used as a screening rather than a diagnostic tool for SDB in stroke,
before making the decision to refer patients for overnight sleep study. This can avoid
unnecessary burden, suffering and extra cost.
2.10.4 SDB and onset time of stroke
Studies using 6-hour time bins have found that most strokes were first noticed in
the morning between 6 am and noon [Elliott 1998]. The time of onset of stroke in
patients with SDB seems to be similar to that in the general stroke population
[Bassetti and Aldrich 1999a]. Two mechanisms have been proposed for the onset of
stroke and myocardial infarction being highest in the morning: (1) increased
prothrombotic state, including blood viscosity and platelet activation, in the morning
[Andrews et al. 1996;Koeltringer et al. 1990] (2) rise in blood pressure in the
morning [Bursztyn 2002;Kario et al. 2003]. Both these mechanisms are present in the
normal population but could conceivably be accentuated in those with SDB [Nobili
et al. 2000].
There were only three published papers dealing with snoring, SDB and onset
time of stroke. The first paper showed snoring was a risk factor for sleep-related
brain infarction [Palomaki et al. 1989]. The second paper, focusing on AHI rather
than snoring, showed that AHI and other sleep characteristics did not differ between
patients with daytime (6 am - midnight) and nighttime (midnight - 6 am) onset of
stroke [Bassetti and Aldrichl999a]. The third paper [Iranzo et al. 2002] revealed that
AHI > 25 was the only independent predictor for sleep-related stroke (OR = 1.02,
95% CI = 1.00-1.05). In that study [Iranzo et al. 2002], two thirds of sleep-related
strokes happened between 6 and 9 am. The hypoxaemia associated with SDB is
usually more severe in the latter half of nocturnal sleep which has a higher density of
rapid eye movement (REM) sleep. The authors proposed that SDB had a direct
impact on stroke onset through haemodynamic compromise. Although the morning
surge of blood pressure may have an influence on stroke onset and patients with SDB
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have sympathetic hyperactivity [Fletcher 2003] and haemodynamic changes
[Franklin 2002;Netzer et al. 1998] the role of SDB in stroke onset is still not clear.
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2.11 Treatment of SDB in stroke
2.11.1 The clinical value of CPAP treatment in stroke
As high prevalence of sleep-disordered breathing (SDB) in stroke was described
previously, screening of SDB in stroke is more meaningful if treatment of SDB in
stroke is effective. There are currently three domains of treatment for SDB in terms
of nasal continuous positive airway pressure (CPAP), oral appliance and surgery.
CPAP is the standard and most commonly prescribed method. I have reviewed the
benefit of treating SDB with CPAP in non-stroke subjects in chapter 1 and 2. In brief,
CPAP not only improves daytime sleepiness, cognitive performance, mood, and
health-related quality of life but also reduces blood pressure and other cardiovascular
risk factors including sympathetic activity, heart rate variability, platelet aggregation,
blood viscosity, and adhesion molecules.
The efficacy, safety and feasibility of CPAP need to be reassessed before
applying it to patients with concomitant SDB and stroke. The problems include
whether these patients can tolerate CPAP, whether treatment of CPAP is effective
and whether the benefit of CPAP outweighs the adverse effects. For instance, CPAP
can prevent patients who receive gastrointestinal surgery from post-operative
hypoventilation but CPAP might theoretically cause anastomotic leaks which could
compromise the outcome [Huerta et al. 2002]. Theoretically CPAP has a
haemodynamic effect on the whole body from heart, blood vessels to brain.
Haemodynamic changes are one of the factors determining the outcome of stroke.
Ischaemic penumbra in acute stroke and neuronal plasticity in subacute and recovery
phase of stroke may be sensitive to swing in cardiac output, systemic blood pressure
and cerebral blood flow (CBF). This means haemodynamic compromise
(bradycardia) might play a role in the onset of stroke. The following haemodynamic
effects of CPAP treatment should be considered before applying it to stroke patients:
• CPAP might improve cerebrovascular reactivity in patients with SDB on
one hand but might decrease CBF in normal adults on the other.
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• Although CPAP can reduce blood pressure in non-hypertensive patients with
SDB it is still unclear whether CPAP also reduces blood pressure in stroke
patients and whether reduction of blood pressure following CPAP treatment
in the acute or subacute phase of stroke compromises CBF.
2.11.2 Comparison between previous CPAP trials for SDB in
stroke
There are only four published original articles about CPAP trial for SDB in
stroke (Table 2.2, P. 86). Two studies were conducted in Europe [Sandberg et al.
2001a;Wessendorf et al. 2001], one in Australia [Disler et al. 2002] and the other one
in Asia [Hui et al. 2002]. Another short CPAP trial was published as "Letter to the
Editor".
The Swedish group first showed in a cross-sectional study that SDB was
significantly associated with depressive symptoms measured by Montgometry-
Asberg Depression Rating Scale (MADRS) in stroke [Sandberg et al. 2001b]. They
further studied 59 patients who were randomized through lots drawn by a person not
involved in the study [Sandberg et al. 2001a]. Thirty-one patients were randomized
to CPAP starting between 7 and 28 days after stroke for 4 weeks. Twenty-eight
patients were randomized to control without CPAP. Outcomes were assessed at 7 and
28 nights respectively in terms of functional capacity (Barthel Index, BI), cognition
(Mini-mental State Examination, MMSE), mood (Montgometry-Asberg Depression
Rating Scale, MADRS) and delirium. They found CPAP could effectively improve
depressive symptoms in stroke patients with SDB. There was no difference in
functional capacity, cognition and delirium. As the prevalence of anxiety and
depression is high (20-50%) following stroke and post-stroke depression is
associated with stroke severity and functional impairment [Berg et al. 2003] this
finding from the Swedish group is interesting.
The study conducted by a German group [Wessendorf et al. 2001] had a larger
sample size (n = 105) but it was not a randomized control trial. They assigned CPAP
to all patients at 51-69 days of stroke and used non-compliant patients as a control for
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comparison. CPAP was applied independently in patients who could tolerate and use
it at home after discharge. Assessment was performed 1 week after stroke. Only 41
unselected patients received measurement of wellbeing by a Visual Analogue Scale
and only 16 unselected patients received measurement for ambulatory blood pressure
(ABP). They found that those with CPAP acceptance (n = 28) had improved
wellbeing but those without CPAP acceptance (n = 13) did not (p = 0.021). They also
found those with CPAP acceptance (n = 11) had significant reduction in mean
nocturnal arterial blood pressure but no pressure change was found in those without
CPAP acceptance (n = 5, p = 0.037).
The study conducted by the Hong Kong group recruited 34 patients for a CPAP
trial of 3 weeks [Hui et al. 2002], This is not a randomized controlled trial either.
Thirty-four patients who had AHI > 10 were prescribed CPAP. However, 14 patients
refused to take part in the treatment and 4 patients could not tolerate overnight CPAP
titration. Only 4 of 16 patients who had successful CPAP titration proceeded to home
CPAP treatment. They did not perform outcome measurement following CPAP
treatment.
The study conducted by the Australian group was presented as a brief report
because they recruited 38 patients for an overnight sleep study but only recruited 5
patients for CPAP trial without randomization [Disler et al. 2002]. There was no end
of treatment phase and all 5 patients were happy to use CPAP at home. They did not
measure outcome either.
In another British study published as "Letter to the Editor" showed none of 15
stroke patients used CPAP [Harbison et al. 2002a]. It is unclear why compliance has
varied so much between studies but it is likely to reflect differences in patient
selection, environment in which treatment is given, the CPAP system used and the
amount and type of support and training given.
The above studies had the following methodology limitations:
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• There was a wide time span of recruiting patients from a few weeks to a few
months after stroke. Some patients might have reached the plateau of
recovery before they were enrolled in the studies.
• There was only one randomized controlled trial. The others were either non¬
randomized controlled or non-controlled trials.
• Only two studies conducted an outcome assessment but even in these, the
spectrum ofmeasurement was incomplete.
2.11.3 Practical problems of CPAP compliance in stroke
The major problem of CPAP treatment in non-stroke subjects is compliance.
Stroke patients are rarely referred for the diagnosis of SDB due to sleepiness or other
major SDB-related symptoms. Patients with SDB but without excessive daytime
sleepiness (EDS) have poor compliance to CPAP and the treatment is less effective
[Barbe et al. 2001].
The CPAP compliance in German and Sweden groups was good. Seventy-four
(70.5%) of 105 patients in the German group continued CPAP treatment at home
[Wessendorf et al. 2001] although compliance was not reported in detail. Sixteen
(51.6%) of 31 patients in Sweden group used CPAP for more than 4 hours per night
with a mean of 4.1 + 3.6 (0-10.9) hours [Sandberg et al. 2001a], The CPAP
compliance in the Hong Kong group was poor [Hui et al. 2002]. Only 4 (11.8%) of
34 patients proceeded to home CPAP treatment without other detailed information. A
British group from Newcastle wrote "a letter to the editor" to doubt previous results
with good CPAP compliance. They had 15 stroke patients who had SDB for CPAP
trials but none of them accepted CPAP treatment [Harbison et al. 2002a]. There was
no report of CPAP compliance for 5 patients in the Australian group [Disier et al.
2002],
As described in chapter 1, auto-titrating CPAP (auto-CPAP) can save time from
in-lab CPAP titration and maintain a minimal necessary pressure [Ficker et al.
1998;Ficker et al. 2000]. It may be more suitable for stroke patients to prevent them
from extra traffic between hospitals and increase tolerability to CPAP pressure. There
73
are two major problems need to be clarified: (1) the value of unattended auto-CPAP
when applied to CPAP naive patients without in-lab titration [Littner et al. 2002]; (2)
whether central sleep apnoea and Cheyne-Stokes respiration which are more common
in stroke will interfere with pressure determination by auto-CPAP.
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2.12 Sleep-disordered breathing and the outcome of stroke
2.12.1 Sleep-disordered breathing acting on the brain
I have reviewed in chapter 1 that the major manifestations of sleep-disordered
breathing (SDB) are, in brief: (1) cognitive deficits in terms of vigilance (excessive
daytime sleepiness, difficulty in maintaining wakefulness), attention, memory and
executive functions; (2) psychosocial maladjustment in terms of mood and health-
related quality of life.
Understanding the prognostic factors of stroke can let us, on one hand, avoid
unnecessary treatment for those who may have a good outcome independent of
treatment and, on the other hand, deal with those treatable factors more precisely.
Many factors might affect functional outcome of stroke and sleep-disordered
breathing (SDB) is one of them through the following two mechanisms:
• SDB indirectly affects the outcome of stroke through causing or enhancing
other prognostic factors such as mood, cognition and motivation for
rehabilitation
• SDB directly affects the outcome of stroke through compromising the
recovery of the damaged central nervous system
The underlying causes of major clinical manifestations of SDB are still




Sleep fragmentation and nocturnal hypoxaemia are also common in stroke. It is
not easy to deal with sleep fragmentation and nocturnal hypoxaemia separately in
clinical studies of SDB. SDB causes frequent arousals which results in sleep
fragmentation, disruption of sleep architecture and sleep loss [Douglas and Martin
1996]. The major difference in sleep architecture between patients with SDB and
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normal control is that patients with SDB have less slow wave sleep (stage III and IV)
and REM sleep. This kind of change is also similar in stroke. A study showed that
patients with stroke had decreased sleep efficiency, total sleep time, rapid eye
movement (REM) sleep and slow wave sleep [Muller et al. 2002].
Hypoxaemia is one of major physiological changes in SDB. Patients with stroke
also have higher risk of developing hypoxaemia due to impaired central regulation of
breathing, weakness of respiratory musculature and respiratory complications. I will
review the objectives in the following two sections.
Recent evidence has shown that SDB is directly associated with "neuronal loss".
Neuronal loss is a major consequence of stroke especially infarction. A study using
magnetic resonance spectroscopy (MRS) showed that N-acetyl aspartate (NAA)
decreased in the grey and white matter of patients with SDB due to cell death. The
other two studies using magnetic resonance imaging (MRI) also showed decreased
volume of grey matter in the multiple areas of brain especially hippocampus [Macey
et al. 2002;Morrell et al. 2003]. Seven-eight previously independent patients with
acute stroke were recruited in another study. CT scans of brain were performed
within 72 hours of admission and evaluated independently by two neuroradiologists
blind to the sleep study results with good agreement [Harbison et al. 2003], The
presence or absence of pre-stroke cerebrovascular diseases was determined using
validated Age-Related White Matter Change (ARWMC) Scale. The result showed
SDB was worse in subjects with pre-stroke cerebrovascular disease than in those
without (mean AHI = 35 ± 21 vs. 23 ± 10, p < 0.01). Multiple regression analysis
was performed and the only factor independently associated with AHI was presence
of pre-stroke cerebrovascular disease. There are two implications from these
pioneering studies of brain morphology when we take treatment of SDB in stroke and
impact of SDB on the outcome of stroke into account:
• Pre-stroke neuronal loss might exist in patients with SDB so they might
have worse neurological status at admission and lower chance of recovery.
• CPAP treatment might not be completely successful in stroke as there has
been some permanent damage in the brain.
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2.12.2 The association of SDB with other prognostic factors in
stroke
Sleep-disordered breathing was reported to be associated with other prognostic
factors of stroke:
• Age and severity of stroke
Age and severity of stroke are two most important factors determining the
functional outcome. A prospective study with a large sample size (1079 patients for
generating the predictive model and 1307 patients for external validation) showed
that old age and initial NIH Stroke Scale (NIHSS) measured within 6 hours of stroke
were associated with both incomplete functional recovery (Barthel Index < 95) and
mortality [Weimar et al. 2004]. A recently published study from the Department of
Clinical Neuroscience in Edinburgh University tried to simplify the predictive model
for the outcome of stroke into six variables. Most of them are related to initial
severity [Counsell et al. 2004]. SDB is common in the elderly. Age might be a
confounder of SDB for the outcome of stroke. Thus controlling for initial severity of
stroke and age should be considered first when we deal with the impact of SDB on
the outcome of stroke.
• Gender
A European multi-centre study involving 7 countries and recruiting 2239 male
and 2260 female patients showed that female sex was a significant predictor for
disability and handicap after controlling for baseline variables [Di Carlo et al. 2003].
SDB is more common in middle-aged men than women but women after menopause
have increased prevalence of SDB. If two groups of stroke patients, one with SDB
and the other without, were compared for the outcome the group with SDB might be
male predominant and the better outcome might be confounded by the effect of
gender difference.
• Excessive daytime sleepiness (EDS)
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There is no direct evidence that people with SDB have more severe strokes than
people without it. Study conducted by Newcastle University in the UK found pre-
stroke EDS was correlated with Barthel score at week 2 after stroke [Harbison et al.
2002b]. Pre-stroke EDS is not equal to SDB but might reflect a group of
symptomatic SDB (SDB with EDS). This implies that pre-stroke EDS might be
associated with initial severity of stroke or early neurological deterioration after
stroke as the latter has been published [Iranzo et al. 2002].
Sleep fragmentation independently causes EDS in patients with SDB [Bennett et
al. 1998] but seems not significantly associated with EDS in stroke [Vock et al.
2002]. This means EDS in stroke either share different underlying mechanism as
EDS in SDB or has a broader spectrum of causes. There is no further study dealing
with EDS and outcome of stroke.
• Cognition and depression
Cognitive impairment and depression are interrelated. Both of them are
associated with functional outcome of stroke. A prospective cohort study following
up 286 stroke patients aged 55-85 years found worsening of Mini-mental State
Examination (MMSE) and Beck Depression Inventory (BDI) at three months after
stroke were independent predictors for dependent living at 15 months [Pohjasvaara et
al. 2002b], The same research group also found that executive dysfunction was most
significant cognitive impairment related to post-stroke depression [Pohjasvaara et al.
2002a].
The function of human sleep is still not very clear but basically slow wave sleep
is reported to be associated with neuronal restoration and rapid eye movement (REM)
sleep, associated with memory consolidation. Decreased slow wave sleep and REM
sleep can also result in cognitive deficits [Verstraeten et al. 1996]. SDB has been
associated with neuropsychological deficits in the domains of vigilance, attention,
memory and executive function. Previous studies showed that impaired vigilance in
patients with SDB is mostly explained by sleep fragmentation resulting from frequent
arousals [Colt et al. 1991]. Executive dysfunction in frontal lobe-related tests is
mostly explained by nocturnal hypoxaemia [Naegele et al. 1995]. Memory
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impairment in SDB might also be due to frontal and subcortical mechanism [Salorio
et al. 2002] which are similar to neuropsychological deficits of vascular dementia
due to stroke [Kertesz and Clydesdale 1994], From the above points of view SDB
and stroke may share common cognitive deficits.
There are two possibilities regarding cognitive deficits in patients with both SDB
and stroke: (1) the cognitive deficits resulting from SDB exacerbate the existing
cognitive deficits in stroke; (2) the cognitive deficits resulted from SDB are
intermixed and masked by the existing cognitive deficits in stroke. If this latter point
is predominant, the impact of SDB or the treatment effect of SDB on the cognitive
outcome of stroke might be less prominent.
Psychosocial maladjustment in stroke usually depends on cognitive deficits in
which impaired vigilance and attention play a more important role than other
neuropsychological deficits. CPAP can reverse both EDS and psychosocial
maladjustment but the effect of CPAP on other neuropsychological deficits is only
partial [Naegele etal. 1998],
Many studies pointed out that post-stroke depression is associated with increased
morbidity. Stroke patients with negative thoughts and fatalism are also associated
with increased mortality [Dennis et al. 2000].
• Other cardiovascular risk and prognostic factors
Blood pressure, atrial fibrillation and hyperglycaemia are three of the proposed
prognostic factors for the outcome of stroke in which SDB might play a role. Control
of blood pressure has been discussed in chapter 5. Extremely high or relatively low
blood pressure is harmful in acute and subacute stroke. SDB might be associated
with abnormal swings of blood pressure and haemodynamic change in these stages.
SDB might predispose to recurrence of atrial fibrillation which not only potentiates
haemodynamic compromise but also increases the possibility of recurrence of stroke.
A study found that recurrence of atrial fibrillation was much higher (82%) in patients
with non-treated or mal-treated SDB in contrast to 42% of CPAP-treated patients and
53% of control [Kanagala et al. 2003], The association of SDB and diabetes is
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largely explained by obesity as reported in Sleep Heart Health Study [Resnick et al.
2003], The other study which used enzyme immunoassay to measure insulin and
calculate insulin resistance found, after adjusting for BMI in a regression model, that
AHI was still independently associated with insulin resistance [Ip et al. 2002]. If so,
SDB might worsen hyperglycaemia in stroke and result in poor outcome.
2.12.3 The hypothesised model of SDB on the outcome of stroke
According to the above reviews, I propose a hypothesis of the impact of SDB on
the outcome of stroke (Figure 2.2, P. 89).
SDB can cause nocturnal hypoxaemia which compromises neuronal function and
results in poor emotional, cognitive and functional outcome. SDB might be
associated with haemodynamic swing due to change of blood pressure or induction of
atrial fibrillation. SDB might also be associated with hyperglycaemia due to
increased insulin resistance. All these factors deteriorate ischaemic penumbra or
neuronal plasticity in patients with acute or subacute infarction in the brain, resulting
in further neuronal death and permanent brain damage.
SDB causes sleep fragmentation. It decreases vigilance, increases EDS and
results in poor emotional and cognitive outcomes. SDB not only reduces rapid eye
movement (REM) sleep which results in impaired memory consolidation and
cognitive function but also reduces non-rapid eye movement (NREM) sleep which
cause neuronal dysfunction, neuronal death and permanent brain damage.
Poor emotional and cognitive outcomes might result in poor motivation in
attending rehabilitation programmes in stroke which further compromises functional
outcome. All above three outcomes are associated with poor health-related quality of
life in stroke.
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2.12.4 Comparison between previous studies for SDB and the
outcome of stroke
There are only seven published original articles about SDB and the functional
outcome of stroke. Four studies were conducted in Europe, two in North America
and one in Israel. The comparison is shown (Table 2.3, P. 87).
The first paper published by the American group applied the Barthel Index (BI)
which is one of the most commonly used scales for functional outcome [Good et al.
1996]. They conducted oximetry for 47 stroke patients and had extra full
polysomnography for 19 of them. They found that the desaturation index (DI) which
was obtained by oximetry and defined as number of desaturation < 4% per hour
underestimated AHI which was obtained by polysomnography although DI might be
closer to AHI than other oximetric variables. The analysis still depended on
oximetric variables including desaturation index (DI), mean Sa02 and percentage of
time with Sa02 < 90%. The results showed oximetric variables were significantly
correlated with lower BI score at discharge, 3 and 12 months after stroke but the
correlation of oximetric variables and BI were more prominent in mean Sa02 and
time at Sa02 < 90% than DI. Mortality at one year (n = 5) was also correlated with
mean Sa02 and percentage of time with Sa02 < 90%. They did not adjust for
baseline data. There was no direct correlation between functional outcome and AHI.
The second paper published by the British group at Newcastle University mainly
focused on a longitudinal change of AHI between 2 weeks and 6-9 weeks [Harbison
et al. 2002b]. The device they used for limited sleep studies consisted of only two
physiological channels, oximetry and nasal cannula. They also performed BI and
Scandinavian Stroke Scale at these two time points. They found there was no
difference in mortality or neurological recovery between patients in whom SDB
improved or deteriorated. The change in AHI did not correlate with change of
neurological deficits or functional capacity. They didn't compare outcome between
two groups according to a cut-off point of AHI.
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The third paper published by the Spanish group recruited 50 patients who had
had their first-ever stroke. They conducted polysomnography on the first night after
stroke onset. They found SDB (dichomatised by AHI > 10), AHI and oxyhemoglobin
desaturation (percentage of time with Sa02 < 90%) were independently associated
with early neurological worsening after adjusting for initial severity of stroke. During
longitudinal follow-up there was no significant difference of BI and Scandinavian
Stroke Scale between groups with AHI < 10 and > 10 at 1, 3 and 6 months after
stroke.
The fourth paper published by the Israel group replaced BI by a more detailed
Functional Independence Measure (FIM) [Cherkassky et al. 2003]. They conducted
oximetry for the diagnosis of SDB. The total sample size was only 30. In univariate
analysis, there was a trend that patients with AHI > 10 defined by number of fall of
Sa02 > 4% per hour (usually taken as DI) had lower FIM scores and FIM gain on
discharge but power might be too low to show statistical significance. In multivariate
analysis by controlling confounders at baseline especially severity of stroke they
found that RDI was an independent predictor for FIM gain (adjusted R-square =
0.209, p = 0.025). The negative coefficient means that the higher the RDI the smaller
the functional improvement. This finding was not strong because the total model
could only explain 20.9% of the total variance. They also found that patients in more
severe group (FIM < 70) had the worst outcome. The sample size might be too small
to show significance as well (p = 0.085).
The fifth paper published by Canadian group also used the FIM [Kaneko et al.
2003b]. They conducted polysomnography (PSG) for 60 stroke patients. After
adjusting for Canadian Stroke Scale and MMSE at baseline using multiple linear
regression, they showed obstructive AHI was an independent predictor for FIM score
at discharge from rehabilitation ward (p = 0.030). The term "at discharge" in their
study was vague in definition. After adjusting for CSS, they also found that
obstructive AHI was an independent predictor for total length of hospitalization (p =
0.043) in chronic rehabilitation units. The latter is an unique finding, which, if
confirmed, could have a major influence on the total cost of stroke in-hospital care
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and enable the treatment of SDB in stroke to be cost-effective by decreasing the total
length of patient hospitalization.
The sixth paper published by Spanish group focused on mortality of the same
cohort [Parra et al. 2004] about four years after they published the paper regarding
the longitudinal changes of the frequency of sleep apnoea and hypopnoea in 161
patients following stroke or TIA [Parra et al. 2000]. A limited sleep study was
conducted in all cases and the entire cohort was followed by a structured telephone
interview. The mean duration of follow-up was 22.8 months (range 0.4-32 months).
The wide range of follow-up time was due to patients died (13.7%) during this
period. In the univariate analysis age, AHI and Cheyne-Stokes respiration (CRS)
were associated with mortality. In multi-variate analysis by Cox's proportional
hazard model age (hazard ratio = 1.14, 95% CI = 1.06-1.21, p = 0.000), AHI
(obstructive predominantly, hazard ratio = 1.05, 95% CI = 1.01-1.08, p = 0.004),
middle cerebral artery (MCA, hazard ratio = 2.86, 95% CI = 1.04-7.84, p = 0.04)
stroke and concomitant coronary artery disease (CAD, hazard ratio = 3.25, 95% CI =
1.05-10.03, p = 0.04) were independent predictors of mortality after adjusting for
other confounders.
The seventh paper published by a British group recruited 120 unselected stroke
patients admitted to hospital in the UK who might be representative of hospitalized
stroke patients in the UK [Turkington et al. 2004]. They had PSG recordings for 24
hours soon after admission and this might reflect the true RDI in patients with acute
stroke because most stroke patients during this stage are bed-ridden and may fall
asleep for most of the time. Follow-up for 6 months was obtained in all but 6
patients. The regression analysis after adjusting for confounders showed both 24-hour
and light-out RDI, which were predominantly obstructive, were significant predictors
for mortality. The minimal oxygen saturation was an independent predictor for
disability (Barthel Index). This did not directly link SDB to poor functional outcome
because desaturation during acute stroke can be caused by many factors other than
SDB, for example, aspiration pneumonia.
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2.13 Discussion
There were inconsistent findings regarding the link between SDB and
cardiovascular risk factors. Only hypertension was independently associated with
SDB based on several well-designed large-scaled prospective case-control and cohort
studies. Several randomized controlled trials also showed that reduction of blood
pressure by CPAP was minimal but clinically significant. Hypertension is one of the
major risks of stroke. Thus CPAP may have a role in the secondary prevention of
stroke.
A high prevalence of SDB in stroke and poor outcome of stroke in patients with
SDB have been reported in cross-sectional studies. These raise the question whether
treatment of the SDB might improve outcomes. However, stroke patients may have
physical difficulty coping with CPAP. CPAP may further decrease cerebral blood
flow velocity. The role of CPAP for treatment of SDB in stroke needs further
research to support.
There have been few trials of CPAP for SDB in stroke, and only one involved
random allocation to CPAP or control. CPAP had no effect on recovery from stroke
but there were fewer depressive symptoms amongst those treated with CPAP. Some
other non-randomised studies have also been published. However, CPAP use was
poor. Based on these studies some centres are now using CPAP to treat SDB after
stroke.
Therefore, we performed a further randomized controlled trial in stroke patients
with SDB to clarify whether CPAP is beneficial. Particularly, we hypothesised firstly
that nasal CPAP might improve sleepiness, fatigue, cognitive function and mood in
stroke patients with SDB and making them more compliant with rehabilitation.
Secondly, we hypothesised that nasal CPAP may stabilize circadian blood pressure in
the recovery phase of stroke; and thus CPAP would result in better functional
outcome.
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Figure 2.1 The influence of SDB and CPAP on haemodynamics and
cerebral blood flow
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Figure 2.2 The impact of SDB on the outcome of stroke
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Chapter 3 General Methodology of Measurement,
Recruitment, Randomization and Data Analysis
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3.1 Introduction
This three-stage study of sleep-disordered breathing (SDB) after stroke was
conducted with the participation of mild to moderately affected stroke sufferers. I
hypothesised that: (1) SDB is related to stroke outcome and (2) treatment of SDB in
stroke patients with CPAP would improve functional outcome. The study included
observational and intervention phases and a longitudinal follow-up conducted serially
within a single patient cohort. I recruited consecutive stroke patients from March
2001 until June 2003 in four NHS teaching hospitals of Edinburgh University:
Western General Hospital, Royal Victoria Hospital, Royal Infirmary of Edinburgh
and Astley Ainsley Hospital. I visited the wards and screened all eligible stroke
patients, performed all sleep studies and scoring and all baseline and outcome
assessment. The flow diagram is shown in Figure 3.1 (P. 113).
The first, observational screening phase involved a limited, non-invasive sleep
study in sub-acute stroke (14-19 days after stroke) for consenting, suitable patients.
This means patients had gone beyond the acute phase of stroke (first two weeks) and
were relatively clinically stable for overnight sleep studies and nasal continuous
positive airway pressure (CPAP) titration. Baseline assessments were performed on
the morning following the sleep study. The second, therapeutic parallel-limb
randomized controlled trial (RCT) phase involved the subgroup of patients
demonstrating moderate to severe obstructive sleep apnoea and hypopnoea (OSAH)
on screening, who then were allocated to either 8 weeks of an auto-titration CPAP,
AutoSet T® (ResMed Ltd., SanDiego USA, Figure 3.2, P. 114) or conservative
treatment for SDB on day 21-25 following stroke. The detail of allocation and
intervention will be described in the chapter 5.3.2. The patients without SDB also
received outcome assessment at 3 months. The third, longitudinal follow-up involved
all recruited patients who received outcome assessment at 6 months after stroke. If
available, patients also received 12 months and 18 months follow-up until the last
recruited patient had had his 6 months follow-up on December 2003.
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3.2 Eligibility criteria
The criteria for inclusion and exclusion were set up based on the randomized
controlled trial of nasal CPAP in order to recruit a group of stroke patients who had
normal functional status or mild functional disability prior to the stroke, mild to
moderate neurological deficits and less complications following stroke so were
thought to be compliant with CPAP treatment and available for longitudinal outcome
assessment.
The inclusion criteria for overnight sleep study were:
• Male and female patients aged between 21-90;
• Stroke 14-19 days previously;
• Pre-stroke Modified Rankin Score (MRS) < 2;
• NIH Stroke Score (NIHSS) > 4.
The exclusion criteria for overnight sleep study were:
• Severe or unstable medical conditions including dementia, severe dysphasia
or confusion that would result in the patient not understanding or tolerating
the diagnostic study or CPAP treatment;
• Unusual stroke including stroke caused by collagen vascular diseases, drug
addiction or brain tumours;
• Either insufficient hand function to put on mask and take it off, or do not
have caregiver present overnight to do this for them.
The following patients were particularly excluded: (1) severe bulbar or pseudo
bulbar palsy which could cause SDB following stroke [Askenasy and Goldhammer
1988]; (2) severe conscious disturbance, dysphasia or cognitive impairment which
could result in inaccurate responses to questionnaire and some assessment scales; (3)
severe medical illnesses, for example, severe congestive heart failure, COPD or
epilepsy in which SDB is co-morbid even without stroke.
The inclusion criteria for RCT after sleep study were:
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• (A+H)-h4 > 30
• <30 central apnoeas or Cheyne-Stokes respiration
The cut-off NIHSS score for recruitment was changed from NIHSS > 6 to > 4.
This change in NIHSS criterion was made before any patients were recruited into the
randomized study - that is after the first 2 patients (chapter 5.4.1) were assessed but
not randomized or treated. The reason for the change was that it became apparent that
recruitment would be too slow if the original criteria were followed.
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3.3 Sample size calculation
The Barthel Index (BI) and the Nottingham Extended ADL Index (EADL)
dealing with functional capacity were chosen as primary outcome measures based on
a priori hypothesis. The ambulatory blood pressure (ABP), Mini Mental State
Examination (MMSE), Addenbrooke's Cognitive Examination (ACE), Hospital
Anxiety and Depression Scale (HADS), EuroQol and SF-36 were chosen as
secondary outcome measures.
A priori sample size was determined for randomised controlled trial (RCT) in
this study based on the following formula:
N in each group = ^ °2 (Z«J2 * zp)2
A2
where a = the common standard deviation of each group,
A = mean difference,
A/a = standardized mean difference (SMD), which is the effect size (mean
difference divided by standard deviation) generally recommended in clinical trials
and other studies assessing treatment effects on outcomes.
a = significance level, and p = 1- Power,
Z = standard normal distribution,
Za/2 = 1.96 (a = 0.05),
Zp = 0.84 (p = 0.20).
Thus 40 CPAP and 40 control patients would provide 80% power at 5%
significance level to show 0.57 point SMD in the EADL, using data from the RCT of
outpatient occupational therapy (OT) for stroke [Walker et al. 1999]. Allowing for
20% dropouts suggested an initial recruitment target of 100 to the RCT with 50
CPAP and 50 control patients (Figure 3.1, P. 113).
A preliminary analysis would be undertaken after 80 subjects were recruited, and
if definitive results had been obtained recruitment would cease. Alternatively, sample
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3.4.1 Portable limited sleep study
I used a pocket-sized portable recording system (Embletta PDS®, Medcare Flaga
Ltd., Iceland) in my study incorporating the following sensors (Figure 3.3, P. 115):
• Nasal pressure transducer: a disposable nasal cannula connected to a
pressure transducer to record the square root of pressure as an index of flow;
• Oral thermistor: measuring mouth leakage;
• Respiratory efforts sensors: a piezo crystal transducer in a stretch Velcro
strap to record thoracic and abdominal respiratory movement;
• Pulse oximeter: recording oxygen saturation and pulse rate;
• Body position sensor: recording supine, prone, left side, right side and
upright positions.
The Embletta PDS® is a device for limited sleep study which records only
cardiorespiratory signals without concomitant recording of EEG and EMG. It was
chosen in my study as this is our standard diagnostic approach [Dingli et al.
2003;Whittle et al. 1997] and also complied with the clinical guidelines proposed by
American Academy of Sleep Medicine and American Thoracic Society which have
been reviewed in chapter 1.5.2.
3.4.2 Validity and reliability in sleep studies
Validity of a portable limited sleep study is estimated according to the
comparison of sleep variables between the device to be tested and a gold standard
device, polysomnography (PSG). Two portable limited sleep study devices are used
in the sleep centre of Edinburgh University, EdenTrace® and Embletta® with
validation based on synchronous studies. One study compared unattended
EdenTrace® recording at home with conventional PSG in the sleep centre in 23
patients with SDB [Whittle et al. 1997]. The overall fail rate was 13%. The mean
difference (PSG - EdenTrace®) in (A+H)-h_1 in bed was 8 ± 12-h"1 with a significant
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correlation between the results of the two studies (r = 0.8, p < 0.001). There was a
bias to lower score on home studies at higher (A+H)-h"' value. Another study
compared unattended Embletta® recording at home with conventional PSG in the
sleep centre in 50 patients with SDB. The overall fail rate was 18% but decreased to
12% if only latter two-thirds of the study was counted which showed learning effect.
The mean difference (PSG - Embletta®) in (A+H)-h_1 in bed was 2 ± 5-h"1 (p = 0.02)
with a significant correlation between the results of the two studies (rho = 0.98, p <
0.001) [Dingli et al. 2003]. The home studies tended to have lower score. The mean
difference increased to 8 ± 16-h"1 if (A+H)-h_1 of Embletta was compared with AHI
of PSG (AHI-h1 in sleep) but returned to 2 ± 5-h"1 if those with > 40-h"1 in bed on
both devices were excluded. This means the difference between two methods was
greater in those with severe SDB.
Reliability in sleep studies is estimated according to the following three
viewpoints that the instrument can yield the same scores when: (1) administered in
different times (test-retest reliability); (2) scored in different times (intra-rater
reliability); (3) scored by different persons who are experienced in the same field
(inter-rater reliability). A study conducted in the sleep centre of Edinburgh University
showed a high intra-rater reliability for scoring apnoea (r = 0.99, mean percentage
difference of apnoea number = 8%) [Whyte et al. 1992]. A similar finding was
shown for scoring hypopnoea even based on thorocoabdominal signals alone (r =
0.98, mean percentage difference of hypopnoea number = 11%). The reliability test
in this thesis was simply to check my ability to interpret sleep studies which will be
presented and discussed in chapter 4.
97
3.5 Baseline and outcome measurement
3.5.1 The severity of stroke
The severity of stroke was measured by the National Institute of Health Stroke
Scale (NIHSS) shown in appendix A. The NIHSS is a 15-item stroke scale [Brott et
al. 1989]. It was designed to measure the severity for all types of stroke according to
11 domains of neurological deficits:




• Motor function of arm





• Extinction and inattention
The higher scores indicate worse neurological status. NIHSS do not require
advanced experience to complete but NIHSS requires more detailed neurological
examination than the Canadian Stroke Scale. NIHSS is more appropriately used in
prospective than retrospective assessment although NIHSS still can be abstracted
from case notes with high degree of validity and reliability [Kasner et al. 1999],
NIHSS at baseline of stroke strongly predicts outcome - in the TOAST Trial of Org
10172 (a low molecular weight heparinoid, danaparoid) in Acute Stroke Treatment
NIHSS < 6 was significantly associated with good outcome of stroke and NIHSS >
16, on the contrary, associated with poor outcome [Adams, Jr. et al. 1999].
NIHSS tends to be used to assess the severity of neurological deficits. In this
study, the a cut-off point of NIHSS > 4 was used as an inclusion criterion at baseline
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(14-19 days after stroke) and also used as a secondary outcome measure 3 months
following stroke.
3.5.2 Functional capacity
The Rankin Scale, Barthel Index (BI) and Nottingham Extended ADL Index
(EADL) have been widely accepted as measures of functional outcome following
stroke. Modified Rankin Scale (MRS) is used to measure handicap following stroke.
Instead, BI and EADL are used to measure disability.
3.5.2.1 Modified Rankin Scale
The Modified Rankin Scale (MRS) is shown in appendix B. The Rankin Scale
was developed in 1957 [Rankin 1957] and later modified [Bonita and Beaglehole
1988]. The MRS is a Likert scale with seven levels (0-6):
• No symptom at all (0)
• No significant disability despite symptoms (1)
• Slight disability (2)
• Moderate disability (3)
• Moderate severe disability (4)
• Severe disability (5)
• Dead (6)
The MRS, along with the Barthel Index (BI) and the Functional Independence
Measure, are three common measures for the activities of daily living (ADL). The
three measures are highly correlated but MRS a more simple scale so is less sensitive
in stroke patients in lower and higher ends of disability [Kwon et al. 2004], The
NIHSS after stroke and MRS prior to stroke were used in this study as two of the
inclusion criteria. The purpose was to include a group of patients who were
independent prior to stroke and had mild to moderate stroke only.
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In this study, the MRS was used at baseline to screen for pre-stroke functional
status and also as a secondary outcome measure for functional status along with
"Status of Independence" scale at 3, 6,12 and 18 months following stroke.
3.5.2.2 Barthel Index
The Barthel Index (BI) is shown in appendix C. The BI was developed in 1965
[MAHONEY and BARTHEL 1965]. There are 10 domains of measurement for the








• Transfer (bed to chair, and back)
• Mobility (one level surfaces)
• Stairs
There are two scoring rules. The maximum score is 100 if 5-point increment is
used but, is 20, if 1-point increment is used. The BI is the most widely used scale for
assessing activities of daily living but the cut-off points used to classify patients with
good outcome in previous stroke trials varied and were arbitrarily defined [Suiter et
al. 1999], Most patients are independent for essential self-care with a score of >
60/100 and are independent with minimal assistance with a score of > 85/100. Both
Barthel Index and motor subscale of Functional Independence Measure show high
internal consistency, concurrent validity and responsiveness to be used in stroke
[Hsueh et al. 2002]. This means they have similar psychometric characteristics.
In this study, the BI was used to assess basic functional capacity at baseline and
as a primary outcome measure at 3 months and 6 months following stroke.
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3.5.2.3 Nottingham's Extended ADL Scale
The Nottingham Extended Activities of Daily Living Scale (EADL) is shown in
appendix D. The EADL which was developed more recently than MRS and BI in
1993 [Gladman et al. 1993]. It consists of 22 items of question in four domains:
• Mobility (6 items)
• Kitchen (5 items)
• Domestic (5 items)
• Leisure abilities (6 items)
Total score can be obtained by summation of four subscores.
The term "functional capacity" has a multi-dimensional nature. The BI designed
for basic activities of daily living usually has a ceiling effect in stroke patients with
favourable outcome in activities of daily living. The EADL is especially designed to
assess extended activities of daily living for stroke patients who live in their own
home. On the other hand, it may have less test-retest reliability both in the total score
and individual items than basic ADL scale such as the BI [Green et al. 2001] and the
effect size before and after the treatment may be small [Harwood and Ebrahim 2000],
In this study, the EADL was used as a primary outcome measure for extended
functional capacity at 3 and 6 months following stroke.
3.5.3 Sleep questionnaire and daytime sleepiness
3.5.3.1 The sleep and stroke questionnaire
The sleep and stroke questionnaire is shown in appendix E. It was developed
based on the sleep questionnaire used in the sleep centre of Edinburgh University.
The sleep and stroke questionnaire consists of two domains of question:
• Time and level of consciousness (sleep or wakefulness) at stroke onset.
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• Major symptoms of SDB: including excessive daytime sleepiness, frequency
and severity of snoring, witnessed apnoea, choking or suffocating episode,
awakening unrefreshed, nocturia and morning headache.
In this study, the sleep and stroke questionnaire was applied to patients at
baseline for general information about sleep-disordered breathing prior to stroke and
association between sleep and stroke onset.
3.5.3.2 Stanford Sleepiness Scale
The Stanford Sleepiness Scale (SSS) is shown in appendix F. The SSS consists
of seven statement regarding seven levels of current sleepiness [Hoddes et al. 1973].
A principal components analysis showed SSS is not a uni-dimensional scale but
contains two components identified as activation and sleepiness [MacLean et al.
1992],
A study recruiting 10 healthy subjects with valid driver licenses for a computer-
based Driving Simulation Task. The results showed the most significant driving
parameters (crashes, excess speed, mean reaction time and lane position variability)
correlated highly (p < 0.01) with objective sleepiness measured by the multiple sleep
latency test (MSLT). Lower but significant correlations (p < 0.05) were found
between the same parameter and subjective sleepiness measured by SSS although the
correlation between SSS and MSLT was not reported [Pizza et al. 2004]. There was
no strong association between objective sleepiness measured by Maintenance of
Wakefulness Test (MWT) and subjective sleepiness measure by SSS. Patients with
moderate sleep apnoea/ hypopnoea have in one study been reported to have higher
SSS scores than patients with severe sleep apnoea/ hypopnoea [Sauter et al. 2000].
In this study, the SSS was used to measure excessive daytime sleepiness at
baseline and as a secondary outcome measure at 3 months following stroke.
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3.5.3.3 Epworth Sleepiness Scale
The Epworth Sleepiness Scale (ESS) is shown in appendix G. The ESS [Johns
1991] has been used widely to assess subjective daytime sleepiness especially in
patients with the obstructive sleep apnoea/hypopnoea syndrome (SDB). It consists of
eight questions for sleep propensity in different daily situations, scored from 0 (no
chance of dozing), 1 (slight chance of dozing), 2 (moderate chance of dozing) to 3
(high chance of dozing) for each question:
• Sitting and reading
• Watching TV
• Sitting inactive in a public place
• As a passenger in a car for one hour without break
• Lying down to rest in the afternoon
• Sitting and talking to someone
• Sitting quietly after a lunch without alcohol
• In a car, when stopped for a few minutes in a traffic
The results of factor analysis showed the SSS, the Profile of Mood Scale
(POMS) and sleepiness-related Visual Analogue Scale (VAS) loaded onto one factor
at a very similar and high rate whereas modified ESS alone loaded highly onto the
other factor [Pilcher et al. 2003], This may indicate that ESS measures a different
aspect of subjective sleepiness from that measured by SSS. The ESS showed a
moderate correlation with mean sleep latency measured by MSLT (rho = -0.37, p =
0.0042) [Chervin et al. 1997]. A high ESS score (> 16) was significantly associated
with a low mean sleep latency in MSLT (< 8).




3.5.4.1 Addenbrooke's Cognitive Examination
The Addenbrooke's Cognitive Examination (ACE) is shown in appendix H. The
limitation of MMSE is insensitivity to the early stage of dementia. There is only one
question related to memory (free recall of three objects), one question related with
visuospatial function (copy of a crossed pentagon) and no question related to
executive function. This limitation might result in the ceiling effect when patients
who have SDB or stroke without dementia are assessed as impairment of both
memory and executive function are the major neuropsychological findings. This
problem can be solved by applying a more comprehensive neuropsychological battery
but this is time-consuming and not well tolerated by stroke patients.
The ACE was originally developed to increase the sensitivity to differentiate
fronto-temporal dementia from Alzheimer's disease [Mathuranath et al. 2000]. It
incorporates the MMSE, expands memory, language, visuo-spatial components and
adds tests of verbal fluency which belong to parts of executive function. Total score
of ACE is 100 including 30 points for MMSE. The ACE had a higher sensitivity
(82% vs. 52%) and predictive value than the MMSE with equal specificity (96%) for




• Verbal fluency (14)
• Language including naming (28)
• Visuospatial (5)
In this study, the ACE was used as a secondary outcome measure for cognitive
function at baseline and 3 months following stroke.
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3.5.4.2 Mini-Mental State Examination
The Mini Mental State Examination (MMSE) is currently one of the most
popular instruments for screening cognitive impairment [Folstein et al. 1975]. The
total score of MMSE is 30. Scores ranged 0-23 indicate impaired cognition. There
are five domains in the MMSE:
• Orientation (10)
• Registration (3)
• Attention and calculation (5)
• Recall (3)
• Language (naming, repetition, comprehension, reading, writing, drawing) (9)
The median of MMSE score in the normal U.S. population was 25 in subjects
aged 80 or older, including 29 in subjects who had undertaken education for > 9
years, 26 in subjects with education 5-8 years and 22 in subjects with education 0-4
years [Crum et al. 1993]. All tests in the MMSE are included in the ACE so the
MMSE can be extracted from completed ACE scores.
Mean score of MMSE was 22.1 in acute and sub-acute stroke (median 7.9 days
following stroke) and 48.7 % of the patients had cognitive decline defined as MMSE
< 24 [Adunsky et al. 2002]. The MMSE was significantly correlated with Clock
Drawing Test (CDT) which was used to evaluate attention, praxis, visuospatial and
executive functions. A significant correlation was also noted between both MMSE
and CDT to parameters of motor outcome assessed by motor score of Functional
Independence Measure (FIM).
In this study, the MMSE was not used alone but the score of MMSE was
subtracted from the ACE for measuring the cognitive function at baseline and the
cognitive outcome at 3 months following stroke.
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3.5.5 Mood and health-related quality of life
3.5.5.1 Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) is shown in appendix I. The
HADS was developed in 1983 [Zigmond and Snaith 1983].
The correlations between HADS and physical measures (Barthel Index and
Modified Rankin Scale) at 6-month following stroke were weak but still significant
[Dennis, O'Rourke, Lewis, Sharpe, and Warlow2000]. Depression subscale in HADS
had higher association with BI (rho = -0.4) and MRS (rho = 0.5) than anxiety
subscale did (rho = -0.2 with BI, rho = 0.3 with MRS).
About 23% of stroke patients at a long-term (5 years) follow-up had scores
suggesting depression and 18 (19%) had scores suggesting anxiety [Wilkinson et al.
1997]. The proportion of depression was significantly higher in those who were
disabled (BI = 0-19/20) than in those who were independent (BI = 20/20).
In this study, the HADS was used to assess mood status at baseline and as a
secondary outcome measure at 3 months following stroke.
3.5.5.2 EuroQol
The EuroQol is shown in appendix J. The EuroQol is a generic measure of health
status developed by EuroQol group in 1990 [1990], It is a simplified questionnaire
including EQ-5D which consists of Visual Analogue Scale (VAS) rated from 0 to







There was a significantly higher response rate in EuroQol group than in SF-36
group in the International Stroke Trial [Dorman et al. 1997]. The absolute difference
of "response without missing data" was 11% and odds ratio was 1.64 (p < 0.0001).
The reproducibility of EuroQol was generally good (un-weighted kappa = 0.63 -
0.80) and similar to those for SF-36 (intra-class correlation coefficient = 0. 67 - 0.80
except mental health and role emotional) in stroke patients [Dorman et al. 1998].
In this study, the EuroQol was used as a secondary outcome measure for general
health status at 3 months following stroke.
3.5.5.3 SF-36
The Medical Outcomes Study short form 36 health survey (SF-36) is shown in
appendix K. The SF-36 is the most widely used scale in assessing health-related
quality of life [McHorney et al. 1993;Ware, Jr. and Sherbourne 1992]. There are
more than 2000 articles regarding the validity of eight subscales of SF-36 with
physical summary score and mental summary score generated from them. The SF-36
consists of:
• Physical function (10 items)
• Role limitations-physical (4 items)
• Bodily pain (2 items)
• General health (5 items)
• Vitality (4 items)
• Social functioning (2 items)
• Role limitations-emotional (3 items)
• Mental health (5 items)
SF-36 obtained by post from old-aged stroke patients had good response rates
(83%) but variable completion rates (66 - 96%) especially for role limitation-physical
and role-limitation emotional subscales [OMahony et al. 1998]. Interview
administration might be more appropriate than self-completing the questionnaire in
stroke wards or rehabilitation units as many patients may have some mental, visual or
physical disability [Anderson et al. 1996].
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SF-36 might also have limitations in a number of subscales in stroke patients
[Hobart et al. 2002], Subscale for role limitation-physical had a notable floor effect.
In contrast, subscales for role limitation-emotional and mental health had ceiling
effects. Assumptions for generating 2 SF-36 summary measures were not satisfied.
Principle components analysis revealed two factors of SF-36 which supported two
summary scores but these two components can only explain less than 60% of the
total reliable variance in all SF-36. Thus all subscales instead of two summary scores
only were used.
In this study, the SF-36 was used as a secondary outcome measure for health-
related quality of life at 3 and 6 months following stroke.
3.5.6 Ambulatory blood pressure
Conventional use of the sphygmomanometer has some problems including: (1)
terminal digit preference; (2) inter-observer variation and (3) improper technique. A
single measurement cannot reflect the circadian rhythm of 24-hour blood pressure.
Especially for ageing people, some physiological changes include: (1) increased
blood pressure variability; (2) arterial rigidity; (3) more pronounced diurnal variation;
(4) baroreceptor insensitivity can make an isolated measurement inaccurate. There is
also the "white-coat effect", an increased blood pressure only in the medical care
environment, which can result in inaccuracy of in-office blood pressure
measurement.
The ambulatory blood pressure (ABP) is not only a convenient device for
detecting 24-hour circadian rhythm of blood pressure but also more objective than
casual blood measurement to represent the true "blood pressure burden". There are
two patterns of common circadian rhythm of blood pressure depending on whether
afternoon dipping is slight or marked: (1) If afternoon dipping is slight, a 24-hour
period of circadian rhythm is noted with a peak in the late afternoon and a nadir in-
between the descending and ascending limbs of overnight dipping [Clement et al.
2003]; (2) If afternoon dipping is as marked as overnight dipping, a 12-hour period of
circadian rhythm is noted [Stergiou et al. 2002].
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In this study the circadian blood pressure was used as a secondary outcome
measure by a compact and light-weighted portable Spacelabs 90207 ABP Monitor®
(SpaceLabs Medical Ltd., Redmond, WA, USA, Figure 3.4, P. 116). The BP monitor
was programmed to measure every 30 minutes for 24 hours, starting between 2-3
PM. We defined pressures between 6:00 AM and 9:59 PM as occurring during the
daytime and between 10:00 PM and 5:59 AM as nighttime, corresponding to the
schedule of the stroke wards.
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3.6 Data analysis
The Nottingham Extended ADL Index (EADL) was chosen as the primary
outcome measure. Secondary outcome measures included: Subscales of EADL, NIH
Stroke Scale (NIHSS), Barthel Index (BI), Stanford Sleepiness Scale (SSS),
Addenbrooke's Cognitive Examination (ACE) and Mini-Mental State Examination
(MMSE), Hospital Anxiety and Depression Scale (HADS), MOS Short Form 36
Health Survey (SF-36) and ambulatory blood pressure. Data was collected from sleep
studies, from information stored nightly in the AutoSet T and from hospital and
home visits. Analysis was performed following two major principles:
• Intention-to-treat analysis
All patients recruited in the RCT study were followed-up at eight weeks
regardless of compliance with treatment. This permitted a conservative estimate of
the effectiveness of treatment in this group of patients. Where patients withdrew sub¬
group analysis was done to ensure that there were no differences between patients
who participated and those who withdrew (i.e. homogeneity of randomization
preserved).
• Hypothesis-driven data analysis
Hypothesis-driven data analysis was conducted for primary and secondary
outcomes to determine: (1) the differences between the CPAP and the conservative
treatment groups after 8 weeks of treatment; (2) the differences between the apnoeic
and non-apnoeic groups at the end of 3 months and 6 months after stroke.
• Post-hoc data analysis
Post-hoc exploratory data analysis was conducted for: (1) the difference between
the CPAP and the conservative treatment groups and between the apnoeic and non-
apnoeic groups in certain subgroups divided by NIHSS, MMSE and HADS; (2)
correlations of the sleep data and the outcome variables and advanced analysis of the
ABP data to support the underlying mechanisms for hypothesis. Post-hoc analysis is
biased in both multiple statistical comparisons and data dredging so it is inherently
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sub-optimal. The results should be interpreted conservatively and are only used for
hypothesis generation for subsequent studies in the future.
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3.7 Ethics and informed consents
Ethics approval has been obtained from the Lothian Research Ethics Committee
(Reference MREC/2000/4/44). Trust management approval has been given by
Research & Developmental Office on behalf of the Trust Chief Executive and
Medical Director (Reference R&D/99/17/08). Written informed consents were
obtained from all participants.
In the first instance we had considered a two-stage consent process i.e. consent
for the prevalence study, and then consent for the RCT. We finally decided against
this after the two patients had been recruited. The novel and most important part of
this study was RCT. As the facilities to perform sleep studies were limited we
determined that recruiting those who were not willing to attend CPAP trial might
delay the time course of the study and decrease the sample size of the RCT. Thus we
focused on the RCT component of the study.
Patients with severe dysphasia (receptive dysphasia, severe expressive dysphasia
and global aphasia) were excluded. Patients with mild to moderate dysphasia (mild to
moderate expressive dysphasia) still could fill in the sleep questionnaire including
onset time of stroke and scales and respond to face-to-face interviews.
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NIHSS: National of Health Stroke Scale, MRS: Modified Rankin Scale, BI: Barthel
ADL Index, ESS: Epworth Sleepiness Scale, SSS: Stanford Sleepiness Scale,
MMSE: Mini Mental State Examination, ACE: Addenbrooke's Cognitive
Examination, HADS: Hospital Anxiety and Depression Scale, EADL: Nottingham
Extended ADL Index, ABP: Ambulatory Blood pressure, SOI: State of
Independence
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Figure 3.2 AutoSet T®: reproduced from ResMed company
(www.resmed.com)
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Figure 3.3 Embletta® PDS recording system: reproduced from
Medcare company (www.medcare.com)
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Figure 3.4 ABP Monitor®: reproduced from SpaceLabs company




Chapter 4 A Cross-Sectional Study of Obstructive Sleep
Apnoea/Hypopnoea in Patients with Stroke
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associated with cognitive impairment (Addenbrooke's Cognitive Examination total
score < 80, p = 0.002).
Conclusions: We supported high prevalence of SDB and related symptoms in
stroke and emphasized the role of SDB in stroke onset and cognitive function.
Key words: Sleep-disordered breathing; stroke; prevalence; snoring; excessive
daytime sleepiness; stroke onset; sleep-related stroke
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4.2 The aims of the study
Scientific background of this randomized controlled trial (RCT) has been
reviewed in chapter 2.10. According to previous reviews, we had five aims in this
cross-sectional study:
• To established the feasibility or not of applying overnight sleep studies to
stroke patients in the UK.
• To find out the prevalence of SDB based on hospital-based stroke patients in
Edinburgh city in the UK.
• To clarify the predictive value of pulse oximetry and major sleep symptoms
for moderate to severe SDB.
• To clarify the relationship between SDB, stroke onset and sleep-related
stroke.
• To assess the influence of AHI and oximetric variables on functional





All participants were contacted in the first 2 weeks following their most recent
stroke at either acute stroke units or stroke rehabilitation wards in four university
hospitals in Edinburgh city. Five stroke specialists made the diagnosis of stroke
according to history, neurological examination and neuroimaging (CT or MRI scan)
findings. The criteria for inclusion and exclusion have been described in chapter 3.
Both ischaemic and hemorrhagic strokes were included. Ischaemic stroke was
classified according to the Oxford Community Stroke Project (OCSP), i.e. total
anterior circulation infarct (TACI), partial anterior circulation infarct (PACI),
posterior circulation infarct (POCI) and lacunar infarct (LACI) [Bamford et al. 1991].
4.3.2 Sleep studies
On day 14-19 after stroke, recruited patients underwent sleep study using a
portable device (Embletta PDS, Medcare Flaga, Reykjavik, Iceland) incorporating:
(1) nasal pressure; (2) oral thermistor; (3) thoraco-abdominal movement; (4) finger
pulse oximetry; (5) body position. The detail of the device has been described in
chapter 3.4.1. The validity and reliability of the Embletta machine has been
demonstrated [Dingli et al. 2003].
The portable device was programmed to record from 9 pm to 6 am. Each patient
was visited about one hour before recording began. It took about 15-20 minutes to set
up all the sensors so he or she had at least half an hour to get used to them. Any
problem during this period was checked and corrected. After I had started recording,
I stayed for a further two hours to make sure that Embletta was working properly.
During that time I also took information from the casenotes. Before leaving I left the
container of the device with simple instructions pasted outside and detailed
instructions inside. Night staff in the ward helped to keep an eye on the sensors
especially when patients went to the toilet. The sensors were removed either when
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patients woke up without further sleep or after 6 am in the morning. The device was
packed up and brought back to the Department of Sleep Medicine for analysis.
Raw data were downloaded onto computer with a sleep analysis programme.
Manual scoring was performed because automatic scoring is not reliable according to
previous clinical experience. As Embletta does not record sleep, the onset of sleep
was taken as the onset of rhythmic stable breathing. The end of the study was taken
as the patient's or caregiver's report of final awakening time or continuous
movement artefacts without coming back to regularity of breathing pattern. The
interval between the onset and the end of the study was calculated as "hours in bed".
Apnoeas and hypopnoeas were scored using standard criteria based on the report
of an American Academy of Sleep Medicine Task Force [1999]. Apnoea was defined
as the absence of nasal airflow for at least 10 seconds. It was classified as obstructive
type if there was concomitant thoracic or abdominal respiratory effort, as central type
if there was no associated respiratory effort and, as mixed type if there was a central
pattern followed by an obstructive pattern. Hypopnoea was defined as a 50% or
greater reduction in the amplitude of either nasal pressure or thoraco-abdominal
movement for at least 10 seconds [Gould et al. 1988]. The total number of apnoea
and hypopnoea per hour in bed after "sleep onset" was reported as (A+H)-h"\
Oxygen desaturation was scored if there was a > 4% decrease of pulse oximetry
preceded by either apnoea or hypopnoea. Total number of oxygen desaturations per
hour in bed after "sleep onset" was reported as oxygen desaturation index (ODI).
4.3.3 Reliability tests
After study was finished, I repeated blind scoring for 31 patients to test intra-
rater reliability who were randomly chosen by an experienced polysomnographer
(MV) in the department who was not involved in the first scoring. She also scored 7
of 31 patients' sleep data herself to test inter-rater reliability. The mean interval
between the first and second scoring was 15 months, ranging from 3 months to 32
months. Intraclass correlation (ICC) was used to measure intra-rater and inter-rater
reliability.
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Bland-Altman plot is a statistical method to compare two methods of clinical
measurement [Bland and Altman 1986]. The differences between the two
measurements are plotted against the averages of the two measurements. In this study
I applied Bland-Altman plot to compare the 2nd scoring of (A-i-H)-h"1 to the 1st one
performed by me and also, to compare the 2nd scoring of (A+H)-h_1 performed by me
to the scoring of (A+H)-h"' performed by MV.
4.3.4 Sleep questionnaire
On the morning following the overnight sleep study, a sleep questionnaire with a
4-choice response for each question was given to all patients. There were four
domains of questions in the sleep questionnaires: (1) Time and conscious state
(asleep or awake) of stroke onset; (2) Nocturnal SDB-related symptoms, namely:
duration, frequency and intensity of snoring, choking episodes, witnessed apnoea and
nocturia. (3) Daytime SDB-related symptoms in terms of awakening unrefreshed,
excessive daytime sleepiness (EDS), morning headaches and road traffic accidents;
(4) Basic information about the sleep study in terms of the subjective sleep/wake
time and quality of sleep, measured by a 5-level Likert scale.
The Stanford Sleepiness Scale (SSS), which is a 7-level Likert scale, was applied
for current sleepiness following stroke. The Epworth Sleepiness Scale (ESS) was
applied for pre-stroke sleepiness if patients were clear and cooperative enough to fill
in the questions.
4.3.5 Onset time of stroke
Every patient was asked about the time of stroke onset defined by the time they
last recalled being unaffected (the last-seen-well principle). The information given by
patients was checked with routine records in the casenotes at admission. If there was
a discrepancy, it was further clarified with partners or caregivers. These data were
analyzed according to the following 3 steps:
• Circadian distribution of relative risk of stroke onset was calculated and
expressed for each 4-hour interval throughout a day (24 hours). The method
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of calculating relative risk has been previously used [Elliottl998], It is
assumed that all events of stroke would be evenly distributed over the 6
intervals, i.e. 11 patients in each interval for total 66 patients. Thus the
relative risk for each interval is calculated by the ratio of the observed
number of strokes to the expected number of strokes.
Stroke onset times were further grouped by 1 hour blocks for patients with
(A+H)-h 1 < 15,15 < (A+H)-h1 < 30 and (A+H)-h_1 > 30. As the sample size
in the three groups of patients were not equal, the number of strokes in each
1-hour block was transferred into odds, defined as number of strokes
occurring in that hour divided by number of non-events (i.e. the number of
strokes in that group occurring in the remaining 23 hrs) for further
comparison between groups. The raw data were smoothed by using a
running average of two consecutive 1-hour blocks before putting them into a
polynomial regression model for curve fitting and plotting as previously
used [Hill and Newcommon 2003].
Two arbitrary time intervals were defined as "sleeping time" (00:00 to 7:59,
8 hours) and "waking time" (8:00 to 23:59,16 hours) according to our
previous definition [Engleman et al. 1996b]. It is also assumed that if all
events of stroke were evenly distributed, 1/3 of events would occur in
"sleeping time" and 2/3 in "waking time". The relative risk for each interval
was calculated using a similar method to that described above and was
compared between groups with SDB ((A+H)-h1 < 15) and without SDB
((A+H)-h_1 > 15) by Chi-square test.
The frequency of sleep-related stroke, defined as stroke noticed on
awakenings, and wake-related stroke was compared between four groups of
patients, i.e. (A+H)-h4 < 15,15 < (A+H)-h4 < 30, 30 < (A+H)-h4 < 45 and
(A+H)-h4 > 45 by Chi-square test.
Logistic regression was used to predict sleep-related stroke by demographic
variables and variables obtained in sleep study in total patients and in
patients SDB ((A+H)-h4 < 15) and without SDB ((A+H)-h4 > 15).
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4.3.6 Baseline assessment and other data collection
Baseline assessment was performed on the morning following the overnight
sleep study at the same time as the sleep questionnaire. The Barthel index (BI) based
on self-report was used to assess functional capacity in terms of independence of
mobility and self-care. Psychological distress was assessed by the Hospital Anxiety
and Depression Scale (HADS) including 7 questions for anxiety and 7 for depression.
The Addenbrooke's Cognitive Examination (ACE) developed by Cambridge
University [Mathuranath et al. 2000] was chosen to assess cognitive function
including six domains of questions in terms of orientation, attention, memory, verbal
fluency, language and visuospatial ability. A Mini Mental State Examination
(MMSE) score can be obtained directly from ACE. The total score is 100 including
30 for MMSE. Total assessment time is about 30 minutes. Detailed information
about the scales has been presented in chapter 3.
Demographic information and baseline data which were collected either from the
casenotes or by patient interviews include: (1) date of birth, gender and duration of
education; (2) body weight and body height for calculation of body mass index (BMI)
as weight/(height) 2; (3) date of stroke, date of admission and discharge; (4) blood
pressure, body temperature and Sa02 at admission (5) past medical history of
cardiovascular risk factors, smoking and alcohol consumption; (6) previous and
current medications.
Results of laboratory tests which were collected from the casenotes were: (1)
haematocrit, haemoglobin, platelet count, erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP); (2) plasma glucose and total cholesterol; (3) chest X-ray,
ECG and echocardiography; (4) neuroimaging study (CT or MRI) and carotid duplex
ultrasonography. Evidence of atrial fibrillation (AF) and left ventricular hypertrophy




The mean number of sleep apnoea and hypopnoea per hour in bed was expressed
as (A+H)'h1 in the text of the article but for the purpose of convenience, as AHI in
tables and figures. All continuous data were presented as a median and an
interquartile range (IQR) and categorical data were presented as a number (n) or
percentage (%). Non-parametric tests were conducted including the Mann-Whitney U
test and the Chi-square Test (Fisher's test in case there were less than 5 patients in a
category) for between-group comparisons. The p value < 0.05 was taken as
significant.
Binary logistic regression was conducted to control confounding factors or to
adjust for interactions. All predictors with p < 0.1 in univariate regression analysis
were entered into the final model. Odds ratio and confidence interval (CI) for each
predictor were expressed. The predictors with p < 0.05 in final model were taken as
significant. Statistical analysis was done by the statistical software, SPSS version
11.0 (SPSS Inc. USA).
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4.4 Results
4.4.1 Recruitment of cases
I screened 658 patients believed to have had a stroke from March 2001 to June
2003 by myself. The recruitment pattern is shown (Figure 4.1, P. 162). Only 96
(15%) of 658 patients were eligible. Informed consent was not given by 25 (26%) of
these. The reasons for refusal were: (1) 7 were not happy with extra research; (2) 4
were not happy with overnight sleep monitoring; (3) 4 were not concerned if they had
SDB; (4) 4 had had a similar study before so were not keen to repeat; (5) 3 were not
happy with nasal CPAP treatment even though they might be randomized to no
treatment; (6) 2 patients' consultants didn't think they would tolerate an overnight
study; (7) 1 patient's family declined. In total 71 patients were successfully recruited
for overnight sleep study.
4.4.2 Sleep studies
The sleep study was performed in an acute stroke unit for 25 patients, in
rehabilitation ward for 42 patients and at home for 4 patients. Eight patients had
inadequate recording in the first night, defined as less than five hours of satisfactory
quality of tracings. Of those eight, one had nocturnal confusion, one had severe
diarrhoea, one had severe coughing and chest discomfort, and one could not sleep
with monitors until midnight and so took them off. The other four patients did not
have clear reasons. Three of these eight patients agreed to have repeated sleep studies
on the next night, which were all successful. Five patients refused to repeat the study.
They were further excluded. This resulted in 66 valid patients. Only one patient was
happy to have three consecutive sleep studies in the 1st, 3rd and 12th week after stroke.
His (A+H)-h_1 was 22.4, 21.5 and 21.3 respectively. There was slight decrease of
(A+H)-h4 from 1 week to 3 months after stroke in this patient. Only the sleep study
in the 3rd week was put into analysis.
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The results of sleep study were shown in Table 4.1 (P. 148). Half of patients had
(A+H)-h4 > 30, 60 % had (A+H)-h_1 > 20, 70 % had (A+H)-h_1 > 15 and 85 % had
(A+H)-h > 10. The distribution of (A+H)-h~1 was positively skewed but the
difference between median (30.5/hr) and mean (30.9/hr) was minimal. All patients
with SDB had predominantly obstructive SDB. Patients were divided into two groups
based on cut-off score of (A+H)-h4 > or < 30 for further comparison. The cut-off
score of (A+H)-h4 > 30 was chosen to discriminate severe SDB from mild (5 <
(A+H)'h1 < 15) and moderate (15 < (A+H)-h4 < 30) SDB according to the definition
described in chapter 1.4.
Hypopnoea was more common than apnoea. The proportion of central sleep
apnoea was low but higher in patients with (A-t-H)-h4 > 30 than < 30. The median of
the central apnoea index (CAI) was only 0.4 (IQR 0.0-1.1). Nine patients had a few
episodes of Cheyne-Stokes respiration (CSR) but none of them fulfilled the proposed
criteria of diagnosis [Bassetti et al. 1997]. Among them, 8 patients belonged to
(A+H)-h4 > 30. Only 1 patient had (A+H)-h4 < 30. The median (A+H)-h4 of those
who had CSR (56.8, n = 9) was significantly higher (p = 0.002) than those without
CSR (23.1, n = 57).
There were significant correlations between (A+H)-h4, oximetric variables and
heart rate variables (Table 4.2, P. 149). Heart rate variability (HRV) was defined as
the standard deviation of overnight pulse rate data recorded by pulse oximetry The
higher the (A+H)-h"' or the more severe desaturation was, the higher the heart rate
variability was. In contrast, the higher the (A+H)-h4 or the more severe the
desaturation was, the lower the lowest heart rate was.
4.4.3 Reliability tests
The sleep study had high intra-rater reliability (Intraclass Correlation Coefficient,
ICC = 0.983, p < 0.001, Figure 4.2a, P. 163) and inter-rater reliability (ICC = 0.977,
p < 0.001, Figure 4.2c, P. 164). The Bland-Altman plot of 31 patients for the
comparison between the 1st and 2nd scoring of (A+H)-h 1 performed by me showed
that the (A+H)-h4 of the first scoring was slightly higher than the second scoring
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(mean difference = 0.4, SD = 6.3, Figure 4.2b, P. 163). The Bland-Altman plot of
seven patients for the comparison between the scoring of (A+H)*h1 performed by me
and by an experienced research nurse showed that there was no clear difference of
scoring in four patients with (A+H)-h_1 < 20 but I scored slightly higher (A+H)-h_1 in
three patients with (A+fTflf1 > 25 (mean difference = 1.7, SD = 3.1, Figure 4.2d, P.
164).
4.4.4 Demographic characteristics and baseline assessments
The demographic characteristics for 66 patients undergoing initial sleep study
analysis were shown in Table 4.3 (P. 150). All patients had normal Sa02 on air (>
90%) on admission and all were apyretic on admission and during the sleep study.
The mean age was 72 (SD = 11) median age was 74 (IQR = 65-81). There were 45
men and 21 women. There was no significant difference in age between patients with
(A+H)-h"' > 30 and < 30. The (A+H)-h_1 increased with age from 40s to 70s but
dropped down in 80s (Kruskal-Wallis test, p < 0.001, Figure 4.3, P. 165). There was
no gender difference between patients with (A+H)-h_1 > 30 and < 30. Although those
who had (A+H)-h4 > 30 also had slightly higher BMI and BMI was positively
correlated with (A+H)-h_1 (Spearman rho = 0.308, p = 0.012, Figure 4.4, P. 166)
patients with SDB were not obese (BMI < 30). Sixty percent of patients had a history
of hypertension. There was no significant difference in history of hypertension and
other cardiovascular risk factors between the two groups but patients with (A+H)-h_l
> 30 seemed to have higher proportion of diabetes, atrial fibrillation (AF) and left
ventricular hypertrophy (LVH).
Stroke was classified into different subtypes by me according to Oxford
Community Stroke Project (OCSP) [Bamford et al. 1991]. Most of the patients (n =
41) had PACI, 13 patients had TACI, 3 had POCI and 4 had LACI. The other 5
patients had primary ICH. The group with (A+H)-h~' > 30 consisted of more patients
with TACI and POCI and the group with (A+H)-h4 < 30 consisted of more patients
with PACI and LACI. Six of nine patients who had CSR belonged to PACI, one
belonged to TACI, one belonged to ICH and one belonged to POCI.
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The baseline assessments were shown in Table 4.4 (P. 151). All patients were
functionally independent prior to their most recent stroke (MRS < 2). Pre-stroke
MRS was "0" in 56, "1" in 7 and "2" in 3 patients. Median NIHSS score was 6.
There was no significant difference in NIHSS, MMSE, ACE, BI, HADS between
patients with (A+H)-h ] > 30 and < 30 despite patients with (A+H)-h_l > 30 had
relatively lower scores in ACE. There was no significant difference of (A+H)-h_1
between patients with and without dysarthria and, between patients with and without
dysphasia.
Although the stroke patients studied were inevitably a highly selected group they
were similar with "typical" stroke patients admitted to the Western General Hospital
in Edinburgh. A study was performed during the same period (31 October 2001 - 31
October 2003) in the same stroke unit (Western General Hospital) with the same
device of recording (Embletta) to investigate the relationship between hypoxaemia
and stroke [Rowat et al. 2005]. They had entry criteria to recruit any patient who had
a suspected first or recurrent ischaemic or haemorrhagic stroke, was admitted within
working hours on weekdays and could be approached within 24 hours after stroke
onset. Although they had a broad spectrum of entry criteria in contrast to my strict
ones there was still no clear difference in demographic characteristics and baseline
assessment between our data. In their study, 29% of stroke patients had Total
Anterior Circulation Stroke (TACS) and 40% had Partial Anterior Circulation Stroke
(PACS). The median age was 81 (IQR = 74-86) with 50% of male patients in
hypoxic group and the median age was 77 (IQR = 74-84) with 44% of male patients
in non-hypoxic group. The median NIHSS score on day 1 was 6 (IQR = 4-15) and on
day 7 was 4 (IQR = 1-11) in hypoxic group. The median NIHSS score on day 1 was 6
(IQR = 3-15) and on day 7 was 4 (IQR = 1-14) in non-hypoxic group.
As this study (Edinburgh Stroke and Sleep Apnea Study, ESSAS) belonged to
Edinburgh Stroke Study (ESS), the baseline data of patients who refused to sign
informed consent could still be used to investigate selection bias. As non-consenting
patients did not receive any extra assessment only demographic data and type of
stroke were available. The demographic characteristics and baseline assessments of
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25 non-consenting patients and 5 patients who had inadequate sleep studies were not
significantly different from the finally recruited patients. The median age of these 30
patients was 73. There were 20 male and 10 female. Pre-stroke Modified Rankin
Scales were "0" in 28 and "1" in 2 patients. Median NIHSS was 6. Four patients had
TACI, 20 had PACI, 3 had POCI, 1 had LACI and 2 had ICH.
4.4.5 Laboratory data at baseline
The laboratory data at baseline were shown in Table 4.5 (P. 152). There was no
difference in the laboratory data between patients with (A+H)-h_1 > 30 and < 30.
Patients with a history of hypertension also had significantly higher systolic blood
pressure (p = 0.021) and relatively higher diastolic blood pressure on admission than
non-hypertensive ones. The patients with (A+H)-h_1 > 30 had relatively but not
significantly higher ESR level. One patient in the (A+Hfh"1 > 30 group had a stroke
within a few days of abdominal surgery and his ESR increased to 105 and CRP to
300. The statistical significance did not change whether or not the outliers were
included. Twenty-eight patients had had results of carotid duplex ultrasonography
following their most recent stroke. There was no difference of significant stenosis (>
60%) of the internal carotid artery (ICA) on either the left or the right side between
the groups (p = 0.461).
4.4.6 The association between SDB-related symptoms and
(A+H) h1 in stroke
Self-reported snoring and EDS were two predominant symptoms which
distinguished apnoeic and non-apnoeic stroke patients (Table 4.6, P. 153). There was
a significantly higher proportion of snoring (80%, answer of "yes") in patients with
(A+H)-h_1 > 30 (Chi-square p = 0.001). If we take frequency into consideration, the
difference of habitual snoring (answer of "often" or "almost everyday") between
(A+H)-h_1 > 30 and < 30 was smaller and not significant (p = 0.071). Among 33
stroke patients with (A+H)-h_1 > 30, only 6 patients (18.2%) denied a history of
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snoring and 5 patients (15.2%) didn't know whether they snored or not. Five out of 6
patients who answered "don't know" for snoring had (A+H)-^1 > 30.
There was a significantly higher proportion of EDS (66.6%, answer of "yes") in
patients with (A+H)-^1 > 30 as well (Chi-square p = 0.007, Table 4.6, P. 153). If we
take frequency into consideration again, the difference of moderate to severe EDS
(answer of "always" or "4-6 times per week") between (A+H)-h_1 > 30 and < 30 was
also smaller but still significant (p = 0.039). Median pre-stroke ESS in 24 patients
with (A+H)-h 1 > 30 was only 6 although it was significantly higher than patients with
(A+H)-h_1 < 30 (ESS = 4, Mann-Whitney U test, p = 0.03). Only 29.2% of patients
with (A+H)-h1 > 30 had ESS > 10. The SSS results at baseline were not different
between groups. There was a weak correlation between (A+H)-h_1 and ESS
(Spearman's rho = 0.289, p = 0.047, Figure 4.5a, P. 167). Patient with (A+H)-h_1 > 30
had a wider spectrum of ESS and SSS than patients with (A+H)-h" ' < 30 (Figure 4.5b,
P. 167). There was no significant correlation either between (A+H)-h~1 and SSS (p =
0.896, Figure 4.5c, P. 168) or between ESS and SSS (p = 0.055, Figure 4.5d, P. 168).
Almost all (97%) patients with (A+H)-h_1 > 30, in contrast to 3/4 (75.8%) of
patients with (A+H)-h"' < 30, had at least 1 of 5 major SDB-related symptoms in
terms of snoring, EDS, choking episodes, witnessed apnoea and awakening
unrefreshed (p < 0.05, Table 4.6, P. 153). About 90% of patients with (A+H)-h~' > 30,
in contrast to less than 50% of patients with (A+H)-h4 < 30, had at least 2 of 5 major
symptoms (Chi-square, p < 0.001). More than half (57.6%) of patients with (A+H)-h
1 > 30, in contrast to less than 1/4 (24.2%) of patients with (A+H)-h_1 < 30, had at
least 3 of 5 major symptoms (p < 0.01).
The sensitivity and specificity of all major SDB-related symptoms were not high
(< 90%, Table 4.7, P. 154). Snoring, EDS and choking episodes were 3 major
symptoms with a relatively higher positive likelihood ratio (LR+ > 2). The likelihood
ratio of other single variables was low (LR+ < 2).
After controlling for confounding factors in a logistic regression model, only age
(65-79), BMI (> 25) and snoring remained independent predictors for moderate to
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severe SDB, (A+H)*h > 30 (Table 4.8, P. 155). EDS and choking episodes were no
longer significant. I propose a simple clinical pathway of decision making to be used
in the future for moderate to severe SDB in stroke based on the results of logistic
regression with age, BMI, snoring and forced entry of EDS as predictors. A flow
chart of decision making for sleep study in a stroke based on the best-fitted model
was drawn (Figure 4.6, P. 169). Three predictors in the final regression model, age,
BMI and reported snoring and one not in the model, self-reported EDS, were used to
draw the flow chart. EDS was still used to increase the predictive value of the model
because it is a common symptom and there was a significant difference of EDS
between patients with (A+H)-h_1 > 30 and < 30 in my study. The purpose of the flow
chart was to predict the probability of having moderate to severe SDB, i.e. (A+H)-h"'
> 30, in stroke. As the prevalence of SDB with (A+H)-h~1 > 30 in my study was 50%
the probability of > 50% is used as a cut-off point to consider whether stroke patients
can be referred for a sleep study.
4.4.7 The role of pulse oximetry in the diagnosis of SDB in stroke
Oximetric variables in terms of oxygen desaturation index (ODI), percentage of
time with Sa02 < 90% and mean Sa02 obtained from pulse oximetry were used to
calculate the Receiver Characteristics Curve (ROC) for predicting moderate to severe
SDB (AHI > 30) according to sensitivity and specificity at different cut-off points.
The results showed that ODI had low sensitivity (69.7%) but high specificity (90.9%)
at the cut-off point of 11.8/h (Figure 4.7, P. 170 and Table 4.9, P. 156). The area
under the ROC curve was 0.87 (95% CI = 0.77-0.94), which means it had only fair
predictive accuracy (> 0.80). ODI was slightly but not significantly better than the
percentage of time with Sa02 < 90% in predicting moderate to severe SDB. The
predictive value of mean oxygen saturation was significantly lower than ODI and the
percentage of time with Sa02 < 90.
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4.4.8 Sleep-related stroke and onset time of stroke
The distribution of stroke onset in 66 patients showed a peak of relative risk
located in the 4-hour interval between 8 am and noon (Figure 4.8a, P. 171). Three
curves were drawn for the odds of stroke onset in patients with (A+H)-h"' < 15, 15 <
(A+H)*h 1 < 30 and (A+H)-h1 > 30 based on the best fitted polynomial regression
model. Morning peak of stroke onset was evident in all three groups. The circadian
pattern of odds of stroke onset was similar in patients with 15 < (A+H)-h_1 < 30 and >
30 but different from that in patients with (A-i-H)-h"1 < 15 (Figure 4.8b, P. 171).
Patients with (A+H)-h 1 > 15 appeared to have the peak of stroke onset located in the
4-hour interval between 8 am to noon (9:30 am) and patients with (A-i-H)-h"1 < 15
appeared to have the peak of stroke onset located in the 4-hour interval between 4 am
to 8 am (7:30 am). There was about 2 hours of difference of peak time between these
two groups. Because the raw data entered into the regression model were smoothed
by moving average of number of events in two consecutive 1-hour block of time and
the number of events was relatively low, the difference of 2 hours is approximately
equal to 2 hours of error bar, so this difference might not be significant.
Patients with (A-t-H)-h1 >15 had higher odds of stroke onset from midnight to
noon but patients with (A+H)-h4 < 15 had higher odds of stroke onset from noon to
midnight (Figure 4.8b, P. 171). I further compared two groups for waking time and
sleeping time (see chapter 4.3.5) which also approximate the schedule in the stroke
wards. Patients with SDB [(A+H)-h4 > 15] had more strokes presenting in "waking
time" (p = 0.006, Figure 4.8c, P. 172) than in "sleeping time". A similar finding was
seen in patients with atrial fibrillation (AF, p = 0.029).
Twenty-four (36.4%) of 66 patients had sleep-related stroke. Nine of 24 patients
had stroke onset between midnight and 5:59 am. Eleven of 24 had stroke onset
happened between 6:00 and 9:00 am. One of 24 had a stroke during an afternoon nap
and three of 24 during evening naps. There was no significant difference of (A+H)-h1
between patients with (median = 23.5/h, IQR = 12.7-42.5) and without (median =
32.5/h, IQR = 17.2-48.0) sleep-related stroke (Mann-Whitney U test, p = 0.497,
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Table 4.10, P. 157). There was no significant difference of age, type of stroke,
severity of stroke, pre-stroke and post-stroke sleepiness between patients with and
without sleep-related stroke. There was also no significant difference in the
frequency of sleep-related or wake-related stroke in 4 groups of patients from lower
to higher (A-t-H)-h1 (Chi-square test, p = 0.523, Figure 4.8d, P. 172).
In the logistic regression model of prediction, neither (A+H)-h4 nor oximetric
variables were independent predictors for sleep-related stroke either in the total
patient group or in the subgroup of patients with (A+Hj-h"1 > 30. In the subgroup
with (A-i-H)-h"1 < 30, the interaction of lowest Sa02 and lowest heart rate (HR) was
the only independent predictor for sleep-related stroke (p = 0.023, Table 4.11, P.
158). The formula generated from the logistic regression model was:
Log (odds) = -0.002 * (lowest Sa02) * (lowest HR) + 4.103.
Where odds = p/l-p ("p" is the probability of sleep-related stroke),
Coefficient for (lowest Sa02) * (lowest HR) = -0.002,
Constant (also called the "intercept") = 4.103,
A surface plot derived from the logistic regression model according to table 4.11
(P. 158) was drawn to demonstrate this relationship (Figure 4.8e, P. 173). The z-axis
represented odds of sleep-related stroke. The x- and y-axis represented lowest heart
rate and lowest Sa02 respectively. The plot showed the lower the lowest Sa02 and
the lower the lowest heart rate the higher the odds of sleep-related stroke in the group
with (A-l-H)-h"1 < 30.
4.4.9 The relationship between variables in sleep study and
baseline assessment in stroke
Lowest Sa02 and variables related with heart rate were significantly correlated
with cognitive functions measured by MMSE and ACE at baseline (Table 4.12, P.
159). Post-hoc multivariate analysis with logistic regression after adjusting for
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dysphasia showed that dysphasia (p = 0.001) and the interaction of lowest Sa02 and
lowest heart rate (p = 0.002) were two independent predictors for lower cognitive
score (ACE < 80) at baseline (Table 4.13, P. 160).
There was no significant gender difference in age, BMI, (A+H)-h"' and oximetric
variables. Female patients had slightly but significantly lower haemoglobin (p =
0.01), haematocrit (p = 0.001), platelet count (p = 0.017) and score of MMSE (p =
0.048, Table 4.14, P. 161).
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4.5 Discussion
4.5.1 Prevalence of SDB in stroke
The reasons why only 15% of screened stroke patients were eligible in this study
were:
• I had strict entry criteria which were designed for randomized controlled
trial (RCT) of nasal continuous positive airway pressure (CPAP).
• Patients had to agree to both overnight sleep study and CPAP treatment
before being recruited into the observational part of the study.
This might increase the rate of compliance to CPAP treatment but, on the other
hand, could result in bias of reporting prevalence of SDB. The prevalence study in
my research was designed to determine the frequency of SDB in patients 14-19 days
after definite stroke who might be able to cope with CPAP therapy. This might be not
the same as the prevalence of SDB in all patients after stroke. It is a relevant and
theoretically important question and has to be seen in the specific clinical context. By
excluding patients with severe incapacity from stroke the prevalence observed in this
study might be lower than in the whole stroke population whereas by excluding
patients with mild stroke (NIHSS < 4) the opposite effect might have occurred. The
baseline data of stroke patients in my study were similar with those in another study
performed in the same stroke unit with broadened entry criteria which have been
presented in chapter 4.4.4. This reflects that my stroke patients might be similar with
typical in-hospital stroke patients, at least in Edinburgh. Thus the difference of
prevalence of SDB between my study and general stroke population might not be big.
Our study supports the high prevalence of SDB in acute stroke noted by others
[Bassetti and Aldrichl999b]. We found that 50% of stroke patients had (A+H)-h_l >
30 and 60% had (A+H)-h_1 > 20. We also found that SDB increased in patients aged
from age 40s to 70s but dropped in patients aged in the 80s although a previous study
showed there was no significant change of AHI over time unless it was associated
with increased BMI [Ancoli-Israel et al. 2001]. The difference between their study
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and mine is that I did a cross-sectional study and conducted an analysis for four
different age groups of stroke patients but they did a longitudinal follow-up for a
group of non-stroke elderly patients with SDB. SDB may not change over time in the
elderly but the proportion of patients with SDB could be higher in older age. The
reason why (A-i-H)-h"1 decreased in the age group of 80s could be: (1) those who had
SDB died before their 80s due to cardiovascular diseases or other mortality [Ancoli-
Israel, Kripke, Klauber, Fell, Stepnowsky, Estline, Khazeni, and Chinnl996]; (2)
very old stroke patients were too ill to participate the study.
High prevalence of SDB in stroke means that SDB is related to stroke. This
could be because (1) SDB is a cause of stroke; (2) SDB is a consequence of stroke;
(3) some risk factors are confounders between SDB and stroke. Like many other
previous publications, we face the following problems in the cross-sectional
prevalence study:
• There is selection bias in recruiting stroke patients.
• There is no control.
It is more difficult to conduct a community-based study to clarify the relationship
between SDB and stroke. Recruitment in this study was hospital-based without a
standardized sampling method. Admitted stroke patients could have had more
complicated medical illness prior to stroke which may include SDB so the prevalence
of SDB could be higher than that obtained from community-based studies.
Prospective cohort studies and individually matched case-control studies are
better epidemiological designs in determining the prevalence of an illness. To apply
these two methods to study the relationship between SDB and stroke is not only time
consuming but also difficult in collecting suitable controls. Some large population-
based prospective studies are on their way although results of cross-sectional parts
had been published. Only one individually matched case-control study has been
published but that dealt with TLA which is much more stable than stroke.
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4.5.2 Diagnosis and screening of SDB in stroke
The apnoeas and hypopnoeas detected after stroke were mainly obstructive in my
study. Predominant central sleep apnoea and Cheyne-Stokes respiration were
reported in a study recruiting 32 patients with ischemic stroke [Nachtmann et al.
1995] and another study recruiting 161 patients with first-ever stroke, either ischemic
or haemorrhagic, or TIA [Parra et al. 2000]. Their sleep studies were conducted in
the acute phase of stroke. For example, all stroke patients of Parra et al. were
admitted within 48 hours of onset of stroke and limited sleep studies were performed
during the first 48-72 hours after admission. Sleep-disordered breathing was also
obstructive predominantly in the study conducted by Bassetti et al. recruiting 128
patients [Bassetti and Aldrichl999b]. In their study polysomnography was recorded 9
days (1-71 days) after stroke which was similar to our study in both methodology and
result.
The failure rate of overnight Embletta recording was only 7% in our study. If we
count three repeated, the failure rate was 11.3% for the first recording. We had a
lower failure rate than the previous study in non-stroke subjects conducted in our
sleep centre (18%) [Whittle et al. 1997]. The reasons could be:
• I excluded most of the severe or complicated stroke patients so patients
recruited were more stable and could tolerate overnight sleep study better.
• The Embletta study was partially attended. I stayed with patients in the first
two hours of recording to check whether all monitors were in position
properly.
• Most of the recordings were performed in the ward. Nurses on the ward
could, though not constantly, keep an eye on the patients.
Three problems are faced in a time-consuming overnight sleep study in stroke:
(1) it is an extra burden for patients especially when they are unstable and have many
other critical diagnostic and treatment procedures waiting to be done; (2) patients
could have unstable vital signs, fluctuating consciousness, risk ofmortality, cognitive
impairment and emotional distress especially in the acute and subacute phase; (3) it is
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expensive especially for in-lab sleep studies which need extra space, attendant and
transfers between stroke unit and sleep laboratory and this can increase the total cost
of stroke care. According to these practical problems we need to sort out how to
make the diagnosis of SDB in stroke more feasible.
The devices used in stroke patients in previous publications ranged from pulse
oximetry [Cherkassky et al. 2003;Good et al. 1996], portable limited sleep study
[Harbison et al. 2002b;Parra et al. 2000] to full portable or in-lab PSG [Bassetti and
Aldrichl999b;Kaneko et al. 2003b].
Pulse oximetry which is one of the most available devices in stroke unit, has
been used as not only an initial screening [Epstein and Dorlac 1998] but also, when
combined with sleep-related history [Bennett and Kinnear 1999] or heart rate
variability [Raymond et al. 2003], as a direct diagnosis of SDB to reduce clinical
loading of PSG. A repetitive and profound desaturation is highly specific for SDB
[Douglas, Thomas, and Janl992] but this kind of pattern can happen in central sleep
apnoea and Cheyne-Stokes respiration which are common in acute stroke
[Nachtmann et al. 1995;Parra et al. 2000]. According to my study, oxygen
desaturation index (ODI) had high specificity (90%) but relatively lower sensitivity.
About 30% of patients with moderate to severe SDB could be missed by oximetry
alone so pulse oximetry is better to be used as a screening instead of diagnostic tool
for SDB in stroke.
I chose a portable limited sleep study instead of pulse oximetry alone because of
the following reasons:
• It is no more inconvenient than overnight pulse oximetry.
• It is recommended as a higher level of diagnostic tool for SDB by the
American Academy of Sleep Medicine.
• It has been proved to be valid in comparison with the gold standard of PSG
in diagnosis of SDB [Dingli et al. 2003].
• It can save time and money [Douglas 2003].
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There are several kinds of commercial portable devices for limited sleep study,
which are rated level 3 or level 4 by APSS. The device we used (Embletta) belongs
to level 3 and it actually contains full cardiopulmonary signals and sensor for body
position. For unstable stroke patients, more cardiorespiratory sensors can ensure a
higher success rate because if one of them comes off or fails during the recording one
can still make the diagnosis with the remaining sensors. Oximetry alone is rated level
4. If the single signal comes off during an unattended sleep study the procedure is
completely failed and no diagnosis can be made at all. This situation is common in
stroke studies than ordinary studies performed in sleep centres. In our study only 3 of
8 patients who had an inadequate sleep study in the first night were happy to repeat
the recording.
A limited sleep study using the Embletta device is different from conventional
polysomnography. Embletta does not include electroencephalography (EEG),
electrooculography (EOG) and electromyography (EMG) so might be better tolerated
by stroke patients. On the contrary, without EEG, EOG and EMG we can not score
sleep stages and arousals so could overestimate AHI. Thus we use (A+H)-h_1 instead
of AHI to express the total amount of apnoea and hypopnoea events in bed instead of
during sleep and set up a higher cut-off criteria ((A+H)-h"1 > 30 and < 30) for further
randomization and comparison of outcome between groups which will be discussed
in chapter 5.
4.5.3 Characteristics of SDB in stroke
Our stroke patients with SDB were older (74 year-old) but had lower BMI (26
kg/m2) than those referred to a sleep centre (47 year-old, 30 kg/m2) [Engleman et al.
1998]. There are two possibilities to explain these findings:
• SDB and stroke are more common in older age. Those who have
symptomatic SDB since younger age could have either been treated or died
of other cardiovascular diseases before they had a stroke.
141
• There is increased frequency of SDB in women after menopause. Women
usually have lower BMI than men so could "dilute" the mean BMI in the
elderly.
Frequency of self-reported habitual snoring was variable in stroke ranging from
32 to 56 % in all patients and 28 to 100% in patients with SDB [Bassetti and
Aldrich1999b;Cherkassky et al. 2003;Harbison et al. 2002b;Iranzo et al. 2002], In
our study, we found self-reported snoring was significantly higher in patients with
(A+H)-h1 > 30 than (A+H)-h1 < 30 but difference of habitual snoring between
groups was less prominent.
A similar phenomenon happens in self-reported EDS. In my study I found that
patients with (A+H)-h_1 > 30 had significantly higher proportion of self-reported EDS
prior to stroke than those with (A+H)-h4 < 30 although logistic regression did not
show EDS was an independent predictor for (A+Hj-h"1 > 30. We did not apply ESS
to all patients to assess pre-stroke sleepiness because we found patients in acute
phase of stroke were sometimes not able to make proper judgment for all situations
mentioned in ESS especially for some questions which were difficult to answer, for
instance, dozing off in front of traffic lights and in meetings or a theatre. We found
that SSS for post-stroke sleepiness was not sensitive enough to tell any difference
between groups. Although ESS can make a difference the ESS score in stroke
patients with SDB is low and it is for pre-stroke sleepiness only. Stroke patients with
SDB are less sleepy than those seen in sleep centres probably because patients
referred to sleep centre are usually symptomatic and coming from the community.
This is rather different from stroke patients who usually don't know they have any
problems related to SDB until they receive a screening test in the ward. Lowering the
cut-off score of ESS in combination with taking self-reported symptom of EDS into
account can make a more accurate diagnosis in the elderly with stroke.
It is common for patients with acute or subacute stroke to have a certain degree
of disturbance of consciousness resulting from their brain lesion which may not equal
to the sleepiness measured by ESS. A new sleepiness scale for stroke which can
distinguish between true sleepiness and consciousness disturbance might be helpful.
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Previous studies depending on self-reported sleep symptoms without applying
scales of sleepiness to the elderly also showed clear association between EDS and
falls [Brassington et al. 2000], increased rate of myocardial infarction in women
[Newman et al. 2000] and poor functional outcome [Gooneratne et al. 2003]. A few
stroke studies [Bassetti et al. 1996;Iranzo et al. 2002] had similar findings to mine
that ESS was not high in stroke patients who had SDB. Only one study emphasized
pre-stroke ESS as it was associated with poor outcome of stroke [Elarbison et al.
2002b].
About 4% of men and 2% of women in general population have SDB with EDS
[Young et al. 1993]. Whether treating patients with SDB and without EDS is
effective, is still controversial [Barbe et al. 2001]. Elderly patients with symptomatic
SDB could be neglected because their SDB-related symptoms are usually vague and
they might have many other medical problems which shift the attention of their
partners, family, caregivers and even first-line physicians who could care more about
other medical problems than SDB-related symptoms.
4.5.4 A propose clinical pathway for SDB in stroke
A practical problem we face is that whether we can perform a simple bedside
screening test for SDB in stroke units or stroke rehabilitation wards. I propose a
clinical pathway with four predictors, age, BMI, reported snoring and EDS. The flow
chart is more convenient than pulse oximetry for screening SDB and is easily used by
first-line physicians who have little experience in SDB. The model allows prediction
for moderate to severe SDB, i.e. (A+H)-h_1 > 30, in stroke patients. It can avoid too
many unnecessary overnight sleep studies in case some first-line physicians tend to
refer stroke patients with snoring to sleep centre. Two problems are faced before
using this model:
• The proposed clinical pathway needs model validation. The prediction
model was generated in this study and should be validated by applying it to
another group of stroke patients in the future.
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• The proposed clinical pathway assumes that a sleep study is worthwhile in
stroke but this depends on whether stroke patients benefit from CPAP
treatment or not. The results of randomized controlled trial (RCT) which
will be presented in chapter 5 do not convince that this is the case.
4.5.5 SDB and stroke onset
The time onset of stroke in my study using 4 hr blocks for analysis has a peak in
the morning hours, that is to say, between 8 am to noon confirming earlier
observations [Elliottl998]. However, there was no evidence that patients with SDB
had an excess of sleep related strokes.
I found in my study that there was no significant difference in sleep-related
stroke between patients with higher and lower (A+H)-h"\ Furthermore, patients with
SDB, defined as (A+H)-h~l > 15, had more strokes happening in the waking time
(8:00 am to 11:59 pm) rather than in the sleeping time (0:00 am to 7:59 am). These
finding, which showed that patients with SDB ((A+H)-h_1 > 15)) might be associated
with daytime stroke, is in contrast to previous finding which showed that patients
with SDB (AHI > 25) were independently associated with sleep-related stroke
[Iranzo et al. 2002]. However timing of stroke onset is not an exact science and may
be influenced by cultural factors such as normal waking time. In addition the number
of patient in my study is relatively low.
Most of the sleep-related strokes (66%) in the study performed by Iranzo et al.
happened between 7:01 - 9:00 am. As there was a higher percentage of REM sleep
during this period which might aggravate pre-existing SDB they proposed that
repetitive episodes of desaturation caused by SDB might provoke ischaemic stroke.
Unfortunately they did not find that oxygen desaturation played a significant role. On
the contrary, we could not find a strong association between SDB and sleep-related
stroke. In further sub-group analysis although it was sub-optimal and biased in post-
hoc analysis, I found the interaction between oxygen desaturation (lowest Sa02) and
bradycardia (lowest heart rate) was significantly associated with sleep-related stroke,
but, this was only found in patients with less severe SDB ((A+H)-h 1 < 30). The
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significance perhaps reflects the large number of comparisons based on post-hoc
analysis. Bradycardia has been recognized in SDB [Brown et al. 1996;Zwillich et al.
1982] and may be explained by increased vagal tone associated with hypoxia [Hanly
et al. 1989]. Bradycardia is more common than hypotension in patients with SDB
[Guilleminault et al. 2001]. Bradycardia and hypoxaemia could impair cerebral
circulation especially in patients who have impaired cerebrovascular autoregulation
[Livera et al. 1991]. Although oxyhaemoglobin desaturation alone was not found to
play a significant role in sleep-related stroke in previous study [Iranzo et al. 2002]
our study showed interaction between hypoxia and bradycardia is more important.
Iranzo et al. thought that stroke in patients who first noticed neurological deficits
immediately following awakening between 6:00 am to 7:59 am could be
overestimated as stroke happened in the daytime rather than during sleep. I did not
face this problem as I defined the daytime period from 8:00 am to 11:59 am for
analysis of stroke onset. Actually almost half of sleep-related stroke in our study
happened between 6 and 9 am.
My results also support the previous finding that patients with atrial fibrillation
also have more strokes appearing in the daytime [Lip et al. 2001]. SDB was reported
to have an influence on recurrence of AF [Kanagala et al. 2003]. Whether or not the
interaction of SDB and AF plays a role in daytime onset of stroke needs further
clarification. The underlying mechanisms for excessive stroke onset in the morning
could be enhanced by the existence of SDB through the following complications:
• Swings of blood pressure [Akashiba et al. 1999;Guilleminault et al.
2001]and heart rate [Sato et al. 1997].
• Increased blood viscosity [Nobili et al. 2000], platelet aggregation [Sanner
et al. 2000] and fibrinogen [Wessendorf et al. 2000].
• Aggravation of AF or paroxysmal AF [Kanagala et al. 2003],
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4.5.6 Influence of bradycardia and hypoxaemia on baseline
cognitive function in stroke
In ischaemic stroke, any further haemodynamic compromise in terms of hypoxia,
bradycardia or hypotension could turn vulnerable areas called ischaemic penumbra
into permanent infarction in acute stage and compromise neuronal plasticity to
prevent damaged areas from recovery in subacute stage. We found cognitive
functions at baseline (14-19 days after stroke) were correlated with lowest oxygen
saturation, lowest heart rate and heart rate variability. Logistic regression was
performed to control strong confounders of cognitive deficits, i.e. dysphasia and
depression. In the final model interaction of lowest oxygen saturation and lowest
heart rate remained independently associated with cognitive impairment. Hypoxia
and bradycardia are highly associated with severity of SDB as mentioned in a
previous section. Thus we think SDB has an influence on the cognitive function of
stroke patients in the subacute stage through haemodynamic compromise as well.
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4.6 Conclusions
In this cross-sectional study we have the following conclusions:
• Overnight limited sleep study can be applied to a group of highly selective
(about 15%) stroke patients with low failure rate.
• The prevalence of SDB in hospital-based stroke patients is high in
Edinburgh, UK.
• The characteristics of stroke patients with SDB are similar to those of non-
stroke patients with SDB but the former are older, less obese and less sleepy.
• The predictive value of pulse oximetry alone for SDB in stroke is not high
as 1/3 (31.3%) of stroke patients with moderate to severe SDB can be
missed.
• Combination of age, BMI, snoring and EDS based on logistic regression
model may be useful as a simple screening tool at bedside in stroke unit.
• Patients with (A+H)-h~1 > 15 had more strokes happening between 8:00 am
to 11:59 pm than between 0:00 am to 7:59 am. A similar finding was seen in
patients with atrial fibrillation.
• Interaction of lowest oxygen saturation and lowest heart rate in a regression
model was independently associated with sleep-related stroke in patients
with (A+ffflT1 < 30 and cognitive impairment (ACE score < 81) in all
recruited patients.
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Table 4.1 Findings of overnight sleep study (n=66)
Total AHI <30 AHI >30
Apnoea Hypopnoea Index, n/hr 30.5 (14.5-45.5) 14.5 (8.0-21.8) 44.8 (36.5-55.3)
Obstructive Apnoea Index, n/hr 3.1 (0.5-11.8) 0.7 (0.2-2.3) 11.7 (7.1-20.2)
Mixed Apnoea Index, n/hr 0.0 (0.0-0.2) 0.0 (0.0-0.0) 0.2 (0.0-1.2)
Central Apnoea Index, n/hr 0.4 (0.0-1.1) 0.2 (0.0-0.5) 0.5 (0.2-1.6)
Hypopnoea Index, n/hr 20.5 (12.3-32.1) 12.4 (6.6-16.7) 32.0 (23.5-39.1)
Desaturation Index, n/hr 7.8 (3.7-21.0) 4.8 (2.2-7.3) 20.5 (8.7-34.9)
Mean Sa02, % 94.0 (92.8-95.4) 94.7 (93.4-95.7) 93.3 (92.0-94.6)
Lowest Sa02, % 83.0 (79.8-86.0) 86.0 (82.5-88.0) 81.0 (73.5-85.0)
Mean DESAT, % 5.1 (4.8-5.7) 4.9 (4.5-5.5) 5.2 (4.8-5.9)
% Time Sa02 < 90% 1.2 (0.2-7.8) 0.3 (0.1-1.3) 3.9 (1.1-16.5)
Mean A/H duration, sec | 18.5 (16.0-21.1) 17.9 (15.4-20.4) 18.8 (17.0-21.8)
Mean Heart Rate 63.7 (55.8-70.3) 60.1 (55.1-67.6) 64.3 (59.4-73.0)
CSR, n (%) 9 (13.6%) 1 (3.0%) 8 (24.2%)
AHI > 30, n (%) 33 (50%)
AHI > 20, n (%) 42 (63.6%)
AHI > 15, n (%) 48 (72.7%)
AHI > 10, n (%) 57 (86.4%)
t A/H: apnoea or hypopnoea
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Table 4.2 Correlation between heart rate variables and other sleep
variables (n = 66) 11
Mean HR HRV t MinHR
Apnoea Hypopnoea Index r = 0.147 r = 0.353 r = -0.372
P = 0.240 p = 0.004** p = 0.002**
Desaturation Index r = 0.246 r = 0.428 r = -0.307
P = 0.046 p < 0.001*** p = 0.012*
Mean Sa02 r = -0.238 r = -0.342 r = 0.249
P = 0.054 p = 0.005** p = 0.043*
% Time Sa02 < 90% r = 0.216 r = 0.553 r = -0.467
P = 0.081 p < 0.001*** p < 0.001***
Lowest Sa02 r = -0.182 r = -0.516 r = 0.407
P =: 0.143 p < 0.001*** p = 0.001**
IT Spearman's rank correlation
t HRV: heart rate variability, defined as standard deviation of overnight pulse rate
data recorded by pulse oximetry
*
p < 0.05, ** p < 0.01, *** p < 0.001
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Table 4.3 Demographic characteristics, past medical history and
classification of stroke in patients with AHI > 30 (n = 33) and AHI < 30
(n = 33)
Total AHI <30 AHI >30 p ValueH
Age 74(65-81) 74(59-82) 74(72-79) 0.149
Male/Female, N 45/21 22/11 23/10 0.792
Body mass index, kg/m2 25.3 ± 4.9 24.3 ± 4.0 26.3 ±5.5 0.087
Hypertension, % 60.6 60.6 60.6 1.000
Diabetes mellitus, % 9.1 6.1 12.1 0.392
Hypercholesterolemia, % 43.9 48.5 39.4 0.457
Previous stroke or TIA, % 25.8 24.2 27.3 0.778
First ever stroke, % 90.9 90.9 90.9 1.000
Coronary artery disease, % 24.2 27.3 21.2 0.566
Atrial fibrillation, % 19.7 12.1 27.3 0.122
Left ventricular hypertrophy, % 12.3 9.7 18.5 0.423
Current smoking, % 25.8 30.3 21.2 0.398
OCSP classification 0.342
TACI, n 13 5 8
PACI, n 41 23 18
POCI, n 3 0 3
LACI, n 4 2 2
ICH, n 5 3 2
f Mann-Whitney U test or Chi-square test
§ OCSP: Oxford Classification of Stroke project; TACI: Total anterior circulation
infarct; PACI: Partial anterior circulation infarct; POCI: Posterior circulation
infarct; LACI: Lacunar infarct; ICH: Intracerebral haemorrhage
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Table 4.4 Baseline assessment in patients with AHI < 30 and AHI > 30
U
AHI < 30 AHI >30 p Value
NIH Stroke Scale (0-42) 6 (5-8) 6 (5-9) 0.974
Barthel Index (0-20) 12 (8-17) 12 (9-17) 0.918
Mini-mental Status Exam (0-30) 27 (25-29) 27 (24-29) 0.703
Addenbrooke's Cognitive Exam (0-100) 84 (71-91) 80 (64-86) 0.248
Orientation (1-10) 10 (8-10) 10 (8-10) 0.923
Attention and concentration (0-8) 8 (6-8) 7 (6-8) 0.576
Memory (0-35) 29 (26-33) 29 (20-32) 0.434
Verba I fluency (0-14) 8 (6-9) 6 (4-9) 0.213
Language (0-28) 27 (23-28) 26 (22-27) 0.228
Visual spatial (0-5) 3 (2-5) 3 (1-4) 0.326
Hospital Anxiety Depression Scale (0-42) 9(6-14) 9(6-15) 0.989
Anxiety (0-21) 4 (2-7) 4 (2-6) 0.808
Depression (0-21) 5 (3-8) 5 (3-9) 0.935
11 Mann-Whitney U test
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Table 4.5 Laboratory data in patients with AHI > 30 (n = 33) and AHI
< 30 (n = 33)
AHI <30 AHI >30 p Value f
Systolic BP on admission 153 (132-173) 150 (133-169) 0.898
Diastolic BP on admission 86 (75-94) 85 (79-92) 0.635
Haemoglobin 142 (135-155) 143 (136-153) 0.949
Haematocrit 42.1 (39.8-45.1) 42.4 (39.7-44.9) 0.923
Platelet 230 (203-279) 216 (196-241) 0.089
Plasma glucose 5.9 (5.4-6.6) 6.1 (5.8-7.4) 0.142
Total Cholesterol 5.3 (4.8-5.9) 5.1 (4.3-6.3) 0.639
Fibrinogen (N = 19/18) 3.7 (2.8-4.5) 3.7 (3.0-5.0) 0.523
ESR (n = 26/25) 10 (6-23) 20 (10-30) 0.058
CRP (n = 17/13) 6.9 (3.1-14.0) 6.9 (0.8-13.5) 0.615
Carotid stenosis, n f 6/13 4/15 0.461
f Mann-Whitney U test
t Stenosis of internal carotid artery > 60% on either side measured by duplex
ultrasonography and compared between groups by Fisher's exact test
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Table 4.6 Sleep questionnaire in patients with AHI > 30 (n = 33) and
AMI < 30 (n = 33)
AHI < 30 AHI >30 p Value II
Sleep Questionnaire
Snoring 37.5 78.6 0.001**
Snoring including "don't know", % 39.4 81.8 < 0.001**'
Habitual snoring, %(1) 24.2 45.5 0.071
Witnessed apnoea, % ^ 19.2 25.0 0.623
Choking episode, % 9.1 24.3 0.099
Awakening unrefreshed, % 54.5 69.7 0.205
Excessive daytime sleepiness (EDS),
%
33.3 66.7 0.007**
Moderate to severe EDS, % (3) 6.1 24.2 0.039*
Road traffic accident, N 1 0 0.396
Morning headache, % 21.2 18.2 0.757
Nocturnal polyuria, % ^ 18.2 24.2 0.547
Major symptoms in sleep questionnaire ^
> 1 of 5 major symptoms, % 75.8 97.0 0.012*
> 2 of 5 major symptoms, % 45.5 87.9 < 0.001**
> 3 of 5 major symptoms, % 24.2 57.6 0.006**
> 4 of 5 major symptoms, % 3.0 15.2 0.087
5 major symptoms, % 3.0 6.1 0.555
Epworth Sleepiness Scale (0-24)(6) 4 (2-7) 6(3-11) 0.030*
Epworth Sleepiness Scale > 10, % 8.3 29.2 0.064
Stanford Sleepiness Scale (1-7) 2 (2-4) 3 (1-4) 0.459
(1) "often" or "almost everyday"; (2) available for N = 26,24; (3) "always" or "4-6
times per week"; (4) more than 2 times per night; (5) snoring, EDS, choking
episode, witnessed apnoea, awakening unrefreshed; (6) pre-stroke sleepiness, N =
24,24
11 Mann-Whitney U test or Chi-square test
*
p < 0.05, ** p < 0.01, *** p < 0.001
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Table4.7hpredictivevalueofmajorSDB-re at dsympt msf ro e att v rDB(AHI>30) ItemsS nsitivity(CI)pecificiLR+-PPV%N Snoringf81.8(68.7-95.0)60.6(43. -77.3)2.08(1.32-3.27)*0.30 0.14 0 657 55 8276 9(60 7 93 1 EDS63.0(44.7-81.2)8.8(52. - 4.8)2.01(1.12-3.63)*0.54(0.31 0.938 Witnessedapno a25.0(7.7-42.3)80 8 65.6-95.9)1.30(0.4 3.710 93 69-1 2554.5 2 1 84 03 38 2 69.5) Chokingepisode24.2(9.6-38.9)90 9 81.1-100)2.67(0.77-9.1 )*0.83 0 7 . 472. (46 4 99.54 5 . -67.7 Unrefreshed71.0(55.0-86.9)43 8 26.6-60.9)1.26(0.8 1.840.6 34 3055.0 39. -7 . )60 9(40 9 8 8 Any197.0(91.1-100)24 2.6-38.92(1 05 .57)00 0 945 .43.3 69.088 96 4- Any287.9(76.7-99.0)54.5(37.6-71.5)1. 3(1.30 2.870 22 0 08-0 5965.9 51.9 981 8 5 7 7. Any351.5(34.5-68.6)78.8(64.8-92.7)2.43(1.16-5.07)*0.62 0.42 0.9170.8(52.6- .0)61 9(47. 76 6 Any415.2(2.9- 7.4)97.091.1-100)5.0(0.62-40 5)*880 75 . 283 35 . .40 7 66.0) fincluding"don'tknow"answer;*LR+>2 LR+(positivelikelihoodratio)=(sensit vity)/1-pec ficity) LR-(negativelik lihoodr tio)=1-sensitivity)/(sp cifici PPV(positivepred ctivevalue)=(t upos tive)/+falspositive) NPV(negativepredictivev lue)=(trun gative)/+falsneg ti ) 154
Table 4.8 Prediction ofmoderate to severe SDB by demographic data
and SDB-related symptoms (n = 66) H
Dependent variable Sleep-disordered breathing ((A+H)-h4 >30)
Predictors Age (p = 0.001), BMI (p = 0.049), snoring (p =
0.001), EDS (p = 0.007), choking (p = 0.099)
Variables Odds Ratio Confidence Interval p Value
Age (65-79) | 6.160 1.230-23.273 0.007**
BMI (> 25) f 4.389 1.149-16.759 0.030*
Snoring $ 9.016 2.072-39.225 0.003**
EDS 1.460 0.402-5.308 0.565
Choking 2.655 0.537-13.117 0.231
Model Chi-Square 30.143 (df = 5) < 0.001
Correct Predictions 78.8%
Nagelkerke-R2 0.489
f Age (65-79 and others) and BMI (> 25 and < 25) were treated as dichotomous
variables to increase power of model fit.
$ "Don't know" answer is included.
11 Logistic regression with enter method
*
p < 0.05, ** p < 0.01
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Table 4.10 Comparison between patients with sleep-related stroke (N =





Age i 73 ± 10 72 ±11
Baseline NIH Stroke Scale f 6 (5-7) 6 (5-8)
Baseline Stanford Sleepiness Scale f 2 (2-3) 3 (2-4)
Pre-stroke Epworth Sleepiness Scale f 4 (2-9) 6 (3-9)






(A-t-H)-h"1 f 23.5 (12.7-42.5) 32.5 (17.2-48.0)






20:00 - 23:59 1 5
Total N 24 42
$ Mean and SD
f Median and IQR
§ TACI: Total anterior circulation infarct; PACI: Partial anterior circulation infarct;
POCI: Posterior circulation infarct; LACI: Lacunar infarct; ICH: Intracerebral
haemorrhage
! Mann-Whitney U test: all p > 0.05
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Table 4.11 Prediction of sleep-related stroke by oximetric variables in
patients with mild SDB (AHI < 30, n = 33) IT
Dependent variable Sleep-related stroke
Predictors Lowest Sa02 (0.030), Lowest HR (0.029)
Variables Coefficient Odds Ratio p Value










11 Logistic regression with forward likelihood method
*
p <0.05, **p <0.01, *** p < 0.001
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Table 4.13 Prediction of cognitive impairment at baseline by logistic
regression analysis 11
Dependent variable Addenbrooke's Cognitive Exam total score < 81
Predictors Lowest Sa02 (p = 0.079), Min HR (0.017), HRV
(p = 0.004), dysphasia (p = 0.013), HADS
depression (p = 0.094)
Variables Odds Ratio Confidence
Interval
p Value
Lowest Sa02 x Min HR 1.002 1.001-1.003 0.002
Dysphasia 22.424 2.932-171.490 0.001
Model Chi-Square 21.072 (df= 2) < 0.001
Correct Predictions 71.9%
Nagelkerke-R2 0.374
11 Logistic regression with forward likelihood method
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Table 4.14 Gender differences of demographic, sleep and baseline data
11
Male Female p Value
Age 73 (62-78) 75 (73-81) 0.151
Body mass index, kg/m2 25.1 (22.0-28.2) 22.5 (21.2-28.3) 0.315
Apnoea Hypopnoea Index, n/hr 33.5 (14.6-49.6) 28.5 (13.9-31.2) 0.540
Desaturation Index, n/hr 9.4 (3.6-22.1) 7.0 (3.1-18.4) 0.441
% Time Sa02 < 90% 1.2 (0.3-10.0) 1.2 (0.1-4.5) 0.412
Haemoglobin 146 (137-155) 135 (129-145) 0.010*
Haematocrit 42.8 (41.1-45.5) 39.3 (38.2-42.4) 0.001**
Platelet 216 (187-251) 246 (215-323) 0.017*
Plasma glucose 6.0 (5.6-7.3) 6.1 (5.6-6.6) 0.929
OCSP classification 0.388
TACI, n (%) 11 (24.4) 2 (9.5)
PACI, n (%) 26 (57.8) 15 (71.4)
POCI, n (%) 3 (6.7) 2 (9.5)
LACI, n (%) 1 (2.2) 1 (4.8)
ICH, n (%) 4 (8.9) 1 (4.8)
Epworth Sleepiness Scale 6 (3-10) 3 (2-7) 0.188
Stanford Sleepiness Scale 3 (2-4) 2 (1-4) 0.272
NIH Stroke Scale 6 (5-8) 6 (5-7) 0.590
Barthel Index 12 (9-17) 14 (7-16) 0.403
Mini-mental Status Exam 27 (25-29) 25 (22-28) 0.048*
Addenbrooke's Cognitive Exam 84 (70-89) 75 (61-87) 0.100
Hospital Anxiety Depression Scale 8 (6-13) 9(7-16) 0.289
Anxiety 4 (2-7) 4 (2-6) 0.903
Depression 5 (2-7) 5(4-11) 0.097
If Mann-Whitney U test
*
p < 0.05, ** p < 0.01, *** p < 0.001
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Figure 4.1 Flow chart of patient recruitment
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Figure 4.2 Intra-rater and inter-rater reliability of sleep study
(a) Scatter plot and intraclass correlation coefficient (ICC) across 1st and 2nd scoring
by me (Chung-Yao Hsu)
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(c) Scatter plot and intraclass correlation coefficient (ICC) across rater 1 (me) and
rater 2 (MV)
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Figure 4.3 Relationship between AHI (median and IQR) and age




Figure 4.4 Relationship betweenAHI and BMI
BMI
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Figure 4.5 Relationship between pre-stroke Epworth Sleepiness Scale,
and Stanford Sleepiness Scale at baseline and AHI
(a) Correlation between AHI and pre-stroke Epworth Sleepiness Scale
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(b) Differences of distribution of Epworth Sleepiness Scale and Stanford Sleepiness
Scale between patients with (A+H)-h~1 > 30 and < 30
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(d) Correlation of pre-stroke Epworth Sleepiness Scale and Stanford Sleepiness
Scale at baseline
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Figure 4.6 Flow chart of decision making for referring sleep study in
stroke unit
Decision Making for Sleep Study in a Stroke Patient
Age 65-79 < 65 or > 79
BMI 25+ <25 25+ <25
Snoring Yes No Yes No Yes No Yes No
EDS Yes No Yes N o Yes No Yes b o Yes b o Yes Nolo Yes No Yes N<
Predicted




(Probability = 50-100 %)
JL
No Sleep Study
(Probability < 50 %)
BMI: body mass index; EDS: excessive daytime sleepiness
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Figure 4.7 ROC curves of oximetric variables in prediction of
moderate to severe SDB (AHI > 30)
100-Specificity
ODI
% Time Sa02 < 90%
Mean Sa02
170
Figure 4.8 Diurnal difference of stroke onset
(a) Relative risk of stroke onset displayed in 4-hour interval (n = 66)
2.5
0000-0359 0400-0759 0800-1159 1200-1559 1600-1959 2000-2359
Time
(b) Odds of onset times of stroke in three groups with AHI > 30 (n = 33), AHI =
15 - 29.9 (n = 15) and AHI < 15 (n = 18)
Time
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(c) Relative risk of stroke onset in 2 specific time interval between patients with
(A+H)-h-1 > 15 (n = 48) and < 15 (n = 18)
0.00 - 7.59 8.00 - 23.59
Time

















i n sleep-related strokes
O wake-related strokes
Chi-square p = 0.523
n = 18 n = 15 n = 17 n = 16




(e) Odds of sleep-related stroke across lowest oxygen saturation and the lowest
heart rate m patients with (A+H)-h": < 30 (n = 33)
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Chapter 5 Randomized Controlled Trial of Continuous




Backgrounds: The prevalence of sleep-disordered breathing (SDB) in stroke is
high but there are only four publications dealing with the treatment of obstructive
sleep apnoea/hypopnoea syndrome (SDB) in stroke. All of them used nasal
continuous positive airway pressure (CPAP) as the choice of intervention but only
one of them was a randomized control trial. One randomized controlled trial had
outcome measures in the domains of functional capacity, cognition and wellbeing but
showed that CPAP only improved wellbeing. Another non-randomized controlled
trial found CPAP might improve wellbeing and ambulatory blood pressure. The other
two studies had no outcome measure.
Methods: Thus we conducted a randomized controlled trial for stroke patients
who had (A+H)-h4 > 30 with predominant obstructive events, i.e. either central
apnoea or Cheyne-Stokes respiration < 30%, starting from 21-25 days after stroke.
The duration of treatment was 8 weeks and blind outcome assessment was performed
at 3 months and 6 months after stroke.
Results: Thirty patients were recruited in the study with 15 randomized to CPAP
and the other 15 to conservative treatment for SDB. Conventional treatment for
stroke was maintained in all patients. The result showed compliance to CPAP was
poor with mean 1.40 hours and median 0.16 hours per night. Increased length of
keeping CPAP was correlated with higher score of language subscale in
Addenbrooke's Cognitive Examination (Spearman's rho = 0.544, p = 0.036) and
lower score in depression subscale of Hospital Anxiety and Depression Scale
(Spearman's rho = -0.538, p = 0.039). Increased CPAP compliance was correlated
with a higher Nottingham Extended ADL Index (EADL) score at post-treatment
phase but this turned into insignificant after adjusting for baseline Barthel Index (BI).
The outcome assessment showed patients randomized into CPAP had a lower
EADL mobility subscale score (p = 0.048) and lower scores of physical function (p =
0.006), role physical (p = 0.025), mental health (p = 0.044) and physical summary (p
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= 0.022) in SF-36. The difference in the EADL mobility subscale score became
insignificant after adjusting for baseline BI but the difference in physical summary
score of SF-36 remained after the same procedure. Imbalance due to chance in
functional capacity at baseline between groups was the most likely explanation for
outcome difference at post-treatment phase. Post-stroke depression in CPAP group
might play a role for poorer functional outcome but this could hardly be explained by
negative effect of CPAP treatment. There was no difference between groups at 6
months after stroke which might be due to the effect of regression to mean.
The 24-hour ambulatory blood pressure at post-treatment phase showed that
lower systolic blood pressure (SBP, Spearman's rho = 0.490, p = 0.015) and diastolic
blood pressure (DBP, Spearman's rho = 0.279, p = 187) were associated with lower
EADL total score at the post-treatment phase. Instability in circadian rhythm of blood
pressure was defined as either SBP/DBP mismatch (difference of periods > 1 hour)
or rapid cyclic pattern (period < 8 hours). This was associated with old age (p =
0.012), lower mean saturation (p = 0.013), higher % time of desaturation < 90% (p =
0.011) and stroke onset at baseline, a lower EADL leisure subscale score (p = 0.013)
and a lower role emotional subscale score in SF-36 (p = 0.008) at the post-treatment
phase.
Conclusions: I concluded that CPAP compliance was a major problem in this
study but might be enhanced on a highly selective basis by choosing patients with
higher functional capacity, higher cognitive function especially language and less
depression in acute or subacute phase of stroke. For unstable patients or poor
compliant, CPAP treatment may be delayed to a more stable chronic phase of stroke
as it still can have an effect on controlling blood pressure for secondary prevention.
Controlling blood pressure in stroke is a complicated issue and the role of reducing
blood pressure of CPAP and its influence on cerebral blood flow in acute and
subacute stroke needs further clarification with more randomized controlled trials.
Key words: Sleep-disordered breathing; stroke; randomized controlled trial;
continuous positive airway pressure; compliance; outcome
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5.2 The aims of the study
Scientific background of this randomized controlled trial (RCT) has been
reviewed in chapter 2.11. The hypothesis in this chapter was that continuous positive
airway pressure (CPAP) treatment for SDB in patients with stroke could improve
outcomes. According to previous reviews, we designed a prospective single blind,
randomized control CPAP trial with treatment period of 8 weeks and a longitudinal
follow-up with a broad spectrum of outcome measures at 3 months and 6 months
after stroke. The aims of this study were to establish the:
• Feasibility of CPAP: to find out the compliance of stroke patients suffering
from SDB with CPAP.
• Effectiveness of CPAP: to find out the influence of CPAP on functional,
cognitive, emotional outcome and health-related quality of life in stoke.
• Haemodynamic effect of CPAP: to find out the effect of CPAP on 24-hour,
day and night blood pressure and heart rate in stroke.
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5.3 Methods
The Consolidated Standards of Reporting Trials (CONSORT) comprises a
checklist and flow diagram to help improve the quality of reports of randomized
controlled trials (RCT) [Begg et al. 1996]. RCT in this study was designed and
reported in accordance with the CONSORT guidelines.
5.3.1 Participants
Stroke patients were approached and recruited in two acute stroke units and two
stroke rehabilitation units located in Edinburgh city. The eligibility criteria have been
described in chapter 3.2 and sample size calculation has been described in chapter
3.3.
5.3.2 interventions
All patients with (A+H)-h_1 > 30 received conservative (behavioural) treatment
for SDB. For example, an advice on weight loss and abstinence from alcohol and
other sedatives was given when appropriate. Using a randomization schedule 21-25
days after stroke, they were randomised either to CPAP (Autoset T) or conservative
treatment only for SDB for 8 weeks. Conservative treatment means both groups
received advice on weight loss, alcohol avoidance and conventional rehabilitative
and medical therapy for stroke and its complications when appropriate. Throughout
the study all medications and programmes for stroke were maintained as usual and
were recorded on the Follow-up Form. For example, this might include
rehabilitation, changes of drug treatment for hypertension, atrial fibrillation or carotid
artery surgery.
I did not choose sham CPAP as control. This involves the use of the nasal mask
and CPAP machine, but with inadequate pressure generated to overcome upper
airway obstruction during sleep. The reasons of not using sham CPAP were: (1) sham
CPAP with subtherapeutic pressure might be harmful to stroke patients; (2) it is not
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clear whether sham CPAP is a truly inactive treatment; (3) sham CPAP cost extra-
funding.
Nasal CPAP therapy was performed following routine patient education about
CPAP, mask fitting and familiarization by an auto-titration device, AutoSet T®
(ResMed Ltd., SanDiego USA, Figure 3.2, P. 114). There is a pressure sensor and
internal computer to monitor the patient's breathing and a clock in the device to
provide objective data on CPAP usage. It adjusts pressure on a breath-by-breath basis
to minimize the pressure required for effective therapy.
All patients on CPAP were given intensive support from a highly experience
CPAP nursing sister (Marjorie Vennelle). The reasons for any non-compliance were
investigated and efforts made to solve problems. Reasons for declining to enter the
CPAP study were documented, as should difficulties using CPAP and reasons for
withdrawal from trial/abandoning CPAP. A standardized form was filled out by the
investigator. If they continued to be non-compliant at the next visit, they were
withdrawn from the study. The Withdrawal Form was completed.
Patients who experienced an adverse event were withdrawn at any time from the
study at the discretion of the investigator. If a patient was withdrawn wholly or in
part because of an adverse event, both the Withdrawal and Adverse Events Forms
were completed.
5.3.3 Objectives
The main hypothesises of this study were based on the RCT:
• Nasal CPAP might improve sleepiness, fatigue, cognitive function and
mood in stroke patients with SDB so they may be more compliant to their
rehabilitation programme and other treatment procedures. This might result
in better functional outcome.
• Nasal CPAP may stabilize circadian blood pressure in acute and subacute
phase of stroke. This might not only result in better outcome but also
prevent recurrence of stroke.
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5.3.4 Outcomes
The Barthel Index (BI) and the Nottingham Extended ADL Index (EADL)
dealing with functional capacity were chosen as primary outcome measures based on
a priori hypothesis. The ambulatory blood pressure (ABP), Mini Mental State
Examination (MMSE), Addenbrooke's Cognitive Examination (ACE), Hospital
Anxiety and Depression Scale (HADS), EuroQol and SF-36 were chosen as
secondary outcome measures.
5.3.4.1 Baseline data
Baseline data collection was done on the day of sleep study and baseline
assessment was done on the morning after overnight sleep study but before the
analysis of sleep data. The details have been described in chapter 4 including
demographic data, basic laboratory data, Modified Rankin Scale (MRS), NIH Stroke
Scale (NIHSS), Stanford Sleepiness Scale (SSS), BI, ACE and HADS.
5.3.4.2 Ambulatory blood pressure monitoring
All randomized patients received 24-hour ABP monitoring in the last week of
the 8-week treatment phase. ABP monitoring was conducted with Spacelabs 90207
(Spacelabs, Redmond, USA). The device has previously been validated for the
elderly [Iqbal et al. 1996] and recommended by European Society of Hypertension
for clinical use [OBrien et al. 2001]. The detailed description of the device has been
given in chapter 3.
ABP monitoring was programmed beforehand to automatically measure blood
pressure every 30 minutes for 24 hours. The recording started between 2-3 pm at the
bedside or patients' home. Instruction was given before putting on the monitor.
Information about current medication, estimated sleep/wake time and daily activity
were collected at the end of the recording. Raw data of systolic blood pressure (SBP),
diastolic blood pressure (DBP), arterial blood pressures (MAP) and heart rate (HR)
were downloaded into a computer. MAP was calculated by the device automatically
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according to the formula: MAP = (SBP - DBP)/3 + DBP. Mean SBP, DBP, MAP
and HR were calculated for three time intervals: 24 hour, daytime and night time. We
defined the interval between 6:00 am and 9:59 pm as daytime and the interval
between 10:00 pm and 5:59 am as night time because these were closer to the
schedule of stroke patients in the wards. "Dipper" was defined as a drop of at least
5% in both systolic and diastolic blood pressure during the night [Engleman et al.
1996b]. "Borderline dipper" was defined as either systolic or diastolic blood pressure
fulfilling the criteria of dipper. Others were defined as "non-dippers".
Patients with successful ABP readings > 70% of the recording time were further
analyzed by the single Cosinor method to evaluate circadian rhythm of blood
pressure. The best-fit cosine model of circadian SBP and DBP rhythm was obtained
by regression analysis according to the following formula:
(2n (Time - Acrophase) \Period /
Three data were derived from the Cosinor model for each patient: (1) mesor of
24h ABP: mean of cosine wave; (2) amplitude of 24h ABP: perpendicular distance
from peak or nadir of cosine wave to horizontal line of mean of cosine wave; (3)
period of 24h ABP: duration of cosine wave. F-test was applied to test the
significance of the best-fit Cosinor model of SBP and DBP by examine the null
hypothesis of the amplitude.
Each patient was categorized into one of two groups according to the duration
and matched pattern of the period of ABP: (A) Regular ABP rhythm: SBP and DBP
were matched in period (difference < 1 hour) in a single patient with duration of
period > 12 hours; (B) Irregular ABP rhythm: either SBP and DBP rhythm were
mismatched in period (difference > 1 hour) or duration of period in any rhythm <12
hours. These two groups were compared for demographic, sleep, and outcome
variables.
181
Group A was further divided into three subgroups: (Al) normal 24-hour
circadian BP rhythm; (A2) reverse 24-hour circadian BP rhythm; (A3) 12-hour
circadian BP rhythm. Group B was further divided into two subgroups: (Bl) Both
SBP and DBP periods are > 12 hours but mismatched; (B2) Either SBP or DBP
period was < 12 hours 9 (rapid cycling). The predicted data of SBP and DBP in group
Al, A2 and A3 obtained from the Cosinor model are were plotted according to mean
and standard error in each time point. The time of stroke onset is marked and shown
on the plot of ABP curves to find its relationship to blood pressure swing. The
predicted data of SBP and DBP in group Bl are plotted without calculating the mean
and standard error of mean (SEM). Patients in group B2 had rapid cyclic SBP and
DBP so the circadian rhythms were biased for comparison with stroke onset.
5.3.4.3 Follow-up
All patients who were successfully randomized received a regular follow-up by
face-to-face interview and assessment. Post-treatment follow-up was performed
within the last three days before the end of CPAP treatment including repeated
measurement of NIHSS, MRS, SSS, Bl, HADS and ACE. Three extra scales were
given in terms of EADL, EuroQol and MOS Short Form-36 (SF-36). The EADL was
developed by the Department of Psychology in the University of Nottingham for
assessing functional capacity which consists of four domains of questions in terms of
mobility, kitchen, domestic activity and leisure activity [Gladman et al. 1993]. It has
less ceiling effect than the Barthel Index so is more suitable to be used in mild to
moderate stroke. EuroQol and SF-36 assess health-related quality of life. EuroQol is
a standard instrument to assess health outcome which consists of two domains of
questions, Visual Analogue Scale (VAS) and 5-dimension (5D) score, and has
proven validity and reliability in stroke study [Dorman et al. 1997]. If the patient was
still in the hospital, nursing staff were informed to hide the machine if they were at
the bedside before I went to do the assessment. If the patient was at home or in the
nursing home, carer was informed beforehand to do the same procedure.
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Six-months follow-up were performed at 6th calendar month calculated from the
onset of current stroke (± 2 weeks), which focused on functional capacities (MRS,
BI, EADL) and health-related quality of life (SF-36).
5.3.5 Randomization
Patients were randomised as long as 21 days after stroke onset. The rationale was
to recruit a group of patients who had subacute stroke, i.e. 14-19 days following
stroke and might be more stable physically and mentally to tolerate CPAP trial. The
effect on the ischaemic penumbra would be minimal by this point of time but patients
still had great potential of recovery from stroke based on the neuronal plasticity.
On day 21-25 following stroke, patients who had (A+H)-h-1 ^ 30 with < 30%
central sleep apnoea or Cheyne-Stokes respiration detected by the overnight sleep
study proceeded to randomization conducted by a senior staff member in the
Department of Sleep Medicine who was not involved in recruiting and assessing
patients. Sequence generation was made using the random permuted block (RPB)
method where each block consisted of 6 patients with a 50% chance of being
assigned to either CPAP or conservative treatment. There are 64 different possible
block arrangements. A random number of sequence was used to choose a particular
block which set the order of allocation for consecutive 6 patients. Allocation
concealment was maintained during the whole course of the study. I was responsible
for recruitment, sleep studies, follow-up and assessment and was completely blind to
all information of randomization including details of block size. Patients were
unblinded when the final assessment of the last randomized patients was completed.
The senior staff member who conducted randomization was also in charge of
performing the CPAP treatment. Patients were either randomized to an add-on nasal
CPAP treatment with Autoset T (auto-titrating mode, ResMed, Sidney, Australia) or
conservative (behavioural) treatment for SDB. Intensive input by a senior sleep
research nurse who was experienced in CPAP treatment was arranged on day 1, day
3, day 5, week 1, week 2, week 4 and week 6 of treatment to optimize compliance.
The nurse managed all problems related to the mask, the machine and any
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complications of CPAP. The CPAP machine was kept by the patient's side unless
they refused to use it anymore and asked for it to be taken away. The treatment period
lasted for 8 weeks (56 days). Duration of keeping the CPAP equipment was recorded
in days. After 8 weeks of CPAP treatment, hours of CPAP usage on a nightly basis
was downloaded from the machine. Compliance with CPAP was calculated as the
median and mean hours of CPAP use per night. All medications and programmes for
stroke were maintained as usual. For example, this might include rehabilitation,
changes drug treatment for hypertension, atrial fibrillation, or carotid artery surgery.
5.3.6 Blinding
I was in charge of overnight sleep study and data analysis. All the baseline and
outcome assessments were performed face-to-face. I was blinded to the results of
sleep study as I performed baseline assessment on the morning following sleep study
but before analysis of sleep data. Follow-up was also arranged and performed by
myself so I was not blinded to the results of sleep study when I performed assessment
at post-treatment phase and 6 months after stroke. The primary outcome measures
dealing with functional capacity were self-administrated including BI and the EADL.
Most of the secondary outcome measures except those dealing with cognition, i.e.
MMSE and ACE, were also self-administrated including SSS, HADS, EuroQol and
SF-36. Thus the bias might be reduced to the minimum.
I was blinded to treatment allocation when I performed follow-up at the post-
treatment phase and at 6 months after stroke. As CPAP machines were either
apparently left at the bedside if patients were still in the hospitals or easily discovered
if patients were at homes or nursing homes, the research nurse contacted with
patients or caregivers for me beforehand and asked them to hide the machines when I
visited them.
I was unblinded to treatment allocation in the first two patients because at that
time formal RCT in this study had not started yet. The data of these two patients were
not taken into account in the analysis of RCT.
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5.3.7 Statistical methods
Data were analyzed on an intention-to-treat basis including a priori hypothesis-
driven and post-hoc exploratory analysis which have been described in chapter 3.6.
Psychometric data are rarely normally distributed so were presented as median and
interquartile range (IQR). Data from ABP monitoring are mostly normally distributed
so were presented as mean ± standard deviation (SD). Statistical analysis was done
by the statistical software, SPSS version 11.0 for Windows (SPSS Inc. USA).
Non-parametric tests were conducted including Mann-Whitney U test and Chi-
square Test (Fisher's test in case there were less than 20 patients in a category) for
between-group comparisons. The p < 0.05 was taken as statistically significant.
Spearman correlation was used to find out association between variables.
Multivariate analysis was conducted to control confounding factors or for
adjustment of interactions. Multiple linear regression with the "enter method" was
used if the dependent variable was continuous and normally distributed. All
predictors with p < 0.1 in univariate regression analysis were entered into the model
and coefficient and confidence interval (CI) were expressed. Logistic regression with
"forward likelihood method" was used. If dependent variables were binary or non-
normally distributed' they were dichotomized before entering into the model. All
predictors with p < 0.1 in univariate regression analysis were entered into the model
and the adjusted odds ratio (OR) and CI were expressed. Those variables with p <
0.05 in the final model were taken as statistically significant.
Standardized effect size [Cohen's d, Cohen 1988] instead of mean difference
between CPAP and conservative groups was calculated and presented in tables. The
formula of calculating effect size is:
d = Ml - M2 / a pooled where:
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Confidence interval (CI) of effect size (Hedges' g with CI, bias corrected)
[Hedges and Olkin 1985] was also calculated and shown in figures to explain the




Thirty-three of 66 patients with a successful sleep study had (A+H)-h4 > 30.
Two of the 33 patients with (A+H)-h_1 > 30 had sleep studies before the protocol of
randomization was started and another dropped out before randomization. Thus 30
patients were randomized, 15 to CPAP and 15 to conservative treatment for SDB.
Flow chart of participants through each stage was shown in Figure 5.1 (P. 220). The
trial was terminated before we had recruited our target of 80 patients because
recruitment was much more difficult than expected and funding ended. The first
patient was randomized in March 2001 and the last patient was randomized in June
2003.1 finished follow-up for the last randomized patient at 6 months after his stroke
in December 2003.
5.4.2 Baseline data
Patients randomized to CPAP were relatively older (median age = 74, IQR 73-81
vs. median age = 73, IQR 65-77), and had relatively lower (A+H)-h_1 (43.1 vs. 47.7),
casual blood pressure at admission (151 ± 30 mmHg vs. 164 ± 39 mmHg) in
comparison with patients randomized to conservative treatment (Table 5.1, P. 206).
Baseline assessment showed that the CPAP group had relatively poor functional
capacity (Barthel Index, BI = 11 vs. 14) and emotional status (Hospital Anxiety and
Depression Scale, HADS = 10 vs. 7). However, the conservative group had
significantly lower score in Mini Mental State Examination (MMSE, p = 0.033) and
on the attention/concentration subscale of Addenbrooke's Cognitive Examination
(ACE, p = 0.025, Table 5.2, P. 207). There was no significant difference of daytime
sleepiness between groups (Table 5.2, P. 207).
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5.4.3 CPAP compliance
Among 15 patients randomized to CPAP, 2 patients rejected treatment after
mask fitting and a brief trial in the afternoon on day 1 of treatment phase, 1 patient
rejected treatment after the first night of CPAP use, 1 died of adult respiratory
distress syndrome (ARDS) on day 4 of CPAP limb and 1 rejected treatment after one
week of CPAP use. Seven of 15 patients were happy to keep the machine for more
than four weeks under intensive education and encouragement (Figure 5.2a, P. 221).
The length of keeping CPAP was negatively correlated with the depression subscale
of HADS (p = 0.039, Figure 5.3a, P. 222) and positively correlated with the language
subscale of ACE (p = 0.036, Figure 5.3b, P. 222) at baseline. This suggests that
patients who had less depression and language problem were willing to try CPAP for
a longer time.
Apart from one fatal case, compliance with CPAP, calculated as mean hours per
night of CPAP use, was 7 hours in one patient, 6 hours in one patient, 2 hours in two
patients, 1 hour in one patient and less than 1 hour in the other nine patients (Figure
5.2b, P. 221). Mean CPAP use was 1.40 hours and median was only 0.16 hours. The
baseline data of five patients with better compliance (> 1 hour, mean 3.8 + 2.8,
ranged 1.02-7.27 hours) showed that mean (A+H)-h~1 was 46.1 ± 10.1/h (35.6-58.4),
BMI was 29.3 ± 5.9 (21.8-38.1), ESS was 6 ± 4 (3-14), SSS was 2 ± 1 (1-3), NIHSS
was 6 + 4 (4-13) and BI was 15 + 6 (4-19). These were not significantly different
from other randomized patients.
Problems with compliance with CPAP in 15 patients were categorized into four
domains (Table 5.3, P. 208): (1) Eight patients had problems with either the mask or
the machine. Two of four patients who were not able to breathe properly and 2 of 3
patients who were claustrophobic abandoned CPAP quickly. (2) Eight patients
developed upper airway symptoms in the following treatment days. Although all
symptoms were managed by topical medications 3 patients still withdrew due to
these symptoms. (3) Nine patients had problems coming from stroke which caused
their non-compliance. Two patients who had total anterior circulation infarct (TACI)
188
also had problems keeping the mask in position probably due to facial weakness or
nocturnal confusion. Two patients had involuntary movement of the head. One
patient improved gradually and could keep using CPAP. The other didn't improve
and abandoned CPAP quickly. Two patients fell due to gait disturbance with wounds
on the face and withdrew from that time on. One patient developed adult respiratory
distress syndrome (AJRDS) following chest infection on the day of CPAP titration
and died 3 days later. (4) Two patients did not think that they needed CPAP on a
nightly basis but this was not a major reason for withdrawal after education and
encouragement. CPAP compliance was positively correlated with BI and the
language subscale of ACE but negatively correlated with depression subscale in
HADS at baseline (Table 5.4, P. 209).
5.4.4 Outcomes at post-treatment phase
Post-treatment follow-up showed that patients randomized to CPAP had
significantly lower mobility subscale of Nottingham Extended ADL Index (EADL, p
= 0.048, Table 5.5, P. 210). As they also had lower BI at baseline multivariate
analysis was conducted to deal with this confounder. After adjusting for BI at
baseline, randomization to CPAP was no longer an independent predictor (Table 5.6,
P. 211). On the other hand, increased mean hours of CPAP use per night was
associated with higher EADL total score at post-treatment phase (Figure 5.4a, P. 223)
but after adjusting for BI at baseline again, CPAP compliance was no longer an
independent predictor either (Table 5.7, P. 212). Of the CPAP-treated patients, there
were only two who on most criteria would have been regarded as having adequate
compliance; of the five with "better compliance", the other three used the treatment
for only two hours per day or less on average.
Figure 5.4b (P. 223) was used to demonstrate the result of regression analysis
shown in Table 5.7 (P. 212). The two patients located in the right upper corner of the
figure were those who had the best compliance. These two good compliers were
relatively younger in CPAP group (age = 65 and 73 vs. 76 year-old) and had less
severe stroke (BI = 19 and 18 vs. 11). Among the two good compliers, one had
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previous history of habitual snoring, witnessed apnoea and unrefreshed sleep.
Another had previous history of unrefreshed sleep and mild EDS (post-prandial).
Both of them might have pre-existing obstructive sleep apnoea but their (A+H)-h~1
was not higher in CPAP group (35.9 and 35.6 vs. 43.1) and their ESS was normal (4
and 5).
Apart from functional capacity, the CPAP group also had significant lower
scores in subscales of SF-36 including physical function (p = 0.006), role physical (p
= 0.025), mental health (p = 0.044) and physical summary score (p = 0.022, Table
5.8, P. 213). After adjusting for AHI and BI at baseline, the difference remained (p =
0.008, Table 5.9, P. 214).
If we take a look at those variables in EADL (Figure 5.5, P. 224), HADS (Figure
5.6, P. 225) and SF-36 (Figure 5.7, P. 226) which did not show statistical
significance we can see the confidence intervals of Hedges' effect size (bias
corrected, Hedges 1985) between CPAP and conservative groups were wide. The
upper confidence limit of effect size in favour of CPAP was mostly less than 0.5
(small or no effect) and the lower confidence limit in favour of conservative
treatment was higher than 1 (big effect). The main reason for not rejecting null
hypothesis might be due to inadequate statistical power.
5.4.5 Outcomes at 6 months after stroke
At 6-month after stroke the differences between CPAP and control groups
disappeared (Table 5.10, P. 215). In terms of NADL and SF-36 scales, previous
lower scores in CPAP group increased slightly and previously higher scores in the
control group decreased slightly. Both of them were approaching to an average level,
nearly identical to the scores in the control group ((A+H)-h < 30, Figure 5.8a, P.227
to 5.8e, P. 228). From statistical point of view, the effect of "regression to mean" or
"wearing off' might be a suitable explanation.
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5.4.6 Ambulatory blood pressure monitoring
Ambulatory blood pressure (ABP) monitoring was arranged for 32 patients (30
randomized with (A+H)-h1 > 30 and 2 non-randomized patients with (A+H)-h_1 =
49.8 and 17.7 respectively). Two patients died before ABP monitoring. Three
patients refused the study. One patient was too unwell to have the recording. This
resulted in 26 of 32 patients (81.3%) accepted ABP monitoring. Among 26 patients,
2 failed to have any reading of ABP due to confusion and detachment of the device.
Excluding 2 non-randomized patients, 22 randomized patients had valid ABP
data for comparison between CPAP (n = 12) and the conservative group (n = 10).
The median of successful recording in 26 ABP monitoring was 89% (IQR 70-93%,
minimum 0% and maximum 100%).
There was no significant difference in 24-hour, daytime and nighttime SBP,
DBP, MAP and HR between CPAP and conservative groups. The CPAP group had a
relatively lower value of 24-hour ABP and ABP in the daytime (Table 5.11, P. 216)
but had relatively higher value of ABP in the night time. The confidence intervals of
the mean difference of the ABP between groups was wide, ranging from positive
difference up to 27 mmHg to negative difference up to 27 mm Hg. The (A+H)-h_l
and oximetric variables were not correlated with ABP variables.
Patients in the conservative group had a significantly bigger day to night dipping
of SBP (p = 0.021) and MAP (p = 0.037, Table 5.12, P. 217 and Figure 5.9a and
5.9b, P. 229). According to our definition, 7 of 9 patients in conservative group were
dippers, 1 was a borderline dipper and 1 was a non-dipper. On the contrary, 2 of 12
patients in the CPAP group were dippers, 1 was a borderline dipper and 9 were non-
dippers. The CPAP group had significantly more non-dippers than the conservative
group (Chi-square p = 0.019).
Mean 24-hour SBP was positively correlated with total EADL score at 3 months
after stroke (Figure 5.10a, P. 230). A similar trend was also found between mean 24-
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hour DBP and total EADL score. No significant correlation was found between mean
ABP and EADL at 6 months after stroke (Figure 5.10b, P. 230).
Cosinor analysis was performed for 24-hour circadian rhythm of ABP data in 18
randomized and 2 non-randomized patients who had successful ABP readings > 70%
of the recording time. Twelve of 20 patients were categorized into group "A" which
indicated regular ABP rhythm (Table 5.12, P. 217). In group "A" six patients had a
normal 24-hour circadian ABP rhythm ("cosine" pattern, Figure 5.11a, P. 231). Three
patients had 24-hour ABP rhythm which showed day-night reverse ("sine" pattern,
Figure 5.11b, P. 231). Three patients had a 12-hour ABP rhythm (double-peak
pattern Figure 5.11c, P. 232). Eight of 20 patients were categorized into group "B"
which indicated irregular rhythm (Table 5.13, P. 218). In group B two patients had
12/24-hour SBP and DBP mismatch ("mismatch pattern", Figure 5.lid, P. 232). Six
patients had less than 12-hour circadian ABP rhythm (rapid cycling pattern) and their
ABP data were too irregular to be shown in the figure. The best-fit regression models
for a cosinor waveform of ABP rhythm were statistically significant in all patients
except these who had rapid cyclic pattern (Table 5.12, P. 217 and 5.13, P. 218).
We examined the relationship between circadian ABP rhythms and stroke onset.
As I have mentioned in chapter 4, most of the stroke onset in this group of patients
(moderate to severe SDB, (A+H)-h"' > 30) were located outside the period from 10
pm to 6 am. Eight of 12 patients had stroke onset in the ascending limb of ABP
rhythms (Figure 5.11a to 5.11c, P. 231-232). The other two patients in group B1 also
had stroke onset in the ascending limb of SBP.
Patients in group B (n = 8) were significantly older and had significantly worse
desaturation in baseline sleep study than those in group A (n = 12, Figure 5.12a to
5.12d, P. 233-234). From the viewpoint of functional outcome, they showed a trend
of lower scores in mobility, kitchen and domestic subscale of EADL and significant
lower score in the EADL leisure subscale (p = 0.013, Table 5.14, P. 219). From the
viewpoint of health-related quality of life, they had relatively lower scores of physical
function, mental health and mental summary and significantly lower score of role
emotional (p = 0.008, Table 5.14, P. 219).
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5.4.7 Adverse events
One patient in CPAP group and one in control group died. The patient
randomized to CPAP treatment died on the first day of CPAP trial. He tried CPAP
shortly in the afternoon when the research nurse (MV) visited him at stroke
rehabilitation ward. He suffered from adult respiratory distress syndrome (ARDS) in
the evening and died two days later. The patient randomized to conservative
treatment died before follow-up at post-treatment phase. She collapsed and died
before being transferred to the hospital.
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5.5 Discussion
We had strict criteria for recruiting more stable patients in stroke so only 30
patients who had moderate to severe SDB ((A+H)-h4 > 30) were enrolled and 15 of
them were randomized to nasal CPAP treatment. Even though our patients were in
the mild to moderate end of stroke the compliance to CPAP was still poor.
5.5.1 Acceptance of and compliance to nasal CPAP
If we take acceptance of CPAP into account first, 4 of 15 patients who were
allocated CPAP in our study withdrew in the first week of treatment limb. This is not
much different from the previous study conducted by German group that 30% of their
patients rejected CPAP either on titration night or within a few days of titration. Ours
is also not worse than the study conducted by the Hong Kong group where 53% of
patients rejected CPAP either after a brief trial in the afternoon or during the first
night of titration.
Then examining compliance with CPAP, in our study, although 7 of 15 patients
were willing to keep CPAP for more than 4 weeks, the compliance with CPAP was
very poor (mean = 1.40 and median = 0.16 hours per night). This means that they
kept the machine but did not use it. The compliance in our study was quite different
from that in Swedish group [Sandberg et al. 2001a] which showed 4.1 ± 3.2 mean
hours of CPAP use in 31 patients. Half of them used CPAP for more than 4 hours.
However our finding was more similar to that reported by the Hong Kong group [Hui
et al. 2002] which showed mean hours of CPAP use in 4 of 34 patients who were
willing to proceed to home therapy was 2.5 ± 0.6 hours. The following factors are
considered for poor compliance to CPAP from the viewpoint of study design:
• Is the diagnosis of SDB accurate?
• Is CPAP machine and interface suitable?
• Are intensive education and follow-up successful?
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I used a portable semi-attended limited sleep study for the diagnosis of SDB in
stroke. The cut-off point of (A+H)-h4 for this device (Embletta) was recommended
to be 20/h according to previous validity study [Dingli et al. 2003]. I further
increased the cut-off point to 30/h to focus on stroke patients who had moderate to
severe OSAH breathing abnormality. This might increase the acceptance and
compliance of CPAP. I didn't use SDB-related symptoms, for instance, patients
having at least two of the major symptoms; as adjunctive criteria to recruit more
symptomatic patients because we wished to investigate whether the treatment of the
disordered breathing of OSAH would be beneficial. In addition we were concerned
that identification of excessive sleepiness in the 2 weeks post stroke would be very
difficult in this disabled and largely sedentary elderly population. The standard
sleepiness questionnaire the Epworth cannot be used in these circumstances. We used
an unattended auto-titrating CPAP for the treatment of SDB in stroke for the
following two reasons: (1) it is not easy to transfer stroke patients to the sleep centre
for an in-lab CPAP titration. Stroke patients were admitted to four hospitals in
Edinburgh city but sleep centre is located in one of them; (2) auto-CPAP has been
reported to decrease mean effective pressure so might be more comfortable for old
and weak stroke patients. Intensive education and follow-up were maintained by an
experienced staff in sleep centre who had been keeping in contact with patients who
were randomized to CPAP regularly. If patients didn't comply with the CPAP well,
encouragement and reinforcement were given before bringing the machine back.
According to these, poor compliance might not be due to study design.
The following factors may explain poor compliance with CPAP in this study:
• Patients were not very sleepy and thus might neither tolerate the obtrusive
treatment nor perceive obvious benefit which might reinforce CPAP use.
• They were older.
• They were seriously ill physically and probably psychologically.
• They had problems in comprehension of and cooperation with the treatment.
• They and their family were concerned more about stroke than SDB.
• They had difficulty tolerating the mask and side effects of CPAP.
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• Most of them could not manage the mask and machine by themselves.
Admitted stroke patients are usually older and have more severe deficits or
complications. They are frequently approached by different medical teams for many
procedures and treatment plans. Although patients who had severe dysphasia,
confusion or cognitive impairment were mostly excluded in our study, the length of
keeping CPAP was still negatively correlated with degree of dysphasia and
depression. This means the above problems are very common in stroke and stroke
patients find it much more difficult than those without brain damage to understand
what SDB is, how it is worthy to have a trial as an extra treatment and how to wear a
mask properly.
On the other hand stroke patients are not very sleepy and they usually are not
concerned by snoring and daytime sleepiness as these are common in old age. Even
in patients who had agreed to attend the study and been randomized to CPAP, two of
15 patients still didn't think they had to use CPAP regularly. Poor compliance of
nasal CPAP treatment was present in the early days of treatment. One of the reasons
might be that stroke patients had lack of insight into the consequences of untreated
SDB.
A mask covering the nose or a full-face mask might be a stressor as stroke
patients could have a feeling that they were more seriously ill or getting worse.
Stroke patients might not only tolerate adverse nasal and oral symptoms of CPAP
less but also more easily get upper airway or chest infections which could make these
symptoms more troublesome. All of these factors might reduce compliance.
Problems resulting from stroke itself also have an influence on the compliance.
Falling is a common complication in stroke and this could result in facial wounds or
bodily pain which shift patients' attention to other more serious problems and
prevent them from further using CPAP. Hemiparesis and facial palsy are so common
in stroke that patients might have insufficient hand function to put on a mask and
turn on the machine by themselves but also have mouth leaks or have their mask
coming off easily from original position. They have to be dependent on caregivers for
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CPAP. In hospitals, caregivers are nursing staff on night duty; they are other non¬
professional workers when patients move back home or are transferred to a nursing
home. Although we arranged a session to introduce and demonstrate CPAP for
nursing staff on night duty in two acute stroke units and two rehabilitation wards they
usually were very busy and could not keep a constant eye on patients when they were
using CPAP. It was even more difficult when stroke patients were discharged home
or moved to nursing homes. In conclusion, all of these factors could explain poor
compliance with CPAP in our study.
5.5.2 Outcome assessment at post-treatment phase and 6
months after stroke
We did not measure EDAL and SF-36 at baseline. Questions in SF-36 relate to
an inappropriate time frame, i.e. the last 4 weeks, thus spanning stroke onset and
activities. Questions in both SF-36 and EADL refer to many activities which cannot
be performed by hospitalized patients, i.e. house work, shopping, climbing stairs and
walking for more than a mile. For these reasons they were not applied at baseline.
The value of an RCT is that the analysis that is critical is the comparison of the
primary outcomes after treatment. The primary variables at baseline is not part of the
analysis [Engleman et al. 1994a;Engleman et al. 1997;Engleman et al.
1998;Engleman et al. 1999]. It is important that the patients are selected by the same
criteria and then truly randomized as they were in this study. If the number of
subjects studied is big enough that will result in comparable groups. I accept that in
smaller studies than planned differences in baseline may occur by chance and this is
one of the limitations that I have pointed out in this study.
We cannot show any beneficial effect of CPAP on all domains of outcome in
stroke. Although CPAP compliance (mean hour per night of CPAP use) was
positively correlated with functional capacity (total EADL score) at post-treatment
phase it was no longer an independent predictor for NADL total score after
controlling baseline BI. What we can say is that patients who had better functional
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capacity at baseline used CPAP longer and more frequently and their better
functional outcome at post-treatment phase could be directly due to baseline
difference. That is to say, a chance imbalance still existed with small sample size (N
= 15,15) even though randomization was conducted.
On the other hand, we showed that patients who were randomized to CPAP
treatment had a trend toward a worse outcome in functional capacity (EADL), mood
(HADS) and health-related quality of life (SF-36) at post-treatment phase. There are
two possible explanations: (1) we can explain the results by chance at baseline due to
limited sample size as well; (2) CPAP had an adverse effect.
The first point is inadequate sample size. The results showed that the CI of effect
size in all domains of outcome between CPAP and conservative groups is wide.
Although we can not reject the null hypothesis we also can not exclude that power of
the study was too low to tell the difference. We did a priori power analysis.
Estimated sample size was 40 patients in each group for a randomized control trial to
achieve 90% power to detect a difference with a significant level (alpha) of 0.05
using a two-sided two sample-sample test. We unfortunately only reached a sample
size of 15 patients in each group before we stopped after recruiting patients for 27
months or so. The major reason is that this was a two-year research project funded by
the British Heart and Lung Association and the accessory reason is that patients
randomized to CPAP had a very poor compliance (median hours of CPAP use was
0.16 hours per night), which was far below the compliance in clinical practice
defined as more than 5 hours per night.
The second point is chance imbalance. The 95% CI of effect size in EADL and
SF-36 is mostly located on the negative side in favour of conservative treatment. The
possibility that the difference in functional capacity, mood and health-related quality
of life between groups might exist but it is possible that those who were randomized
to CPAP were worse in functional capacity and other obscured factors at baseline
regardless of the treatment. Even we conducted a standardized randomization chance
imbalance might exist if sample side is small (n = 15/15). At 6 months after stroke
scores for functional capacity and health-related quality of life increased in
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previously lower CPAP but decreased in previously higher conservative groups. This
means scores became much closer with no more statistical significance. This could
be explained by the effect of "regression to mean". Patients with lower scores and
higher scores at baseline tend to get closer to the mean of the scores in the follow-up
periods.
Post-stroke depression can result in lower physical score in SF-36 even though
there is no deterioration of neurological deficit and functional capacity [Suenkeler et
al. 2002]. The reason may be that depressed patients in stroke tend to give rating for
SF-36 worse scores [Fruhwald et al. 2001]. In our study we found lower CPAP
compliance was independently associated with lower physical summary score in SF-
36 at post-treatment phase after adjusting for baseline BI. Post-stroke depression
might be one of the explanations because patients randomized to CPAP also had
lower depression sub-score of HADS and mental sub-score of SF-36 at post-
treatment phase. One of the possibilities is that CPAP treatment might be more
stressful for non-compliant patients in my study so resulted in or enhanced pre¬
existing psychological problems, for instance, anxiety and depression. More than half
of our patients were willing to keep CPAP for longer period. This means they did not
reject trying CPAP but they couldn't use it because of their physical, psychological
illness or complications from either stroke or CPAP.
A non-randomized control trial in stroke showed better outcome following
CPAP treatment in terms of well-being and 24-hour ABP [Wessendorf et al. 2001].
Although they had 105 patients recruited in the study only 41 of them had results for
well-being which was assessed by a simple Visual Analogue Scale only. Only 16 of
them had results for ABP. The major bias in this study was that they used
noncompliant patients as controls. Noncompliant might have more psychological or
physical problems than compliant. Thus they might have lower score in wellbeing
and higher ambulatory blood pressure which were independent of allocation. In my
study I also found CPAP non-compliant patients had similar problems which have
been described in the previous paragraph.
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The other study with a randomized control trial for SDB in stroke found that
only depressive symptom was improved following CPAP treatment (n = 31) in
comparison with conventional stroke treatment only (control, n = 28). According to
their description, the CPAP group decreased 5 points of MADRS (CI = -8.2 to -1.8)
but the control group, on the contrary, increased 2.6 points of MADRS (CI = 0.1 to
5.1). The effectiveness of CPAP treatment is statistically significant. The effect took
place in the assessment on day 7 [Sandberg et al. 2001a]. The validity and reliability
of MADRS and HADS [Aben et al. 2002] are both satisfactory in assessing
depression in the elderly ill patients. MADRS consists of 10 questions related with
depression with 6-level of Likert scale in each question. The maximum score is 60.
Depression subscale of HADS consists of 7 questions related with depression with 4-
level Likert scale. The total depression subscale is 21. Sensitivity and specificity in
predicting moderate to severe depression in non-stroke patients seemed to be higher
in MADRS (sensitivity = 93.5%, specificity = 83.3%) [Muller et al. 2003] than
HADS (sensitivity = 85%, specificity = 76%) [Lowe et al. 2004] from two separate
study without comparing each other. Their randomized controlled trial of CPAP in
stroke further supports their previous finding that depression associated with SDB in
stroke can be counteracted by CPAP intervention. The only drawback was that they
conducted a parametric test (repeated measure ANOVA with contrast analysis) but
they didn't mention whether MADRS in the study was normally distributed. It is very
common for a psychological variable to be not normally distributed. Their sample
size for comparison is about the lower limit for which the "central limit theorem" can
be applied regardless of whether it is normally distributed.
The other studies with CPAP trials in stroke didn't have any outcome assessment
so it not possible to compare my data to theirs. I have two significant findings
regarding ABP monitoring and functional outcome:
• The higher the blood pressure the better the functional outcome and the
lower the blood pressure the worse the functional outcome in the post-
treatment phase.
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• The older the patient and the more severe the desaturation at baseline, the
less stable the circadian BP rhythm and the worse the functional outcome in
the post-treatment phase.
These will be discussed in the following two sections:
5.5.3 Ambulatory blood pressure and functional outcome of
stroke
As ambulatory SBP and DBP are about 10 mmHg lower than those measured by
sphygmomanometer [Bur et al. 2002], a new classification of ABP based on the risks
of cardiovascular diseases was proposed: (1) normal (< 132/81 mmHg); (2) stage I (<
140/88 mmHg); (3) stage II (< 148/94 mmHg); (4) stage m (> 148/94 mmHg).
According to the above definition, mean SBP and DBP in both the CPAP and the
conservative groups in our study were basically within a normal range. The upper
confidence limit of SBP/DBP was around 160/90 mmHg and lower confidence limit
of SBP/DBP was around 90/55 for both groups of patients. This means that the
higher end of ABP in our patients is still acceptable in acute and subacute phase of
stroke but the lower end of ABP might be at risk of compromising cerebral perfusion
pressure.
Controlling blood pressure is an important issue in stroke. A large sample (n =
308) cross-sectional study showed low blood pressure below 180 mmHg was harmful
in acute stroke [Castillo et al. 2004]. They found the lower the BP below that point,
the worse the neurological deficit. The other randomized controlled trial was
conducted on a group of stroke patients who had bigger ischaemic penumbra defined
by perfusion diffusion mismatch in magnetic resonance image (MRI) [Hillis et al.
2003]. Patients were randomized to either blood pressure elevation or conventional
treatment. The results showed beneficial effect of elevation of blood pressure on
functional outcome in acute and subacute stage. It is still not clear whether blood
pressure reducing effect of CPAP in patients with SDB is also observed in patients
with stroke but it is important to think over this issue especially in acute or subacute
phase of stroke as lower level of blood pressure may be harmful to stroke patients.
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One study using ABP monitoring for 219 stroke patients found that 24-hour SBP
higher than 160 mmHg might predict long-term mortality after a median follow-up
for 2.5 years [Robinson et al. 2001]. This supports that reduction of blood pressure in
the chronic phase of stroke is beneficial. The other study using ABP monitoring
showed that the odds ratio of early neurological improvement was higher in patients
with a day to night decrease of SBP and DBP [Bhalla et al. 2001], This means that
dippers had a better outcome even in the acute phase of stroke although extreme
blood pressure dipping at night might be worse [Kario et al. 2001]. The other study
also showed lower risk of stroke in dippers [Phillips et al. 2000;Yamamoto et al.
1998]. One of the beneficial effect of CPAP is to convert non-dippers into dippers
[Akashiba et al. 1999;Engleman et al. 1994b]. All of these are good points
supporting CPAP treatment for SDB in stroke from a long-term point of view.
As I have described in chapter 2, CPAP increases intrathoracic pressure and
decreases venous return to the heart. This further increases intracranial pressure
(IICP). The systemic effect of IICP is increased mean arterial pressure but this can be
counteracted by vasoconstriction in the brain through autoregulation. The BP
subsequently decreased. So the effect of blood pressure elevation induced by CPAP
disappears. On the other hand CPAP abolishes SDB, hypoxia and arousal response.
This can decrease sympathetic tone and systemic blood pressure. The effect of blood
pressure reduction by CPAP is stronger especially in the night time during the
treatment. The net effect of CPAP is to reduce blood pressure. In our study patients
randomized to CPAP had relatively lower ambulatory SBP, DBP and MAP in 24-
hour and in the daytime but higher in the night time. This can hardly be explained by
the treatment of CPAP.
The group randomized to CPAP in our study had significantly more non-dippers
than dippers which is in contrast to previous study [Wessendorf et al. 2001], Non-
dippers are commonly seen in stroke regardless of SDB [Lip et al. 1997;Jain et al.
2004]. My patients were not different in type, location and risks (hypertension,
diabetes) of stroke to patients in previous studies. Those who were randomized to
CPAP but could not tolerate it might have more mask-fitting problem or air leak.
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This could turn true CPAP into sham CPAP (CPAP with subtherapeutic pressure)
and have a negative effect on blood pressure at night [Pepperell et al. 2002], Stroke
patients who were not compliant with CPAP could have psychological stress during
CPAP usage and this might increase their blood pressure at night. I don't think the
above two possibilities are high as our patients had very poor compliance. It is hard
to say that CPAP kept on the bedside can increase blood pressure psychologically.
The most possible explanation is chance imbalance as well. That is to say, we
incidentally randomized a small group of patients into CPAP limb who had an
unclear reason for lower blood pressure at baseline and follow-up period and this was
associated with poorer functional outcome. There is probably nothing related to
CPAP treatment.
5.5.4 Instability of circadian ABP rhythm
One study found that two peak of stroke onset in the morning and evening were
associated with surge of blood pressure and increased physical activity at that time
[Stergiou et al. 2002]. SDB is one of the trigger factors for surge of blood pressure
either at night or in the daytime which might explain the link between SDB and long
standing hypertension. One of the possible mechanisms for stroke onset in the
daytime for patients with SDB is sympathetic activation which could result in
circadian BP swing. This is compatible with our findings described in the chapter 4
that patients with (A+H)-h_1 > 30 had more stroke onset in the daytime and onset time
of stroke was mostly located in the ascending limb of circadian BP rhythm in this
chapter.
We also found both SBP/DBP mismatch (Bl) and rapid cycling of ABP with
period less than 12 hours (B2) were also associated with poor functional outcome.
Age and desaturation are two significant factors resulting in these two types of
circadian BP rhythm. We showed in chapter 4 that older stroke patents (apart from
those in their 80s) had more severe SDB which could result in more severe
desaturation. In this chapter we found that more severe desaturation was associated
with more unstable circadian BP swing (Bl and B2). We propose a hypothesis
203
through the post-hoc exploratory analysis that this kind of blood pressure instability
may be associated with stroke onset. This is also compatible with previous
publications that, stroke onset which is located in the morning might be associated
with surges of blood pressure.
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5.6 Conclusions
We have the following conclusions in this single blind randomized controlled
trial:
• We cannot show any beneficial effect of CPAP on the outcome of stroke but
one of the reasons is that our sample size was too small which resulted in
wide confidence interval.
• Compliance with CPAP treatment was poor even we had strict criteria to
recruit more stable stroke patients and performed an intensive CPAP
education and follow-up.
• Compliance with CPAP may be enhanced in further studies on a even more
highly selective basis by choosing patients with higher functional capacity,
higher cognitive function especially language and less depression in the
acute or subacute phase of stroke.
• Rapid swing of ambulatory blood pressure in stroke may be associated with
increased age, more severe SDB, more profound desaturation and stroke
onset.
• If stroke patients are unstable in the acute or subacute phase, CPAP
treatment may be delayed to a more stable chronic phase, i.e. 3 months after
stroke. At this stage CPAP may still be useful in secondary prevention of
stroke through controlling blood pressure and cardiovascular risk factors.
This needs further randomized controlled trials to evaluate.
• The effect of CPAP on blood pressure reduction and CBF need to be
clarified in acute and subacute stroke as I showed that the lower the blood
pressure the poorer the functional outcome.
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Table 5.1 Baseline demographic, sleep and laboratory data in patients
randomized to CPAP (n = 15) and conservative treatment (n = 15)
Control CPAP p Value H
Age 72 (58-84) 76 (65-87) 0.173
Male/Female, N 9/6 11/4 0.439
Body mass index, kg/m2 25.1 (22.1-33.1) 26.8 (21.9-28.5) 0.548
OCSP classification 0.465
TACI, n 4 4
PACI, n 7 9
POCI, n 1 2
LACI, n 2 0
ICH, n 1 0
Hypertension, n 11 7 0.136
Diabetes mellitus, n 3 1 0.283
Previous stroke or TLA, n 4 4 1.000
Current smoking, n 3 2 0.624
Systolic BP at admission 164 ± 39 151 ± 30 0.307
Diastolic BP at admission 87 ±11 85 ±14 0.723
Apnoea Hypopnoea Index, n/hr 47.7 (36.5-60.2) 43.1 (35.6-51.8) 0.237
Desaturation Index, n/hr 25.5 (7.0-40.3) 15.8 (8.1-22.7) 0.330
Mean Sa02, % 93.2 (92.5-95.0) 93.3 (91.8-94.3) 0.678
Lowest Sa02, % 81 (76-86) 80 (66-85) 0.360
% Time Sa02 < 90% 3 (0.9-10.0) 4.9 (2.1-20.9) 0.561
Haemoglobin 145 (133-153) 139 (135-150) 0.648
Haematocrit 42.3 (37.9-43.2) 41.9 (39.3-45.0) 0.950
Platelet 209 (196-236) 21.7 (21.0-25.8) 0.271
Plasma glucose 6.3 (5.9-7.3) 6.4 (5.5-8.3) 0.726
Total cholesterol 5.1 (4.0-6.6) 4.9 (4.3-6.2) 0.771
II Mann-Whitney U test or Chi-square test
§ OCSP: Oxford Classification of Stroke project; TACI: Total anterior circulation
infarct; PACI: Partial anterior circulation infarct; POCI: Posterior circulation
infarct; LACI: Lacunar infarct; ICH: Intracerebral haemorrhage
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Table 5.2 Baseline assessment in patients randomized to CPAP (n =
15) and conservative treatment (n = 15)
Control CPAP p Value 11
Pre-stroke Modified Rankin Score 0 (0-0) 0 (0-0) 0.654
Pre-stroke Epworth Sleepiness Scale 6 (2-10) 6(4-14) 0.373
Stanford Sleepiness Scale (1-7) 3 (1-4) 2 (2-3) 0.966
NIH Stroke Scale (0-42) 6 (5-8) 5 (4-9) 0.736
Barthel Index (0-20) 14 (9-17) 11 (7-16) 0.358
Mini-mental Status Examination (0-30) 25 (23-28) 28 (26-29) 0.033*
Addenbrooke's Cognitive Exam (0-100) 79 (61-85) 84 (69-88) 0.245
Orientation (1-10) 10 (8-10) 10 (8-10) 0.963
Attention and concentration (0-8) 7 (5-8) 8 (7-8) 0.025*
Memory (0-35) 23 (15-32) 32 (21-33) 0.103
Verbal fluency (0-14) 6 (4-8) 5 (4-9) 0.950
Language (0-28) 25 (21-27) 26 (22-27) 0.690
Visual spatial (0-5) 3 (1-4) 3 (2-4) 0.391
Hospital Anxiety Depression Scale (0-42) 7(5-15) 10 (6-15) 0.479
Anxiety (0-21) 4 (2-5) 5 (2-6) 0.402
Depression (0-21) 5 (3-9) 5 (2-9) 0.983
If Mann-Whitney U test
* P < 0.05
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Table 5.4 Factors correlated with CPAP compliance (mean hours of
use per night, n = 14) at baseline




Pre-stroke Epworth Sleepiness Scale (n = 11) -0.377 0.253
Stanford Sleepiness Scale 0.022 0.941
NIH stroke scale -0.487 0.077
Barthel Index 0.565 0.035*
Mini-mental Status Exam -0.050 0.864
Addenbrooke's Cognitive Exam total 0.248 0.392
Orientation 0.257 0.375
Attention and concentration -0.282 0.329
Memory 0.003 0.991
Verbal fluency 0.231 0.426
Language 0.643 0.013*
Visual spatial 0.471 0.089











































































































































Table 5.6 Factors predicting mobility subscale ofNottingham
Extended ADL Index at post-treatment phase in stroke patients under
randomization 11
Dependent variable NADL Mobility Subscale > 5
Predictors Age (p = 0.061), randomization (p =
Barthel ADL score at baseline (p =
= 0.014),
0.010)
Variables Odds Ratio Confidence Interval p Value
Age 0.854 0.716-1.019 0.081
Treatment allocation 0.142 0.016-1.234 0.077
Baseline Barthel ADL 1.492 1.065-2.091 0.020*
Model Chi-Square 18.851 < 0.001
Correct Predictions 50%
Nagelkerke-R2 0.622
If Logistic regression with enter method
* P < 0.05
The parenthesis following predictor shows p value in univariate regression analysis.
Only those with p < 0.1 are entered into full model.
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Table 5.7 Factors predicting Nottingham Extended ADL total score at
post-treatment phase in patients randomized to CPAP treatment
Dependent variable Nottingham ADL Total score
Predictors CPAP compliance (p = 0.023), Barthel ADL at
baseline (p < 0.001)
Significant Variables Coefficient Standard error t Value p Value
CPAP compliance t 8.484 6.397 1.326 0.212
Baseline Barthel ADL 2.273 0.597 3.807 0.003**
Full model F (df) 14.471 (2,11) < 0.001
Full model R2 0.845
H Multiple linear regression with enter method
f CPAP compliance is treated as dichotomous variable (> lh/night and < lh/night)
**P<0.01, * P < 0.05
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Table 5.9 Factor predicting physical summary score of SF-36 at post-
treatment phase in stroke patients under randomization II
Dependent variable Post-treatment SF-36 Physical Summary Score
Predictors AHI (p = 0.1), Randomization (p = 0.032),
Barthel ADL at baseline (p = 0.011)
Significant Variables Coefficient Standard error t Value p Value
AHI -0.361 0.134 -2.685 0.013
Randomization -9.819 3.370 -2.913 0.008
Baseline Barthel ADL 0.898 0.356 2.524 0.019
Full model F (df) 7.641 (3,24) 0.001
Full model R2 0.489
If Multiple linear regression with enter method
* P < 0.05
The parenthesis following predictor shows p value in univariate regression analysis.
Only those with p < 0.1 are entered into full model.
214










































































































































































































































































































































































































































































































































































































































































Figure 5.1 Diagram of randomized controlled trial of CPAP treatment
for obstructive sleep apnoea/hypopnoea after stroke
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Figure 5.2 Length of keeping CPAP in days (a) and mean hours of
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Figure 5.3 Correlation of length of keeping CPAP with depression
subscale ofHospital Anxiety Depression Scale (a, N = 15) and language




Spearman's rho = -0.538, P = 0.039
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
HADS Depression Subscale (Baseline)
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
ACE Language Subscale (Baseline)
• •
Spearman's rho = 0.544, P = 0.036 •
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Figure 5.4 Correlation of CPAP compliance with Nottingham
Extended ADL total score at post-treatment phase (a, N = 15) and
after adjusting for Barthel Index at baseline (b)
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Figure 5.8 Longitudinal changes ofmobility subscale in (a)
Nottingham Extended ADL Index and (b) mental health, (c) physical
function, (d) role physical, (e) physical summary score of SF-36
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Figure 5.9 Systolic (a) and diastolic (b) blood pressure dipping in

























































Figure 5.10 Correlation of ambulatory blood pressure and Nottingham























SBP Pearson r = 0.150, p = 0.494
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Figure 5.11 Circadian rhythm of blood pressure and its association
with stroke onset: (a) normal 24-h circadian ABP rhythm, n = 6 (b)
Reverse 24-h circadian ABP rhythm, n = 3 (c) 12-h circadian ABP
rhythm, n = 3 (d) Circadian ABP rhythm with 12/24-h SBP/DBP
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Figure 5.12 The association between stable circadian ABP rhythm
(group A), unstable circadian ABP rhythm (group B) and (a) age (b)
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Chapter 6 The Impact of Obstructive Sleep




Backgrounds: Sleep-disordered breathing (SDB) is common in stroke. More
evidence is needed to support the small number of publications showing that SDB
has a significant impact on the functional and emotional outcomes of stroke. The
impact of SDB on other outcome domains in terms of cognition and health-related
quality of life is also not clear. Whether the influence of SDB is more prominent in
mild or in severe stroke is still waiting to be clarified.
Methods: Sixty-six patients with successful overnight sleep study were recruited
for longitudinal follow-up at 3, 6 12 and 18 months following stroke. Outcome
measures at 3 months consisted of NIH Stroke Scale (NIHSS), Stanford Sleepiness
Scale (SSS), Barthel Index (BI), Nottingham Extended ADL Index (EADL),
Addenbrooke's Cognitive Examination (ACE), Hospital Anxiety and Depression
Scale (HADS), EuroQol and MOS Short Form-36 (SF-36). Outcome measures at 6
months consisted of BI, EADL and SF-36. A Modified Rankin Scale (MRS) and
status of independence were recorded during the whole course of follow-up.
Results: The results showed patients with (A-t-H)-h"1 > 30 had a trend of worse
functional capacity in both BI and EADL than patients with (A+H)-h_1 < 30. There
was a significant difference in mobility subscale of EADL between the groups (p =
0.033). Multivariate analysis after adjusting for gender, baseline BI and ACE showed
that (A+Hfh1 was an independent predictor for mobility subscale of EADL (> 6, cut¬
off by median) at 3 months after stroke (p = 0.011).
The negative influence of SDB on functional capacity and health-related quality
of life following stroke was more prominent in patients with mild stroke (NIHSS < 7)
at both 3 and 6 months after stroke, including total score (p < 0.01), mobility (p <
0.01), kitchen (p < 0.05), domestic (p < 0.05), leisure (p < 0.05) subscale of EADL
and physical function (p < 0.01), social function (p = 0.01), physical summary score
(p < 0.01) of SF-36. There was no difference in cognitive and emotional outcome but
patients who had (A+H)-h_1 < 30 also had significant higher total EADL score than
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patients who had (A+H)-h1 > 30 in the subgroup with lesser emotional distress
(HADS < 8) at both 3 and 6 months and in the subgroup with lesser cognitive
impairment (Mini Mental State Examination, MMSE > 28) at 6 months after stroke.
Lowest Sa02 obtained from the sleep study was significantly correlated with
MMSE (p = 0.016) and orientation subscale of ACE (p = 0.015) at 3 months after
stroke. Mean Sa02 was significantly correlated with orientation subscale of ACE (p
= 0.029). There was no significant correlation between (A+H)-h_l and cognitive
outcome.
There was no clear change of MRS scores in patients with (A+H)-h_1 > 30 over
time but MRS scores were gradually decreased from 3 months to 12 months after
stroke in patients with (A+H)-h_1 < 30. The difference of MRS between groups was
significant at 6 months after stroke (p = 0.026). There was a higher proportion of
"independence at home" in patients with (A+H)-h_1 < 30 than those with (A+H)-h~1 >
30 which was significant at 6 months after stroke (p = 0.033). No significant
difference ofmortality rate was noted.
Conclusions: In my study I focused on a group of patients with mild to moderate
neurological deficits (median NIH Stroke Scale = 6) in a narrow time span (14-19
days) following stroke. We concluded that SDB is independently associated with
poor functional outcome in stroke but the effect of SDB on cognitive and emotional
outcomes, health-related quality of life, and mortality is small. Hypoxaemia might
play a more important role than sleep fragmentation in cognitive outcome. Many
other factors resulting from brain damage or complications of stroke might have a
stronger influence on functional outcome and length of hospitalization than SDB.
Initial severity of stroke is a strong confounding factor. Cognitive function and mood
might be two accessory factors. We propose that SDB may start to play a role when
these factors are getting more stable or under control.
Key words: Sleep-disordered breathing; stroke; outcome; activities of daily
living; mood; cognition; health-related quality of life
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6.2 The aims of the study
Scientific background of this randomized controlled trial (RCT) has been
reviewed in chapter 2.12. The hypothesis in this chapter was that untreated SDB
predicted poor outcome. According to previous reviews, some questions still need to
be clarified regarding the association of SDB with the outcome of stroke:
• I focused on SDB instead of oxygen desaturation. Although oximetric
variables (e.g. DI) and apnoea hypopnoea index (AHI) are closely related
with each other the former reflects the degree of hypoxaemia and the latter,
sleep apnoea and hypopnoea. Strictly speaking, they do not reflect the same
thing but whether they have same association with outcome of stroke is still
not clear.
• I did multivariate analysis instead of univariate analysis. Many previous
paper using univariate analysis to predict the outcome of stroke have had
serious methodological shortcomings. Thus multiple linear regression or
logistic regression analysis was essential and used in my study.
• I did a broad spectrum of outcome measures. Although functional outcome
is a major factor determining whether a patient with stroke can live
independently, stroke patients can have impaired health-related quality of
life because of depression, anxiety, cognitive impairment, fatigue, sleepiness
and poor social relationship even they have relatively better functional
outcome. A broad spectrum of outcome measures including neurological
deficits, functional capacity, daytime sleepiness, cognitive function,
emotional status and health-related quality of life might be more helpful than
functional outcome alone.
• I followed up stroke patients for at least six months after stroke. Some stroke
patients are getting better but others may die or deteriorate to a status that
institulization is needed in the following couple of months or years. Whether
SDB plays a role in the natural course of recovery of stroke is also not clear.
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Thus we performed a longitudinal follow-up for the same cohort of stroke
patients described in chapter 4 and chapter 5. I performed an extensive follow-up
including face-to-face interviews at 3 and 6 months and telephone interviews at 12
and 18 months after stroke. We measured several domains of outcome including
stroke severity, functional, cognitive, emotional outcome, health-related quality of
life, status of independence and mortality. We conducted a multivariate analysis to




Recruitment of patients and performance of sleep study have been described in
chapter 4. Criteria used for recruiting patients were based on our randomized
controlled trial of CPAP which has also been described in chapter 5.
6.3.1 Subjects
Sixty-six patients with valid overnight sleep studies were followed up in this
study. Patients were divided into two groups according to the cut-off point of
(A+H)-h4 > 30 and (A+H)-h4 < 30.
6.3.2 Treatment
Conventional treatment for stroke was maintained in all 66 patients. Regular
medications (Aspirin, Statin, anti-hypertensive drugs etc.) and rehabilitation
programmes (physiotherapy, occupational therapy and speech language therapy etc.)
were given which depended on each patient's physical or neurological condition.
Thirty of 33 patients with (A+H)-h4 > 30 were included in the randomized
controlled trial (RCT) and 15 of them were allocated to nasal CPAP. The compliance
with CPAP and outcome measures between CPAP and control groups have been
described in chapter 5. Three of 33 patients (two were enrolled before starting project
of RCT and one declined after allocation) with (A+H)-h_1 > 30 and 33 patients with
(A+H)-tf1 < 30 received conventional treatment for stroke only.
6.3.3 Assessment and follow-up
6.3.3.1 Baseline
Baseline assessment performed at 14-19 days of stroke was used for adjustment
in multivariate analysis including Modified Rankin Scale (MRS), NIH Stroke Scale
(NIHSS), SSS, BI, ACE and HADS. The detail has been described in chapter 4. All
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missing data were checked, questions were read out and patients were asked to fill in
or choose the most suitable answer.
6.3.3.2 3 months after stroke
As patients with and without RCT were not on the same schedule the definition
of "3 months after stroke" was not based on calendar month. For randomized patients
((A+H)-h1 > 30), 3-month follow-up was performed within the last three days before
due of 8 weeks of CPAP treatment but after ambulatory blood pressure (ABP)
monitoring. For non-randomized patients ((A-i-H)-h"1 < 30), 3-month follow-up was
performed in the 12th week of stroke.
Three months follow-up included repeated measurement of patients on scales
previously conduced at baseline: NIHSS, MRS, SSS, BI, HADS and ACE. Three
extra scales were provided in terms of EADL, EuroQol (Visual Analogue Scale and
5-dimension score) and SF-36. The 6-level "Status of Independence" was assessed by
me as follows: home without social or nursing support, home with social or nursing
support, residential home, nursing home, hospital and death.
6.3.3.3 6 months after stroke
Six months follow-up were performed at the 6th calendar month calculated from
the onset of current stroke (± 2 weeks), which focused on functional capacities
(MRS, BI, EADL) and health-related quality of life (SF-36). The 6-level "Status of
Independence" was also recorded.
6.3.3.4 12 and 18 months after stroke
A regular telephone interview was performed at 12 and 18 calendar months (+ 2
weeks) after stroke, which included MRS and "Status of Independence". If telephone
contact was not available a letter was sent for collecting data. If there was no reply of
the letter, the patient was taken as "lost follow-up". No further attempt was made to
discover whether the patients lost to follow-up were still alive.
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6.3.4 Statistical methods
All continuous data were presented as median and interquartile range (IQR).
Non-parametric tests were conducted including Mann-Whitney U test and Chi-square
Test (Fisher's test in case there were less than 20 patients in a category) for between-
group comparisons. The p < 0.05 was taken as significant. Effect size (ES) was also
expressed. The ES of > 0.2 was taken as mild, > 0.5 as moderate and > 0.8 as marked
difference.
For a more conservative statistical analysis, non-parametric statistics were still
used to compare all scale-related measurements. Mann-Whitney U Test was
conducted for between-group comparisons ((A+H)-h J > 30 and < 30) at 3 months
and 6 months after stroke. A scatter plot and Spearman correlation were conducted to
confirm the linear relationship between sleep variables and two groups or outcome
measure at 3 months after stroke: (1) functional capacity: BI and EADL; (2)
cognitive function: MMSE and ACE.
Multivariate analysis was conducted to control confounding factors. Multiple
linear regression was used if dependent variables were continuous and normally
distributed. All predictors with p < 0.1 in univariate regression analysis were entered
into the model and coefficient and its standard error (SE) were expressed. Logistic
regression was used if dependent variables were binary or not normally distributed.
All predictors with p < 0.1 in univariate regression analysis were entered into the
model and adjusted odds ration and CI were expressed. Those predictors with p <
0.05 in final model were taken as significant.
Post-hoc subgroup analysis was conducted for functional outcome between
patients with (A+Hj-h"1 > 30 and < 30 in the following three domains: severity of
stroke (NIHSS), cognitive function (MMSE) and mood (HADS). The cut-off points
for the above three variables are based on previous publications instead of arbitrarily
chosen: (1) NIHSS > 7 and < 7 [Adams, Jr. et al. 1999]; (2) MMSE > 28 and < 28
[Mathuranath et al. 2000]; (3) HADS > 7 and < 7 [Dennis, O'Rourke, Lewis, Sharpe,
and Warlow2000]. Original p value was expressed in the tables and p value
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following Bonferroni correction were compared and discussed. The data from post-
hoc analysis were used to explain the results more conservatively as they were biased
in multiple statistical testing with small sample size.
The patients followed up for up to 18 months are essentially those from the RCT
(i.e. (A+H)-h_1 > 30) with the addition of those ineligible for the RCT because of
(A+H)-h_1 < 30. So half of the patients with (A+H)-h4 > 30 were allocated to CPAP.
Further regression analysis was done to take into account allocation to CPAP.




Upon completion of the study, 8 patients in total had recurrent stroke with a
confirmed diagnosis in the hospitals. Five of 8 patients had (A+H)-h~' > 30. Among
these 5 patients 1 was randomized to CPAP (compliance 0.16 hours / night).
In total, 9 patients died. Two died before 3 months post-stroke, 2 patients died
between 6-12 months and 5 patients died between 12-18 months post-stroke. Five of
9 patients who died had (A+H)-h_1 > 30. Of these 5 patients 1 was randomized to
CPAP but died within a few days of initiation of treatment and the other one died
after 6 months which was a long time after the end of CPAP treatment. On the other
hand, 4 of 9 patients who died had (A+H)-h_1 < 30. Two of them had (A+H)-ff1
between 20 and 29.9. Among 4 patients who had (A+H)-h4 > 30 and died, 3 had
cardiovascular mortality and 1 died before she was sent to hospital. Among 4 patients
who had (A+H)-h~' < 30 and died, 3 had cardiovascular mortality and 1 died of
complication of pneumonia.
6.4.1 Outcome assessment at 3 months after stroke
Sixty-six patients were contacted for a 3-month follow-up. Two patients with
(A+H)-h_1 > 30 died before 3 months after stroke. They were scored "0" on the
Barthel Index (BI) and Nottingham Extended ADL Index (EADL). Other scales were
not scored. Three patients accepted telephone interviews for partial assessment only.
Three of them had scores of Stanford Sleepiness Scale (SSS), BI, and EADL. One
patient also had Hospital Anxiety and Depression Scale (HADS) and EuroQol. One
patient with (A+H)-h_1 > 30 refused a telephone interview so only the Modified
Rankin Scale (MRS) and State of Independence were obtained from brief
communication. Sixty patients completed all the outcome assessments. Thirty-two
had (A-i-H)-h"1 < 30 and 28 had (A+H)-h~1 > 30.
Comparisons of length of hospitalization between patients with (A-i-H)-h"1 > 30
and < 30 are shown in Figure 6.1 (P. 275). There was no significant difference in
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length of hospitalization between groups although patients with (A+H)-h_1 > 30 had
about 1 day longer of staying in an acute stroke unit and 5 days longer in a
rehabilitation ward (Figure 6.1a, P. 275). The correlation between (A+H)-h"' and
length of hospitalization was also not significant (Figure 6.1b, P. 275). After
controlling for severity of stroke and functional capacity at baseline (Table 6.1, P.
262), (A+H)-h1 was an independent but weak predictor for the total length of
hospitalization (coefficient = 0.006, SE = 0.003, p = 0.044) in comparison with the
NIH Stroke Scale (coefficient = 0.085, SE = 0.026, p = 0.002) and Barthel Index
(coefficient = -0.014, SE = 0.016, p < 0.001). Further regression analysis adjusting
for allocation was shown in Table 6.2 (P. 263). The (A+H)-h4 remained significant
(coefficient = 0.010, SE = 0.004, p = 0.025) after adjusting for the factor of
allocation. On the contrary, allocation factor was not independently associated with
length of hospitalization.
The results of sleepiness, neurological deficits, cognitive and functional outcome
are shown (Table 6.3, P. 264). Patients with (A+H)-h4 > 30 had a trend of worse
functional capacity in both BI and EADL than patients with (A+H)-h"] < 30. The
effect size of BI between two groups was moderate (0.47) and the difference was not
statistically significant (p = 0.246). There was a significant difference in the EADL
mobility subscale between groups (p = 0.033). Multivariate analysis after adjusting
for gender, baseline BI and ACE showed that (A-t-H)-h'1 was an independent predictor
for the EADL mobility subscale > 6 (median) at 3 months after stroke (p = 0.011,
Table 6.4, P. 265). Further regression analysis adjusting for allocation was also
shown in Table 6.5 (P. 266). The odds ratio of EADL mobility subscale > 6 in the
group who had (A+H)-h 1 < 30 was 25.056 (95% CI = 2.423-259.095, p = 0.007)
when compared to the group who had (A+H)-h1 > 30 allocated to CPAP treatment.
On the contrary, the odds ratio of EADL mobility subscale > 6 in the group who had
(A+H)-h ' > 30 allocated to conservative treatment was 7.510 (95% CI = 0.693-
81.376, p = 0.097) when compared to the group who had (A+H)-h"' > 30 allocated to
CPAP treatment. This means there was no significant difference of functional
outcome between those allocated to CPAP and allocated to conservative treatment.
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In the subgroup of mild stroke (NIHSS < 7 at baseline, Table 6.3, P. 264 and
Figure 6.2a, P. 276), patients with (A-l-H)-hf1 > 30 had significantly lower scores in
total score (p = 0.003) and all subscales (mobility, p = 0.002, kitchen, p = 0.021,
domestic, p = 0.018, leisure, p = 0.039) of EADL than patients with (A+H)-h~1 < 30.
The effect size of total EADL between groups was 0.40 in the whole group of
patients but increased to 0.99 in the subgroup of mild stroke. The mean difference of
total EADL was about 5 (95% CI = 1-20) in the whole group and about 8 (95% CI =
4-29) in the subgroup of mild stroke. Multivariate analysis after adjusting for
baseline BI also showed that (A-t-H)-h"1 was an independent predictor for total EADL
score > 36 (median) in the subgroup of mild stroke (p = 0.005, Table 6.6, P. 267).
There was no significant difference between patients with (A+H)-h_1 > 30 and < 30 in
the subgroup of moderate to severe stroke (NIHSS > 7 at baseline).
The results of well-being are shown (Table 6.7, P. 268). Patients with (A+Hj-hf1
> 30 had significant lower score in subscale of social function in SF-36 than patients
with (A+H)-h_1 < 30 (p = 0.045). In the subgroup of mild stroke, patients with
(A+H)*1 > 30 also had significantly lower scores on the subscale of 5-dimension in
EuroQol (p = 0.014), subscales of physical function (p = 0.002), social function (p =
0.010) and physical summary in SF-36 (p = 0.004). There was also no significant
difference in the subgroup with moderate to severe stroke.
Subgroup analyses were also conducted for cognitive function (MMSE) and
mood (HADS) at baseline. When patients were stratified according to MMSE (cut¬
off < 28 and > 28, Figure 6.3a, P. 277) and HADS (cut-off < 8 and > 8, Figure 6.4a,
P. 278), the difference of total EADL score between (A+H)-h_1 > 30 and < 30 at 3
months after stroke was significant in the subgroup with HADS < 8 (p = 0.014,
Figure 6.4a, P. 278).
Correlations between sleep variables and functional capacities are shown (Table
6.8, P. 269). Mobility subscale of EADL was significantly correlated with (A+H)-h_1
(p = 0.029) and index of hypopnoea (p = 0.028) but there was no significant
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correlation between oximetric variables and variables of functional outcome (BI and
EADL).
Correlations between sleep variables and cognitive functions are shown (Table
6.9, P. 270). In contrast to the above findings, oximetric variables are significantly
correlated with cognitive functions. Lowest Sa02 was significantly correlated with
MMSE (p = 0.016) and ACE orientation subscale (p = 0.015). Mean Sa02 was
significantly correlated with ACE orientation subscale (p = 0.029). Heart rate
variability defined as standard deviation (SD) of mean heart rate obtained by pulse
oximetry was significantly correlated with total score (p = 0.011), memory (p =
0.008) and language subscales (p = 0.024) of ACE. Lowest heart rate was
significantly correlated with ACE memory subscale (p = 0.035).
Gender difference at 3 months after stroke is shown (Table 6.10, P. 271). Female
patients had lower scores in ACE which was significant in visuospatial subscale (p =
0.004) and lower scores in EADL which was significant in leisure subscale (p =
0.041). Female patients also had lower scores in well-being including HADS, Euro-Q
which was significant in 5-dimension score (EQ-5D, p = 0.044) and lower scores in
SF-36 which was significant in subscales of social function (p = 0.046) and vitality (p
= 0.014).
6.4.2 Outcome assessment at 6 months after stroke
Sixty-four patients were contacted for 6-month follow-up. One patient in the
group of (A+H)\h_l > 30 was lost follow-up. No patients died between 3 and 6
months. Two patients who accepted telephone interview at 3-month assessment also
received telephone interview for BI and EADL. Two patients who refused telephone
interview at 3-month assessment were also contacted to collect brief information
about MRS and "Status of Independence". The other two patients who had complete
assessment at 3 months after stroke were not available for both face-to-face
assessment and telephone interview. One patient in the group of (A+H)-h"1 < 30 was
diagnosed and treated for post-stroke depression and her daughter refused my visit
and telephone interview. The other patient who had (A+Hj-h"1 > 30 had bad temper
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and refused to talk much. Brief information about MRS and State of Independence
was collected from both of them. The BI and EADL of two patients who died before
3 months were also scored "0" as I did at 3-month assessment. Fifty-seven of 63
patients completed all the outcome assessments. Thirty had (A+Hyh"1 < 30 and 27
had (A+H)-tf1 > 30.
The results of outcome assessment at six months after stroke are shown (Table
6.11, P. 272). The effect sizes of functional capacity between patients with (A+H)-h_1
> 30 and < 30 increased slightly in BI (0.47 to 0.48), total (0.40 to 0.51) and mobility
subscale (0.52 to 0.62) of EADL but there was no change of statistical significance.
In the subgroup analysis of mild stroke (NIHSS < 7), the differences between these 2
groups in total score (p = 0.016, Table 6.11, P. 272 and Figure 6.2b, P. 276), mobility
(p = 0.004) and leisure (p = 0.006) subscales of EADL were still statistically
significant (Table 6.11, P. 272). Subgroup analyses for cognitive function (MMSE)
and mood (HADS) are also shown (Figure 6.3b, P. 277 and 6.4b, P. 278). The
differences of total EADL between (A+Hj-IT1 > 30 and < 30 was significant in the
subgroup with MMSE > 28 (p = 0.006) and subgroup with HADS < 8 (p = 0.014).
Multivariate analysis after adjusting for gender, BI and Addenbrooke's Cognitive
Examination (ACE) at baseline also showed (A+H)-h~1 was an independent predictor
for total EADL score at 6 months after stroke in the subgroup with NIHSS < 7 (p =
0.009, Table 6.12, P. 273).
Gender difference at 6 months after stroke is shown (Table 6.13, P. 274). The
difference of EADL between male and female was bigger at 6 months. Female
patients had significantly lower total score (p = 0.033), mobility subscale (p < 0.001)
and leisure subscale (p = 0.029) of EADL. On the contrary, the difference of SF-36
was less prominent and insignificant apart from vitality subscale (p = 0.012).
6.4.3 Time course of functional outcome in stroke
The longitudinal study was terminated when the last recruited patient received 6-
month follow-up so there was limited follow-up of patients at 12 and 18 months.
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Sixty-three patients were contacted for 12-month follow-up through telephone.
Two extra patients were lost. Two extra patients died. Fifty-nine patients had rating
of "status of independence" and MRS. Forty-one patients were contacted for 18-
month follow-up through telephone. No extra patient was lost but five extra patients
died. Forty-one patients had rating of "status of independence" and MRS.
Time course of BI is shown in Figure 6.5 (P. 279). There was a trend of
improvement from 3 weeks to 6 months and it was more prominent from 3 weeks to
3 months after stroke. At 3-month time most patients had BI > 10 and at 6-month
time most patients had BI > 15 with ceiling effect. Although there was no statistical
significance of BI between groups at both 3 months and 6 months as mentioned
previously, the score of BI was higher, distribution was more homogenous and
changes from 3 to 6 months were bigger in the group with (A+H)-h_1 < 30 than
(A+Hyh1 > 30.
Time course of EADL is shown in Figure 6.6 (P. 280). We did not assess EADL
at baseline (3 weeks) because at that time patients, even with mild to moderate
stroke, usually had a floor effect on this scale. The distribution of total score and
mobility subscale of EADL was wide in both groups but there was a trend of
increased EADL from 3 to 6 months which was more prominent in the group with
(A+H)-h ' < 30. Although there was a significant difference of EADL mobility
subscale between patients with (A+H)-h_1 > 30 and < 30, the changes of total and
mobility subscale of EADL from 3 to 6 months between groups were not significant.
It was bigger in the group with (A+H)-h"1 < 30.
Time course of MMSE and ACE is shown in Figure 6.7 (P. 281). As described
in chapter 4 patients with (A-t-H)-h"1 < 30 had a relatively higher cognitive scores than
those with (A+FQ-h"1 > 30. There was also a trend of improvement of ACE and
MMSE from 3 weeks to 3 months in both groups but changes were similar between
groups.
Time course of HADS is shown in Figure 6.8 (P. 282). On the contrary, changes
of HADS were more heterogeneous with some going up and the others going down.
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There was a net trend of minimal improvement of mood (decreased anxiety and
depression scores of HADS) associated with concomitant improvement of
neurological deficit and functional capacity described previously.
Longitudinal follow-up of MRS is shown in Figure 6.9 (P. 283). MRS was
higher in patients with (A+H)-h"' < 30. There was no clear change of MRS scores in
patients with (A+H)-h~1 > 30 from 3 months to 12 months after stroke but MRS
scores were gradually decreased from 3 months to 12 months in patients with
(A+H)-h~' < 30 which means improvement of functional capacity. The difference of
MRS between groups with (A+H)-h_1 > 30 and (A+H)-h"' < 30 was significant at 6
months after stroke (p = 0.026). At 18 months after stroke, sample size was too small
to tell the difference.
6.4.4 Status of independence and mortality
Longitudinal follow-up of "status of independence" is shown (Figure 6.10a and
6.10b, P. 284). There was a higher proportion of "independence at home" in patients
with (A+H)-h4 < 30 than those with (A+H)-h~1 > 30 at each time point of follow-up
but the only significant difference was at 6 months after stroke by Chi-square test (p
= 0.033, Figure 6.10a, P. 284). There was no significant difference of mortality rate




In this study I focused on a group of patients with mild to moderate neurological
deficits (median NIH stroke score = 6) in a narrow time span (14-19 days) following
stroke. As recovery from stroke is an ongoing process stroke patients should be
compared at a set time following stroke. My study is different from previous two
outcome studies which recruited patients in a much wider time span between one and
two months after stroke [Cherkassky et al. 2003;Kaneko et al. 2003b]. I also
expanded the spectrum of outcome assessment from physical and functional domains
to include the following:
• A more detailed cognitive assessment, i.e. Addenbrooke's Cognitive
Examination (ACE) rather than Mini-mental State Examination (MMSE)
• Emotional outcome and health-related quality of life as they are practical
issues in the life of stroke patients.
6.5.1 The prognostic implication of SDB in physical and
functional outcome of stroke
By conducting a longitudinal follow-up we found patients with (A+H)-h4 < 30
had higher score in Barthel Index (BI) at baseline, higher Nottingham Extended ADL
Index (EADL) at 3 months and 6 months after stroke and bigger improvement during
the follow-up periods than (A-i-H)-h"1 > 30. Patients with (A+H)-h~1 < 30 also had
higher scores in Modified Rankin Scale (MRS) and physical domains of SF-36 than
(A+Hyh"1 > 30. The difference between groups was small with effect size around
0.2-0.5. It was only significant in EADLmobility subscale at 3 months and 6 months,
MRS at 6 months and 12 months and SF-36 social function subscale at 3 months
after stroke, mostly in subscales or post-hoc subgroup analysis. All of these should be
interpreted more conservatively as they depend on post-hoc analysis.
An obvious objection to comparing the outcome in the two severity groups is
that half of the more severe group (i.e. (A+Hyif1 > 30) were allocated to CPAP
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treatment. As it appears that patients treated with CPAP fared worse in some ways
than those not treated this might have artificially exaggerated any apparent adverse
prognostic effects of patients with (A+Hj-h1 > 30. After adjusting for the
confounding factor of allocation, the results showed allocation was not independently
associated with length of hospitalization and poor functional outcome at 3 months
after stroke. This means since CPAP treatment had little effect, this had probably
made little difference.
6.5.1.1 Controlling baseline confounders
I found in my study that the difference in functional capacities between groups
with (A+H)-h1 < 30 and (A+Hj-lf1 > 30 was getting bigger from 3 weeks (baseline)
to 3 months after stroke according to the following results:
• There was no significant difference of baseline severity of stroke (NIHSS)
and functional capacity (BI) between groups although we could not
completely exclude the possibility that there might be a small difference but
sample size was not big enough to tell.
• The difference ofmobility subscale of EADL between groups at 3 months
after stroke was still significant after adjusting for baseline confounders
including gender, functional capacity (BI) and cognitive function
(Addenbrooke's Cognitive Examination, ACE).
Controlling severity of stroke or functional capacity at baseline is important as
these have a major impact on the outcome. One study based on oximetry showed the
correlation between oximetric variables and BI existed as early as admission but they
didn't do further multivariate analysis to adjust for confounders at baseline [Good et
al. 1996]. In their study patients who had more severe stroke also had more severe
hypoxemia and this could have resulted in a poor functional outcome. They used an
uncommon statistical method, Pearson's correlation with mortality as a dichomatous
variable, to show a significant association between mortality at 12 months after
stroke and two oximetric variables, namely, mean Sa02 and percentage of time with
Sa02 < 90%. Only 5 of their 47 patients died at 12 months which is quite similar to
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my findings. I applied the Chi-square test for comparison of mortality between
patients with (A+H)-h1 > 30 and < 30 and the difference between groups were not
statistically significant. A more appropriate analysis of mortality might be the Cox
regression model instead of simple correlation. We didn't use this because the
mortality rate was low (9 of 66 patients).
6.5.1.2 Distinction between hypoxaemia and sleep
apnoea/hypopnoea syndrome in outcome study of stroke
The other study dealing with SDB and the outcome of stroke was also based on
oximetry only [Cherkassky et al. 2003;Good et al. 1996]. Good et al. measured
outcome with the BI and Cherkassky et al. used the Functional Independence
Measure (FIM). The former found a significant correlation between oximetric
variables and BI and the latter showed that the respiratory disturbance index (RDI)
was an independent predictor for FIM gain after controlling baseline FIM data. The
RDI they calculated was based on oximetry so it relates to desaturation (DI) rather
than to the true apnoea hypopnoea index (AHI).
Although both Good et al. and Cherkassky et al. highlighted the association
between SDB and the functional outcome of stroke, they actually focused on hypoxia
instead of SDB. By using oximetry only they might have recruited a certain
proportion of Cheyne-Stokes respiration (CSR) and central sleep apnoea (CSA),
which are common in stroke. Many sequelae or complications of stroke might cause
hypoxaemia as well. Thus the major finding of their studies is only the association
between functional outcome of stroke and hypoxemia, and not between functional
outcome and SDB, although most of the hypoxemia might be caused by SDB.
I didn't find any correlation between oximetric variables and two functional
outcome measures, including BI and EADL. A significant correlation was only noted
between oximetric variables and cognitive outcome measured by ACE. A plausible
explanation in our study might be that the functional outcome measure (EADL) was
more sensitive to AHI and the cognitive outcome measure (ACE) was more sensitive
253
to oximetric variables. I didn't perform full polysomnography so there was no
electroencephalography (EEG) information to know whether impaired functional
outcome in patients with (A+H)-h1 > 30 was mainly due to sleep fragmentation.
The difference between our study and the study conducted by Good et al.
regarding desaturation and outcome of stroke needs to be clarified in further studies
which should clearly separate hypoxaemia and sleep apnoea/hypopnoea syndrome
into two distinct domains before studying their association with the outcome of
stroke.
6.5.1.3 Comparison between EADL in our study and FIM in previous
publications
Unlike the study conducted by Good et al., although we found a trend of
difference in BI between patients with (A+H)-h_1 > 30 and < 30 this was not
statistically significant. One other study which applied BI as a measure of functional
outcome in the randomized control trial of nasal CPAP in stroke did not show any
significant difference in BI either [Sandberg et al. 2001a].
I added the other scale to measure functional outcome, EADL, which is more
sensitive than BI and similar to FIM used in previous two publications [Cherkassky
et al. 2003;Kaneko et al. 2003b]. Although we all showed a negative impact of SDB
on functional outcome the size of this impact varied between our studies. Kaneko et
al. showed there was about 10% of difference (mean difference / total score x 100%)
in total score of FIM between patients with (AHI > 10) and without (AFQ < 10) sleep
apnoea at discharge from rehabilitation ward which was statistically significant. By
using linear regression they also showed that obstructive AHI was an independent
predictor for total FIM score and length of hospitalization. On the other hand,
Cherkassky et al. showed the difference in total FIM score between patients with RDI
> 10 and < 10 was not significant. There was actually about 14% of difference
between these two groups of patients which was quite similar with Kaneko's result.
In our study, there was no significant difference of total EADL score and length of
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hospitalization between groups with (A+H)-h l > 30 and < 30 but there was about
14% of difference between these two groups which was also quite similar to the
previous two studies.
The sample size in our study (n = 66) was more than Kaneko's (n = 50) but the
standard deviation (SD) of EADL in our study was much bigger. Although
percentage of mean difference in our study was similar to Kaneko's the effect size
was much smaller. We might need more patients to achieve statistical significance in
total EADL score. This also means our patients had higher variation of EADL score.
From the other point of view the level of functional capacity assessed by EADL
might be higher than that in FIM. As FIM is usually used in assessing the outcome of
in-patient rehabilitation and EADL deals with more after-discharge activities this
explanation might be reasonable. The sample size in Cherkassky's study (n = 30) was
much less than Kaneko's (n = 50) and SD of FIM in Cherkassky's study was also as
big as ours. Type II error might be more prominent in their study than Kaneko's and
our study.
My patients were relatively older than Kaneko's patients (74 vs. 66). The FIM
(score 18-126) was 80-95 at admission and 100-110 at discharge in Kaneko's study.
On the other hand, the BI (score 0-20) of our patients was 12 at admission and EADL
(score 0-66) was 20-30 at 3 months after stroke. According to a rough estimation, we
recruited a group of more severe stroke patients than they did even though the
median of NIHSS (0-42) in our patients was only 6. According to our results
described previously, difference of functional outcome between patients with and
without SDB might be bigger in the group of milder stroke severity.
6.5.2 The prognostic implication of SDB in mental outcomes
I didn't find any significant difference in cognitive function and mood between
patients with (A+H)-h_1 > 30 and < 30 either at baseline or at 3 months after stroke.
The effect size of MMSE, ACE and its subscales at 3 months after stroke was small
(0-0.38). The effect size of HADS at 3 months and mental summary subscale of SF-
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36 at both 3 and 6 months was very small (mostly < 0.1). There are five plausible
explanations:
• There was no difference of cognitive and emotional outcome between
groups.
• Type II error might occur in our patients with small difference of mean
between groups, big SD and small effect size.
• ACE, MMSE, Hospital Anxiety and Depression Scale (HADS) and mental
domains of SF36 were not sensitive enough to detect the difference.
• The influence of SDB was masked by cognitive deficits and emotional
symptoms resulted from stroke itself.
• About half of the patients with (A+H)-h_1 > 30 who were randomized to
CPAP treatment had improvement in these symptoms so the difference
disappeared. This is less likely as compliance to CPAP was very poor.
In terms of cognitive outcome, my findings are similar to the few previous
publications but in terms of emotional outcome, quite different. All previous studies
applied MMSE as the only cognitive measure [Kaneko et al. 2003b;Sandberg et al.
2001a]. We added ACE which also includes MMSE but there was still no significant
difference between groups. ACE, like MMSE is still a screening tool. Although ACE
covers a broad spectrum of cognitive function there is only one test (verbal fluency)
to deal with executive function which might be important in SDB and stroke. It is not
easy to perform a comprehensive neuropsychological assessment in stroke. If we do
apply more difficult tests to differentiate subtle cognitive changes in patients with
SDB we doubt this difference, even it is statistically significant, has a clinically
significant influence on the functional outcome of stroke.
Only one research group identified an association between SDB and distinct
depressive symptoms in stroke [Sandberg et al. 2001b]. They conducted a sleep study
at 23 ± 7 days (11-41 days) of stroke when patients were admitted to rehabilitation
ward. They also measured Montgometry-Asberg Depression Rating Scale (MADRS,
score 0-60) and Organic Brain Syndrome (OBS) Scale including one item for
depressed mood (score 0-3). The mean difference of MADRS between patients with
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AHI > 10 and < 10 was 5.2 (p = 0.013) and effect size was 0.47 (mild to moderate).
The mean difference of "depressed mood" in OBS Scale was 0.41 (p = 0.004) and the
effect size was 0.52 (moderate). The difference between groups was moderate and
significant.
On the other hand, patients with AHI > 10 also had more severe strokes as
measured by BI (7.6 ± 6.0 vs. 11.5 + 6.8, p = 0.001) and delirium (75.3% vs. 55.6%,
p = 0.018). In order to control baseline severity of stroke, they used a logistic
regression model with AHI as the dependent variable and, BI and "depressed mood"
in OBS Scale as independent variables. The result showed "depressed mood" in OBS
Scale was still independently associated with AHI after adjusting for the association
between BI and AHI. There are still some points which need to be clarified in their
study:
• "Depressed mood" is only one item of the 39 neuropsychiatric features
(suspiciousness, delusion, hallucination, personality changes etc.) in OBS
Scale regarding depressive symptoms thus its validity for the diagnosis of
depression should be tested beforehand. This finding might be by chance
due to multiple statistical testing.
• A better way to know whether AHI is independently associated with
depressed mood is to put "depressed mood" in OBS Scale as a dependent
variable and AHI as an independent variable in the regression model and
control for the association between BI and "depressed mood".
• The percentage of delirium was very high in their patients. The answers of
delirious patients to psychometric measures are questionable because the
patients are confused.
• The odds ratio of "depressed mood" in OBS Scale calculated from the
regression model was not high (1.74, CI = 1.02-2.94).
Sandberg et al. conducted the first randomized controlled trail of CPAP in stroke
and showed that depressive symptoms measured by MADRS were significantly
decreased. They didn't mention whether MADRS in the study was normally
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distributed but they conducted a parametric test which might increase the chance of
getting a significant finding. This part has been discussed in chapter 5.
There was no direct evidence in our study that poor functional outcome in stroke
patients with (A+H)-h4 > 30 could be explained by poor emotional outcome which
resulted in low motivation to attend rehabilitation or other treatment programmes.
The underlying mechanisms for poor functional outcome could be the direct impact
of SDB through intermittent hypoxemia, sleep fragmentation or impaired cerebral
blood flow. In summary, ours is the second ever study dealing with SDB and
emotional outcome in stroke which generated a different result from the first
publication. Further studies in this field are required. Mood might not be an
important factor when the outcome of stroke is simply defined as "alive and
independent" but might be more important when outcome is assessed by a more
detailed scale like EADL. Although SDB didn't play a significant role in the
cognitive and emotional outcome of stroke I think that SDB might play a more
significant role in functional outcome in patients with higher cognitive function and
stable mood. This will be discussed in the following section.
6.5.3 The interaction of SDB with other factors on functional
outcome
When we consider mild stroke only (NIHSS < 7), the differences of outcome
between patients with (A+H)-h4 > 30 and < 30 were larger and more significant in
terms of total score and all subscales of EADL, role physical, social and physical
summary subscale of SF-36 and length of hospitalization. The difference of EADL
score was also more prominent in patients with either mild cognitive impairment
(MMSE > 28) or less emotional distress (HADS < 8). If this finding is correct CPAP
treatment would be easier and more practically useful. This is in contrast to a
previous study which showed that SDB affected functional outcome of stroke more
significantly in more severe stroke (FIM < 70) [Cherkassky et al. 2003], If so CPAP
treatment would be more difficult and less practically useful. Cherkassky et al.
showed that only 2 of 6 patients with SDB and FIM < 70 improved by > 30 points
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whereas this occurred in 7 of 9 patients without SDB. However, their sample size
was small and their finding was not statistically significant (P = 0.085).
We would rather take the above findings in the subgroup analysis with caution
because they were obtained from a post-hoc exploratory analysis. This was with at
least six independent multiple statistical tests according to three cut-off points (NIH
< 7 and > 7; MMSE < 28 and > 28; HADS < 8 and > 8) and two Mann-Whitney U
tests for the difference between patients at both 3 and 6 months after stroke for each
cut-off point. If we apply the "6p" value (original p value times 6) as the cut-off point
of statistical significance by Bonferroni correction, total score and mobility subscale
of EADL and physical function of SF-36 were still significant in the subgroup of
NIHSS < 7 at 3 months after stroke (Table 6.3). Mobility and leisure subscale were
still significant in the subgroup of NIHSS < 7 at 6 months after stroke. Total scores
of EADL were still significant in the subgroups of MMSE > 28 and HADS < 8 at 6
months after stroke.
Many other factors resulting from brain damage or complications of stroke have
stronger influence on the functional outcome and length of hospitalization than SDB.
Initial severity of stroke and functional capacity at admission is one of them.
Cognitive function and mood might be accessory factors. We think that SDB starts to
play its role when these factors are getting more stable or under control.
6.5.4 The SDB and mortality after stroke
Only 9 patients died in our study so we did not perform Kaplan-Meir analysis
and Cox's regression model for further analysis. A simple Chi-square showed that
there was no significant difference of mortality between patients with (A+H)-h_1 > 30
and < 30. The study conducted by the Spanish group had a larger sample size (n =
161) and longer longitudinal follow-up (mean 22.8 months) than others [Parra et al.
2004]. They found that SDB was an independent predictor for mortality after stroke.
On the other hand, the study conducted by the Spanish group did not have a very
homogenous cohort as they recruited patients from both stroke and TLA. The
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mortality rate may be higher in stroke than in TIA. The characteristics of mortality
may be different in stroke from that in TIA. Stroke patients would have more
mortality resulted from complications than TIA patients. There was no data showing
whether the mortality group had a higher proportion of stroke patients. The study also
found age was the strongest predictor for mortality. Another predictor, CAD, is
highly associated with old age. The hazard ratio and 95% CI ofAHI in the prediction
model was small. There was also no data showing whether older patients had a
higher proportion of stroke than younger ones. Further studies can be designed to
recruit only young stroke patients (excluding TIA and old age) to clarify whether
SDB does play a more significant role in mortality after stroke.
260
6.6 Conclusions
We have the following conclusions in this prospective cohort study:
• SDB is independently associated with poor functional outcome in stroke.
• The effect of SDB on cognitive, emotional outcomes, health-related quality
of life, and mortality is small.
• Oximetric variables, but not (A+H)-h4, are significantly correlated with
cognitive functions. Hypoxaemia might play a more important role than
sleep fragmentation in cognitive outcome.
• The difference of functional outcome between patients with (A-i-H)-h"1 > 30
and < 30 might be more prominent in the subgroup of patients with mild
stroke, lesser cognitive impairment or lesser emotional distress.
• Many other factors might have a stronger influence than SDB on the
functional outcome and length of hospitalization. The initial severity of
stroke is a strong confounding factor. Cognitive function and mood might be
two accessory factors. We think that SDB starts to play its role when these
factors are getting more stable or under control.
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Table 6.1 Factors at baseline (3 weeks) predicting length of
hospitalization
Dependent variable Logarithm (Ln) of Length of Hospitalization
Predictors Age (p = 0.014), classification of stroke (p =
0.012), NIH Stroke Scale (p < 0.001), Barthel
Index (p < 0.001), Stanford Sleepiness Score (p
= 0.062), Addenbrooke's Cognitive Exam (p =
0.078), Hospital Anxiety and Depression Score
(p = 0.024)
Significant Variables Coefficient Standard error t Value P Value
NIH Stroke Scale 0.085 0.026 3.245 0.002
Barthel ADL -0.104 0.016 -6.577 < 0.001
AHI 0.006 0.003 2.060 0.044
Full model F (df) 47.152 (3,57) < 0.001
F change with AHI 4.244 0.044
Full model R2 0.713
R2 change with AHI 0.021
1. Stepwise multiple linear regression with forced entry of AHI.
2. Length of hospitalization is log transformed into normal distribution.
3. The parenthesis following predictor shows p value in univariate analysis. Only
those with p < 0.1 are entered.
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Table 6.2 Factors at baseline (3 weeks) predicting length of
hospitalization after adjusting for allocation
Dependent variable Logarithm (Ln) of Length of Hospitalization
Predictors Age (p = 0.014), classification of stroke (p =
0.012), NIH Stroke Scale (p < 0.001), Barthel
Index (p < 0.001), Stanford Sleepiness Score (p
= 0.062), Addenbrooke's Cognitive Exam (p =
0.078), Hospital Anxiety and Depression Score
(p = 0.024)
Significant Variables Coefficient Standard error t Value P Value
NIH Stroke Scale 0.081 0.026 3.126 0.003
Barthel ADL -0.105 0.016 -6.735 < 0.001
AHI 0.010 0.004 2.302 0.025
Allocation -0.093 0.101 -0.923 0.360
Full model F (df) 36.433 (4,55) < 0.001
Full model R2 0.726
1. Stepwise multiple linear regression with forced entry of AHI and allocation.
2. Length of hospitalization is log transformed into normal distribution.
3. The parenthesis following predictor shows p value in univariate analysis. Only
those with p < 0.1 are entered.
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Table 6.4 Factors at baseline predicting mobility subscale of
Nottingham Extended ADL Index (EADL) at 3 months after stroke
Dependent variable EADLmobility subscale > 6
Predictors Gender (p = 0.066), AHI (p = 0.026), NIH Stroke
Scale (p = 0.006), Barthel Index (p < 0.001),
Addenbrooke's Cognitive exam (p = 0.071) at
baseline
Variables Wald Odds Ratio CI p Value
Gender 2.810 3.791 0.798-18.012 0.094
AHI 6.233 0.145 0.032-0.660 0.013
Barthel Index 14.242 1.502 1.216-1.856 < 0.001
Addenbrooke's Cognitive Exam 0.363 1.016 0.965-1.069 0.547
Model Chi-Square 36.400 < 0.001
Correct Predictions 77.8%
Nagelkerke-R2 0.585
1. Full model logistic regression.
2. EADLmobility subscale is converted into dichotomous variable according to its
median. AHI is converted into dichotomous variable according to the cut-off point
(30).
3. The parenthesis following predictor shows p value in univariate analysis. Only
those with p < 0.1 are entered.
4. NIH Stroke Scale is not put in the model to prevent from multicollinearity with
Barthel Index.
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Table 6.5 Factors at baseline predicting mobility subscale of
Nottingham Extended ADL Index (EADL) at 3 months after stroke
after adjusting for allocation
Dependent variable EADLmobility subscale > 6
Predictors Gender (p = 0.066), AHI (p = 0.029), Barthel
Index (p < 0.001), Addenbrooke's Cognitive
exam (p = 0.071) at baseline
Variables Wald Odds Ratio CI p Value
Gender 3.294 4.677 0.884-24.746 0.070
AHI 0.024
AHI < 30 vs. AHI > 30 (CPAP) 7.304 25.056 2.423-
259.095
0.007
AHI > 30 (Con) vs. AHI > 30
(CPAP)
2.750 7.510 0.693-81.376 0.097
Barthel Index 13.346 1.520 1.214-1.903 < 0.001
Addenbrooke's Cognitive Exam 0.963 1.026 0.974-1.081 0.326
Model Chi-Square 39.498 < 0.001
Correct Predictions 81%
Nagelkerke-R2 0.621
1. Full model logistic regression.
2. EADLmobility subscale is converted into dichotomous variable according to its
median. AHI is converted into dichotomous variable according to the cut-off point
(30).
3. Regression analysis taking allocation into account is done by dividing AHI into
three groups: (1) AHI < 30; (2) AHI > 30 with conventional treatment for stroke
only (Con); (3) AHI > 30 with conventional treatment for stroke plus CPAP
treatment (CPAP). The results are presented as odds ratio of (1) AHI < 30 to AHI >
30 (CPAP) and (2) AHI > 30 with conventional treatment only (Con) to AHI > 30
with conventional treatment plus CPAP treatment (CPAP).
4. The parenthesis following predictor shows p value in univariate analysis. Only
those with p < 0.1 are entered.
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Table 6.6 Factors at baseline predicting total score ofNottingham
Extended ADL Index (EADL) at 3 months after stroke in patients with
mild stroke (NIHSS < 7)
Dependent variable EADL total score > 36 at 3 months
Predictors AHI (p = 0.009), Barthel Index (p = 0.006) at
baseline
Variables Wald Odds Ratio CI p Value
AHI 6.653 0.055 0.007-0.407 0.005
Barthel Index 6.737 1.536 1.103-2.137 0.011
Model Chi-Square 19.221 < 0.001
Correct Predictions 84.6
Nagelkerke-R2 0.519
1. Full model logistic regression.
2. EADL total score is converted into dichotomous variable according to its
in the group with NIHSS < 7.
3. The parenthesis following predictor shows p value in univariate analysis,
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Table 6.10 Gender difference in outcome at 3 months after stroke
Male Female p Value
Stanford Sleepiness Scale 3 (2-3) 3 (1-3) 0.808
NIH Stroke Scale 2 (1-5) 2(1-7) 0.936
Barthel Index 18 (16-20) 18 (14-20) 0.586
Mini-mental Status Exam 29 (27-29) 29 (25-30) 0.890
Addenbrooke's Cognitive Exam 87 (82-91) 81 (68-92) 0.259
Orientation 10 (9-10) 10 (9-10) 0.609
Attention and concentration 8 (7-8) 8(6-8) 0.667
Memory 31 (26-34) 29 (23-33) 0.190
Verbal fluency 8(6-10) 7(4-10) 0.209
Language 28 (27-28) 26 (24-28) 0.071
Visual spatial 4 (3-5) 3 (3-4) 0.004**
Nottingham Extended ADL 29 (15-56) 26 (9-37) 0.148
Mobility 8 (3-16) 5 (1-10) 0.052
Kitchen 11 (4-15) 11 (3-14) 0.332
Domestic 3 (0-12) 1 (0-8) 0.363
Leisure 8(6-12) 6 (4-9) 0.041*
Hospital Anxiety Depression Scale 8(3-11) 10 (6-15) 0.089
Anxiety 3 (2-5) 5 (3-6) 0.078
Depression 4 (2-6) 6(3-11) 0.088
Euro-Q Visual Analogue 75 (67-80) 70 (61-80) 0.160
Euro-Q 5-Dimention 0.76 (0.59-1.00) 0.69 (0.42-0.79) 0.044*
SF-36 Health transition 4 (3-4) 4(4-5) 0.151
SF-36 Physical function 45 (25-68) 35 (20-50) 0.058
SF-36 Role physical 0 (0-25) 0(0-25) 0.494
SF-36 Role emotional 100 (33-100) 100 (33 -100) 0.489
SF-36 Bodily pain 84 (62-100) 72 (61-100) 0.237
SF-36 Mental health 84 (64-92) 64 (49-87) 0.022
SF-36 Social function 60 (50-75) 56 (25-75) 0.046*
SF-36 General health 67 (49-82) 64 (48-72) 0.171
SF-36 Vitality 60 (50-75) 53 (26-60) 0.014*
SF-36 Physical summary 28.1 (21.6-39.3) 25.8 (21.9-30.8) 0.293
SF-36 Mental summary 56 (51-64) 49.9 (38.2-57.8) 0.073
II Mann-Whitney U test
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Table 6.12 Factors predicting Nottingham Extended ADL Index
(EADL) at 6 months after stroke in patients with mild stroke (NIHSS
<7)
Dependent variable EADL total score at 6 months
Predictors Gender (p = 0.020), AHI (p = 0.017), Barthel
Index (p = 0.001), Addenbrooke's Cognitive
Exam (p = 0.021) at baseline
Variables Coefficient Standard error t Value p Value
Gender 5.455 4.881 1.118 0.272
AHI -0.323 0.116 -2.783 0.009
Barthel Index 2.359 0.627 3.760 0.001
Addenbrooke's Cognitive Exam 0.249 0.144 1.724 0.095
Full model F (df) 9.759 (4,31) < 0.001
Full model R2 0.557
1. Full model multiple regression.
2. The parenthesis following predictor shows p value in univariate analysis. Only
those with p < 0.1 are entered.
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Table 6.13 Gender difference in outcome at 6 months after stroke
Male Female p Value
Barthel Index 19 (17-20) 18 (14-19) 0.159
Nottingham Extended ADL 36 (21-53) 25 (10-39) 0.033*
Mobility 10 (5-17) 4 (2-9) <0.001***
Kitchen 11 (8-15) 11 (2-14) 0.122
Domestic 4(0-12) 4 (0-8) 0.431
Leisure 9(7-11) 8 (5-9) 0.029*
SF-36 Health transition 4 (3-4) 4 (3-4) 0.560
SF-36 Physical function 45 (20-70) 28 (14-40) 0.065
SF-36 Role physical 0(0-25) 0 (0-6) 0.609
SF-36 Role emotional 67 (33-100) 100 (25-100) 0.536
SF-36 Bodily pain 72 (42-100) 100 (49-100) 0.264
SF-36 Mental health 80 (64-92) 72 (67-88) 0.259
SF-36 Social function 63 (25-88) 38 (22-88) 0.126
SF-36 General health 62 (47-77) 69 (52-88) 0.256
SF-36 Vitality 55 (40-70) 38 (29-53) 0.012*
SF-36 Physical summary 27.4 (18.2-36.8) 21.8 (19.5-35.9) 0.525
SF-36 Mental summary 55.9 (45.7-59.9) 51.7 (40.2-59.5) 0.487
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Figure 6.1 Length of hospitalization between AHI > 30 and < 30 (a)
and correlation with AHI (b)
□ Rehabilitation ward
□Acute stroke unit
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Figure 6.2 Subgroup analysis of Nottingham Extended ADL Index
(EADL) between AHI > 30 and AHI < 30 based on NIH Stroke Scale
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Figure 6.3 Subgroup analysis ofNottingham Extended ADL Index
(EADL) between AHI > 30 and AHI < 30 based on Mini-mental State
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Figure 6.4 Subgroup analysis ofNottingham Extended ADL Index
(EADL) between AHI > 30 and AHI < 30 based on Hospital Anxiety
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Figure 6.5 Time course (a) and changes (b) ofBarthel Index (BI)
between patients with AHI < 30 and AHI > 30
3 wk 3 mo 6 mo
AHI <30
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Figure 6.6 Time course (a) and changes (b) of Nottingham Extended
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Figure 6.7 Time course (a) and changes (b) of Mini-mental State
Examination (MMSE) and Addenbrooke's Cognitive Examination
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Figure 6.8 Time course (a) and changes (b) of Hospital Anxiety and
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Figure 6.9 Time course of Modified Rankin Scale between patients














N = 33/33 N = 33/32 N = 30/29 N = 20/21
p = 0.152 p = 0.026* p = 0.039* P = 0.301
I I AHI < 30












Figure 6.10 Cumulative mortality rate (a) and time course of
"independent at home (home with MRS < 2)" (b) between patients
with AHI > 30 and < 30
Dependent
Independent at Home
N = 33/33 N = 33/32 N = 30/29 N = 20/21
p = 0.623 p = 0.033* p = 0.244 p = 0.278











AHK30 AHI=30+ AHK30 AHI=30+ AHK30 AHI=30+ AHK30 AHI=30+










mm Cumulative number of mortality shown on top of the bars
N = 33/33 N = 33/32 N = 30/29 N = 20/21
p = 0.151 p = 0.145 p = 0.284 p = 0.731
0
AHK30 AHI=30+ AHK30 AHI=30+ AHK30 AHI=30+ AHK30 AHI=30+
3 months 6 months 12 months 18 months
284
Chapter 7 Concluding Remark and Future Work
285
7.1 Concluding remark
Stroke is one of the most devastating cardiovascular diseases. Only half of
cardiovascular diseases can be explained by conventional risk factors. Some new risk
factors have been proposed and sleep-disordered breathing (SDB) is one of those
which are treatable [Diaz and Sempere 2004], Stroke usually happens in the elderly.
Similarly, SDB is more common with increasing age [Ancoli-Israel et al. 1991]. The
total cost of road traffic accidents is about £5 million per 500 untreated patients with
SDB in every 5 years [Douglas and George 2002] and the total cost of acute and
long-term care of stroke is about the double per 500 patients [Dewey et al. 2001].
Many previously published and ongoing studies have been trying to clarify the link of
SDB to stroke, treatment effect of continuous positive airway pressure (CPAP) and
impact of SDB on stroke outcomes. The contributions in our study are:
The data supports the high prevalence of SDB in stroke. A portable limited sleep
study is a feasible and reliable tool to confirm the diagnosis of SDB. SDB seems to
be a consequence of stroke rather than directly causing stroke during sleep.
We did not show any benefit in treating patients with SDB post-stroke with
continuous positive airway pressure (CPAP). We cannot exclude clinically
significant benefit or harm from CPAP because of our small sample size, which was
only adequate to identify large treatment effects. The other major problem was that
compliance with CPAP was poor even in our highly selected stroke patients.
Compliance was poor despite our expertise in this area, our exclusion of many
patients in whom we thought CPAP would be difficult, our use of auto-titrating
CPAP and the intensive input from a very experienced specialist nurse. Many of the
patients were inpatients during the treatment phase. Compliance might be improved
in future studies by focusing on less depressed and cognitively less impaired patients
but this would further decrease recruitment and also reduce the generalizability of
any result. We believe that CPAP should only be used post-stroke in those patients
who satisfy the criteria for SDB plus major related symptoms, usually sleepiness.
However in our patients there was no correlation between daytime sleepiness and
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CPAP compliance although this may have been because our sample size was too
small (n = 15).
We found that the influence of SDB on the long-term outcome of stroke, i.e.
three to eighteen months following stroke, was small. SDB may compromise the
recovery of functional capacity following stroke instead of emotion, cognition and
health-related quality of life. The effect might be more prominent after three months
of stroke when patients had gone beyond the highest risk of complication and
mortality. At this stage patients with stroke may be more compliant with nasal CPAP
and CPAP may reduce recurrence of stroke by lowering blood pressure. On the other
hand, SDB could perhaps play a role in the functional recovery of stroke in patients
with less severity, less depression and higher cognitive function.
The merits ofmethodology in our study are:
• We had a more homogenous cohort than most studies. The patients were
recruited at 14-19 days following stroke and had less severe stroke according
to our inclusion and exclusion criteria.
• We performed the second ever randomized controlled trial of nasal CPAP in
stroke.
• We had larger sample size (n = 66) in longitudinal outcome study than most
previous studies.
• We had data collection in diverse domains of outcome in comparison with
other studies which focused on functional outcome and mortality only. As
outcome of stroke has a multi-dimensional nature, several outcome
measures are beneficial.
• Most outcome measures are self-reported questionnaires. These can decrease
the bias of assessment in outcome studies.
• We had interview-based instead of telephone or postal-based follow-up.
This can increase the rate and validity of responses so we have less missing
data during follow-up period.
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• We performed follow-up at set time: 3 months (12th week) and 6,12,18
months (all are based on calendar month) instead of unclear definitions such
as "outcome at discharge" reported in other studies.
• We adjusted for baseline data and confounders in data analysis. Most of the
previous studies did not adjust for baseline cofounders so their results might
be biased by imbalance at baseline.
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7.2 Future work
The prevalence of SDB is high in both the fit elderly and in those with
cerebrovascular disease. In a study conducted in our sleep centre, TIA patients did
not have significantly higher frequencies of sleep apnoea and hypopnoea than age
matched controls. It might be informative to conduct a further study with similar
design recruiting: (1) only young TIA patients (i.e. those aged below 45) and young
controls to find out whether SDB is more prevalent in young TIA patients in whom
SDB and hypertension might play a more important role in the pathogenesis of
cerebrovascular disease than older ones and in whom there would be a much lower
"background" level of SDB in the normal controls; (2) only young stroke patients to
see whether SDB is an independent predictor for mortality after stroke after
subtracting old-aged patients who usually have higher mortality resulting from other
clinical conditions.
We need to test the prediction model of SDB in stroke generated in our study.
This can be done by applying both the screening questionnaire generated from the
model and overnight sleep study for confirmation of SDB to another population of
stroke with similar hospital-based background. The validation of the prediction
model can be performed through either traditional regression analysis or a more
modern computer-assisted neural network. Sensitivity, specificity, positive predictive
value and negative predictive value and area under the curve (AUC) of Receiver
Operating Characteristics (ROC) can be calculated. This model may be helpful to be
used by the first line physicians who do not have much knowledge about SDB.
The relationship - if any- between SDB and sleep-related stroke still needs to be
clarified. Time and sleep-wake state upon stroke onset can be routinely recorded in
the first instance when patients suffering from stroke are sent to emergency
department. If neurological deficits are noted upon awakening, a detailed history
should be taken to try to identify the time when the patient was last intact. The time
interval between these two points should be as narrow as possible.
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In my study, 24-hr ambulatory blood pressure (ABP) was only applied in
randomized controlled trials (RCT) to stroke patients who had moderate to severe
SDB. Further study could use 24-hr ABP monitoring in more stable stroke patients
with or without SDB to clarify the association between SDB, surge or drop of blood
pressure and circadian rhythm of stroke onset.
My study showed no benefit from CPAP and suggested some impairment of
function on CPAP. It is questionable whether further RCTs in this area are justified
given possible deterioration on CPAP but as other study showed some improvement
in depression score and our sample size was low, further study might be justified. An
RCT of stroke patients with features of pre-existing SDB is certainly justified.
The problem will be sample size. According to the results in this thesis, the
effect size of difference in the primary outcome, Nottingham Extended Activity of
Daily Living Scale, between untreated patients with (A+Hj-h"1 > 30 and < 30 at 6
months after stroke was 0.89. Based on a power calculation, a sample size of 64 in
each limb may achieve 80% power to detect the difference of functional outcome of
stroke between treated and untreated groups with a significance level (alpha) of 0.05.
However, this is the minimum size if all the difference was due to sleep apnoeas and
hypopnoeas and all of these were abolished by CPAP with 100% CPAP use. Thus
any further study to attempt to demonstrate a benefit of CPAP in similar patients will
probably need hundreds of patients in each limb.
Placebo instead of "conservative treatment of SDB" can be considered. A sham
CPAP is more similar with true CPAP than oral placebo but may be less feasible. I
would consider using an oral placebo in the next trial as it has been used in several
RCTs conducted in the sleep centre of Edinburgh University. We did not use that on
this occasion because we decided that would add to the complexity of these elderly
patients' treatment for no good ethical reason. In fact, there was no benefit from
CPAP in this study which could have been attributed to a placebo effect anyway. We
also need to identify further ways of trying to improve compliance with CPAP in
stroke patients. A group of stroke patients in a stable chronic phase, for example,
beyond three months after stroke who have less depression and higher cognitive
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function screened through pre-determined inclusion and exclusion criteria can be
recruited for a further RCT of CPAP.
A cohort study with longitudinal follow-up for stroke patients with and without
SDB can be designed with a priori hypothesis that SDB may play a significant role in
the outcome of stroke patients with less severity, less depression and higher cognitive
function to avoid data dredging through post-hoc subgroup analysis. The patients
with severe stroke can be recruited in another independent study of hyper-acute or
acute stroke which will focus on the association between SDB, stroke-in-evolution
(progressive stroke) and mortality. The other studies can recruit patients with central
sleep apnoea and Cheyne-Stokes respiration to see whether they play a more
important role than SDB in the outcome of stroke.
These potential studies are all important, but the results of the studies carried out
in this thesis and by others strongly suggest that CPAP will not be beneficial in most
patients who have irregular breathing after stroke.
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Appendix A National Institute ofHealth Stroke Scale
Please circle the most appropriate response for each section
l.a. Level of Consciousness: 0 Alert
1 Not alert, but arousable with minimal stimulation
2 Not alert, requires repeated stimulation to attend
3 Coma
1 .b. Ask patient the month and
their age:
0 Answers both correctly
1 Answers one correctly
2 Both incorrect
I.e. Ask patient to open and
close eyes and
0 Obeys both correctly
1 Obeys one correctly
2 Both incorrect
2. Best gaze (only horizontal
eye movement):
0 Normal
1 Partial gaze palsy
2 Forced deviation
3. Visual Field testing: 0 No visual field loss
1 Partial hemianopia
2 Complete hemianopia
3 Bilateral hemianopia (blind including cortical
blindness)
4. Facial Paresis (Ask patient
to show
0 Normal symmetrical movement
teeth or raise eyebrows and
close eyes
1 Minor paralysis (flattened nasolabial fold,
asymmetry on smiling)
tightly):
2 Partial paralysis (total or near total paralysis of
lower face)
3 Complete paralysis of one or both sides (absence of
facial movement in the upper and lower face)
5. Motor Function - Arm
(right and left):
0 Normal (extends arms 90 (or 45) degrees for 10
seconds without drift)
1 Drift
Right arm 2 Some effort against gravity
Left arm 3 No effort against gravity
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4 No movement
9 Untestable (Joint fused or limb amputated)
6. Motor Function - Leg (right
and left):
0 Normal (hold leg 30 degrees position for 5 seconds)
1 Drift
Right leg 2 Some effort against gravity
Left leg 3 No effort against gravity
4 No movement
9 Untestable (Joint fused or limb amputated)
7. Limb Ataxia: 0 No ataxia
1 Present in one limb
2 Present in two limbs
8. Sensory (Use pinprick to
test arms, legs,
0 Normal
trunk and face — compare side
to side):
1 Mild to moderate decrease in sensation
2 Severe to total sensory loss
9. Best Language (describe
picture, name items,
0 No aphasia
read sentences) 1 Mild to moderate aphasia
2 Severe aphasia
3 Mute
10. Dysarthria (read several
words):
0 Normal articulation
1 Mild to moderate slurring of words
2 Near unintelligible or unable to speak
9 Intubated or other physical barrier
11. Extinction and inattention: 0 Normal
1 Inattention or extinction to bilateral simultaneous
stimulation in one of the sensory modalities
j
2 Severe hemi-inattention or hemi-inattention to
more than one modality
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Appendix B Modified Rankin Scale
With respect to your functional ability, do you have (circle one):
0 = No symptoms at all
1 = No significant disability despite symptoms; able to carry out all usual duties and
activities
2 = Slight disability; unable to carry out all previous activities, but able to look after
own affairs without assistance
3 = Moderate disability; requiring some help, but able to walk without assistance
4 = Moderate severe disability; unable to walk without assistance, and unable attend
to own bodily needs without assistance
5 = Severe disability; bedridden, incontinent, and requiring constant nursing care and
attention
6 = Dead
7 = Not known
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Appendix C Barthel ADL Index
I want to ask some questions about how you are getting on performing everyday.
This information is important so we can determine whether people are getting the
treatment that they need.
Feeding
0 = unable
1 = Needs help but can do about half unaided (e.g. help with buttons or zip, but can




1 = Independent in bathing or showering (must get in and out unsupervised, and wash
self; or shower unsupervised or unaided)
Grooming
0 = needs to help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterized and unable to manage alone





1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair, and back))
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners
2 = walks with help of one person (verbal or physical)
3 = independent (but may use any aid; for example, stick)
Stairs
0 = unable
1 = needs help (verbal, physical, carrying aid)
2 = independent
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Appendix D Nottingham Extended ADL Index
The following questions are about everyday activities. Please answer by ticking
ONE box for each question. Please record what you haveACTUALLY done in the
last few weeks. DID YOU.
• Not at all; with help; on your own with difficulty; own your own.
1. Walk around outside?
2. Climb stairs?
3. Get in and out of a car?
4. Walk over uneven ground?
5. Cross roads?
6. Travel on public transport?
7. Manage to feed yourself?
8. Manage to make yourself a hot drink?
9. Take hot drinks from one room to another?
10. Do the washing up?
11. Make yourself a hot snack?
12. Manage your own money when out?
13. Wash small items of clothing?
14. Do your own housework?
15. Do your own shopping?
16. Do a full clothes wash?
17. Read newspaper or books?
18. Use the telephone?
19. Write letters?
20. Go out socially?
21. Manage your own garden?
22. Drive a car?
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Appendix E Sleep and Stroke Questionnaire
Please try to answer all questions. Ifyou cannot give an exact answer then give a
"best guess " as your answer (for some questions it will be difficult to give an exact
answer) or ifyou definitely don't knowput "not known" as your answer. Answer
question by placing a circle around the correct/best answer andprovide further
information, ifnecessary, on the line provided.
1) What time did your current stroke happen?
2) At that time you were:
• Awake; asleep.
3) Have you ever been diagnosed with stroke, TIA, angina or leg claudication
previously?
• Yes; no (please go to Q4)
4) Do you snore during sleep?
• Yes; no (please go to Q8)
5) How many years have you snored?
6) How often do you snore?
• Occasionally (less than 3 nights per week); often (3-6 nights per week);
nearly every day.
7) How loudly you snore?
• Quietly; moderately loud (heard in bedroom only); loudly (heard outside the
bedroom).
8) Do you have a regular bed-partner or room-mate?
• Yes; no (please go to Q10)
9) Has your bed-partner/room-mate ever noticed that you stop breathing when
asleep?
• Yes; no.
10) Do you need to go to toilet at night?
• Never or hardly ever; occasionally; 1-2 times per night; more than 2 times
per night.
11) Have you woken in the night with choking episodes or suffocating?
• Never or hardly ever; 1-2 times; 3-6 times; more than 6 times.
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12) Have you woken up in the morning with headache?
• Never or hardly ever; 1-2 times; 3-6 times; more than 6 times
13) In the morning do you feel that your nights sleep was refreshing/satisfactory?
• Never or hardly ever; 1-3 times per week; 4-6 times per week; always.
14) Do you have periods of the day when you feel sleepy or have trouble staying
awake?
• Never or hardly ever; 1-3 times per week; 4-6 times per week; always
15) Do you drive?
• Yes; no (end)
16) Have you ever had, or nearly had an accident because of falling asleep while
driving?
• No; yes (give details):
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Appendix F Stanford Sleepiness Scale
Circle the statement that best describes your alertness or sleepiness right now.
1. Feeling active and vital; alert; wide-awake.
2. Functioning at a high level, but not at peak; able to concentrate
3. Relaxed; awake; not at full alertness; responsive.
4. A little foggy; not at peak; let down.
5. Fogginess; beginning to lose interest in remaining awake; slowed down.
6. Sleepiness; prefer to be lying down; fighting sleep; woozy.
7. Almost in reverie; sleep onset soon; lost the struggle to stay awake.
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Appendix G Epworth Sleepiness Scale
How likely are you to doze offor fall asleep in the following situations, in contrast to
feeling just tired? This refers to your usual way of life in recent times. Even ifyou
have not done some of these things recently, try to work out how they would have
affected you. Use the following scale to choose the most appropriate number for each
situation.
1. Sitting and Reading
2. Watching TV
3. Sitting, inactive in a public place (e.g. a theater or a meeting)
4. As a passenger in a car for an hour without a break
5. Lying down to rest in the afternoon when circumstances permit
6. Sitting and talking to someone
7. Sitting quietly after lunch without alcohol
8. In a car, while stopped for a few minutes in traffic
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Appendix H Addenbrooke's Cognitive Examination
All instructions to the tester are in italics. All instructions to be said aloud to the
patient are in bold non-italicprint.
ORIENTATION
Ask the subject the following question:
Qla) What is the year? season? month? date? day?
Qlb) Where are we? Country; town; hospital/building; floor/level.
ATTENTION/CONCENTRATION
Q2) Tell the subject I am going to ask you to recall the names of three things.
Say aloud. Then ask the subject to repeat them:
• Lemon, key, ball.
Q3) Ask the subject to take away 7 from 100.
If score<5 then ask the subject to Spell WORLD' backwards.
MEMORY
Q4) Ask the subject to recall the names of the 3 things learned earlier in question 2.
Q5) Anterograde Memory: Tell the subject I will read a name and address and ask
you to repeat it when I have finished. Now read aloud the following name and
address. 1st trial; 2nd trial; 3rd trial; 5 min delay.
• Peter Marshall
• 42 Market Street
• Chelmsford; Essex
Q6) Retrograde Memory: Tell me the full name of:
• The prime minister; the last prime minister; the Leader of the Opposition;
the President of the United States of America.
VERBAL FLUENCY
Q7) Letter: Ask the subject to:
• Tell me all the words you can think of, but not people and places, beginning
with the letter P.
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Q8) Category: Say:
• Now tell me the names of as many animals as you can, beginning with any
letter of the alphabet.
LANGUAGE
Q9) Naming: Show the subject the following two line-drawings and ask him/her to
name each of them.
Q10) Naming: Show the subject the following ten line-drawings and ask him/her to
name each of them.
[0-10]
Qll) Comprehension (one-stage): Ask the subject to please obey the following
simple commands.
• Point to the door.
• Point to the ceiling.
Show the subject the following instruction and ask him/her to read this aloud and
obey it.
• CLOSE YOUR EYES
Q12) Comprehension (3-stages): Give the subject a piece of paper and tell him to
take this paper in your hands. Fold it in half. Then put the paper on the floor.
Q13) Comprehension (complex grammar): Ask the subject to please obey the
following commands.
• Point to the ceiling then the door.
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• Point to the door after touching the bed/desk.
Q14) Repetition (single words): Ask the subject to repeat each of these words after
me:
• Brown; conversation; articulate.
Q15) Repetition (phrases): Ask the subject to repeat each of these phrases after me:
• No ifs, ands, or buts.
• The orchestra played and the audience applauded.
Q16) Reading (regular): Ask the subject to read each of these words aloud and show
him/her the following five words. Shed; wipe; board; flame; bridge.
Q17) Reading (irregular): Ask the subject to read each of these words aloud and
show him/her the following five words. Sew; pint; soot; dough; height.
Q18) Writing: Ask the subject to make up a sentence and write it down in the space
below. If stuck suggest a topic e.g. weather, journey.
Q19) Now to check delayed recall ask the subject Can you tell me the name and
address that I told you and that you practised at the beginning of the test.
VISUOSPATIALABILITIES
Q20) Overlapping pentagons: Show the subject the following figure and ask him/her
to copy this diagram in the space provided next to it.
Q21) Wire cube: Show the subject the following figure and ask him/her to copy this
diagram in the space provided next to it.
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Appendix I Hospital Anxiety and Depression Scale
Read each item and choose one response from the four given for each interview
which comes closest to how you have been feeling in the past week. Don't take too
long over your replies: your immediate reaction to each item willprobably be more
accurate than a long thought-out response.
1. I feel tense or "wound up."
• Most of the time; a lot of the time; from time to time, occasionally; not at
all.
2. I still enjoy the things I used to enjoy.
• Definitely as much; not quite as much; only a little; hardly at all.
3. I get a sort of frightened feeling as if something awful is about to happen.
• Very definitely and quite badly; yes, but not too badly; a little, but it doesn't
worry me; not at all.
4. I can laugh and see the funny side of things.
• As much as I always could; not quite so much now; definitely not so much
now; not at all.
5. Worrying thoughts go through my mind.
• A great deal of the time; a lot of the time; from time to time but not too
often; only occasionally.
6. I feel cheerful.
• Not at all; not often; sometimes; most of the time.
7. I can sit at ease and feel relaxed.
• Definitely; usually; not often; not at all.
8. I feel as if I am slowed down.
• Nearly all the time; very often; sometimes; not at all.
9. I get a sort of frightened feeling like "butterflies" in the stomach.
• Not at all; occasionally; quite often; very often.
10.1 have lost interest in my appearance.
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• Definitely; I don't take so much care as I should; I may not take quite as
much care; I take just as much care as ever.
11.1 feel restless as if I have to be on the move.
• Very much indeed; quite a lot; not very much; not at all.
12.1 look forward with enjoyment to things.
• As much as I ever did; rather less than I used to; definitely less than I used
to; hardly at all.
13.1 get sudden feelings of panic.
• Very often indeed; quite often; not very often; not at all.
14.1 can enjoy a good book or radio or TV program.
• Often; sometimes; not often; very seldom.
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Appendix J EuroQol
Byplacing a tick in one box in each group below, please indicate which statements
best describe your own health state today.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain/Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
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Best
To help people say how good or bad a health state
is, we have drawn a scale (rather like a
thermometer) on which the best state you can
imagine is marked 100 and the worst state you
can imagine is marked 0.
We would like you to indicate on this scale how
good or bad your own health is today, in your
opinion. Please do this by drawing a line from the
box below to whichever point on the scale










This questionnaire asks for your views about your health, how you feel and how well
you are able to do your usual activities. Answer every question by marking the
answer as indicated. Ifyou are unsure about how to answer a question, please give
the best answer you can.
1. In general, would you say your health is?
• Excellent; very good; good; fair; poor.
2. Compared to one year ago, how would you rate your health in general now?
• Much better now than one year ago.
• Somewhat better now than one year ago.
• About the same as one year ago.
• Somewhat worse now than one year ago.
• Much worse now than one year ago.
3. The following questions are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
• Yes limited a lot; yes limited a little; no not limited at all.
Vigorous activities, such as running, lifting heavy objects, participating in strenuous
sports
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or
playing golf
Lifting or carrying groceries
Climbing several flights of stairs
Climbing one flight of stairs
Bending, kneeling, or stooping
Waling more than a mile
Walking half a mile
Walking one hundred yards
Bathing or dressing yourself
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During the past 4 weeks, have you had any of the following problems with your
work or other regular daily activities as a result of your physical health?
• Yes; no.
Cut down on the amount of time you spent on work or other activities
Accomplished less than you would like
Were limited in the kind ofwork or other activities
Had difficulty performing the work or other activities (for example, it took extra
effort)
During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result ofany emotional problems (such as feeling depressed
or anxious) ?
• Yes; no.
Cut down on the amount of time you spent on work or other activities
Accomplished less than you would like
Didn't do work or other activities as carefully as usual
During the past 4 weeks, to what extent has yourphysical health or emotional problems
interfered with your normal social activities with family, friends, neighbours, or groups?
• Not at all; slightly; moderately; quite a bit; extremely.
4. How much bodily pain have you had during the past 4 weeks?
• No bodily pain; very mild; mild; moderate; severe.
During the past 4 weeks, how much didpain interfere with your normal work (including
both work outside the home and housework?)
• Not at all; a little bit; moderately; quite a bit; extremely.
5. These questions are about how you feel and how things have been with you
during the past 4 weeks. For each question, please give the one answer that comes
closest to the way you have been feeling. How much of the time during the past 4
weeks.
• All of the time; most of the time; a good bit of time; some of the time; a
little of the time; none
Did you feel full of life?
Have you been a very nervous person?
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Have you felt so down in the dumps that nothing could cheer you up?
Have you felt calm and peaceful?
Did you have a lot of energy?
Have you felt downhearted and low?
Did you feel worn out?
Have you been a happy person?
Did you feel tired?
10. During the past 4 weeks, how much of the time has you physical health or
emotional problems interfered with your social activities (like visiting friends,
relatives, etc.)
• All of the time; most of the time; a good bit of time; some of the time; a
little of the time; none.
11. How TRUE or FALSE is each of the following statements for you?
• Definitely True; mostly true; don't know; mostly false; definitely false.
I seem to get ill more easily than other people
I am as healthy as anybody I know
I expect my health to get worse
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